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CHAPTER 1 
 
 
 
Aim and scope of the thesis 
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The overall median survival in glioblastoma multiforme (GBM) patients is less than one year 
and fewer than 5% of patients survive more than 5 years. The current standard of care for 
GBM patients involves neurosurgical resection of the tumor followed by radiotherapy with 
concomitant and adjuvant temozolomide chemotherapy. After initial treatment, all malignant 
gliomas eventually recur, mostly within a 2-3 cm margin of the original tumor on CT/MRI. 
The poor prognosis warrants research into new treatment modalities for malignant gliomas. 
Novel therapeutic approaches in the treatment of GBM include chemotherapy, targeted 
molecular agents, immunotherapy and virotherapy/gene therapy. Because malignant gliomas 
only rarely metastasize outside the skull, novel locoregional treatment modalities such as gene 
therapy are potentially interesting. The aim of this thesis was to identify bottlenecks limiting 
the efficacy of glioma gene therapy and address some of these bottlenecks in the laboratory. 
 
In chapter 2, a literature overview is presented of clinical trials in malignant gliomas and 
some of the hurdles identified in these trials are discussed. One of the most important issues is 
the limited distribution of viral particles compared to the size of malignant gliomas in 
patients. Various strategies to improve vector distribution and transduction efficiency are 
presented, including convection enhanced delivery, oncolytic virotherapy and genetic 
modification of adenoviral tropism. Finally, some of the molecular imaging tools are 
discussed that will allow the monitoring and quantification of transgene expression levels in 
patients. 
 
In chapter 3, we investigated the therapeutic potential of replication-competent adenoviral 
vectors which are a new and rapidly evolving platform for gene therapy. These viruses have a 
direct oncolytic effect (‘virotherapy’) and, following lysis of the target cells, can subsequently 
spread into the tumor. We studied the interaction of replication competent adenoviral vectors 
and the HSV1-tk/GCV suicide in glioma cell lines and after intratumoral injection in a glioma 
xenograft model. Finally, the potential of a suicide gene as fail-safe in case of spread of the 
vector outside the tumor was evaluated. 
 
Non-invasive imaging and quantification of therapeutic transgene expression would provide 
important information on potential efficacy of glioma gene therapy in clinical trials. Because 
the HSV1-tk gene is the most frequently used therapeutic gene in clinical glioma gene therapy 
trials, we evaluated several nucleoside analogues, that are selectively phosphorylated by 
HSV1-tk, as tracers for monitoring HSV1-tk expression. In chapter 4, we described the 
biodistribution and imaging properties of 123I-FIRU in vitro and in vivo using constitutively 
HSV-tk expressing tumor cells. In chapter 5, we first described a method for radiolabeling 
and purification of FIRU in a clinical setting. Then we compared the in vitro toxicity of FIRU 
to the related compounds ganciclovir, FIAU and IVFRU in a number of cell lines. These 
studies demonstrated lower toxicity of FIRU as compared to FIAU in both constitutively 
HSV1-tk expressing and non-HSV1-tk expressing parental cell lines. The biodistribution and 
biokinetics of  123I-FIRU were further studied in HSV1-tk+ tumor bearing mice. Finally, the 
imaging properties of FIRU were examined using small animal SPECT. 
 
In chapter 6, we set out to identify an adenoviral vector better suited to infect primary glioma 
cells than Adenovirus serotype 5 (Ad5). To this end, we tested a library of fiber-chimeric 
Ad5-based adenoviral vectors on 12 fresh primary human glioma cell suspensions. We found 
significantly improved marker gene expression with several chimeric vectors, predominantly 
vectors carrying fiber molecules derived from B-serogroup viruses (Ad11, Ad16, Ad35 and 
Ad50). To explain this remarkable finding, we examined the expression of several molecules 
involved in adenoviral binding and entry on the primary glioma cells, including CAR, CD46 
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and  v  integrins. Finally, we examined the seroprevalence of Ad35 among Dutch cancer 
patients, including glioma patients. 
 
In Chapter 7, we describe the preliminary results of a prospective, open label, multicenter 
dose escalation study in malignant glioma. This phase I trial was designed to assess the 
maximum tolerated dose (MTD) of IG.Ad.MPLI.TK followed by ganciclovir treatment in 
patients with relapsed glioblastoma assessing clinical and laboratory parameters. Treatment 
consisted of 10 ml of IG.Ad.MLPI.TK vector suspension injected on day 0 after optimal 
tumor resection into the surgical margins of the resection cavity, evenly distributed at 
approximately 50 sites 0.5-1 cm deep into the tissue. The dose levels were 4.6 x 108, 4.6 x 
109, 4.6 x 1010, 4.6 x 1011 vector particles. On day 2 ganciclovir was started and given by i.v. 
infusion over 1 hour, 5 mg/kg bid for 14 days. All patients had recurrent high grade glioma 
and all had received prior radiotherapy. The toxicity and efficacy data are presented in the 
first eleven patients that were enrolled in this study.  
 
In Chapter 8 we provide a summary and discussion of the chapters. 
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CHAPTER 2 
 
 
 
Gene Therapy for Glioma 
 
 
 
Based on: 
D. Nanda, S. Verwijnen and P. Sillevis Smitt 
Educational Book, XVth annual congress of the European Society of Gene and 
Cell Therapy (ESGCT), October 27-30, 2007, Rotterdam, Netherlands 
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Gliomas 
Primary brain tumors represent a diverse group of neoplasms arising from different cells of 
the nervous system. Gliomas are the most frequent primary brain tumors and present 
histological features of glial cells including astrocytes, oligodendrocytes and ependymal cells. 
Malignant or high-grade gliomas are classified by the WHO as either grade III anaplastic 
astrocytoma, anaplastic oligodendroglioma or mixed anaplastic oligoastrocytoma or as grade 
IV glioblastoma multiforme (GBM). At least 80% of malignant gliomas are GBM. 
The annual incidence of malignant gliomas varies between 3 – 7 per 100,000 people per year. 
Despite this relatively low incidence the burden of disease is immense due to the high 
morbidity and mortality of malignant gliomas. The prognosis of anaplastic gliomas varies by 
subtype and is most favourable in patients with an anaplastic oligodendroglioma (median 
survival 4 years from diagnosis). The overall median survival in GBM patients on the other 
hand is less than one year and fewer than 5% of patient survive more than 5 years. The current 
standard of care for GBM patients involves neurosurgical resection of the tumor (as 
extensively as safely possible) followed by radiotherapy with concomitant and adjuvant 
temozolomide chemotherapy 1. After initial treatment, all malignant gliomas eventually recur. 
Interestingly, 80% of these tumors recur within a 2-3 cm margin of the original tumor on 
CT/MRI 2. Also, these tumors only rarely metastasize outside the skull. The poor prognosis 
warrants research into new treatment modalities for malignant gliomas. Novel therapeutic 
approaches in the treatment of GBM include chemotherapy, targeted molecular agents, 
immunotherapy and virotherapy/gene therapy.  
 
Clinical Gene Therapy Trials in Malignant Glioma 
Due to the locoregional nature of malignant gliomas and their poor prognosis, recurrent 
malignant gliomas proved an excellent model to study gene therapy approaches. In fact, 
approximately 7% of the clinical gene therapy trials that were conducted between 1989 – 
2007 included GBM patients (Figure 1). Many different vector systems and transgenes have 
been used for the treatment of malignant gliomas in clinical trials world wide, as depicted in 
Figure 2. The most frequently used vectors included retroviral, adenoviral and herpes simplex 
viral vectors. Almost 40% of GBM gene therapy trials used the suicide gene Herpes Simplex 
virus thymidine kinase (HSV-tk). After several promising phase II clinical trials using 
retroviral vectors encoding HSV-tk, a randomized controlled phase III clinical gene therapy 
trial was conducted in 248 newly diagnosed GBM patients 3. Patients received either standard 
therapy (surgical resection and radiotherapy) or standard therapy plus adjuvant gene therapy 
during surgery. Unfortunately, progression-free median survival, median survival and 12-
months survival rates did not differ significantly between groups.  
Several phase I/II clinical trials were performed using a non-replicating Adenovirus serotype 
5 (Ad5) expressing the HSV-tk gene in combination with ganciclovir in recurrent malignant 
gliomas. These trials have clearly demonstrated the feasibility and safety of the approach 4-9. 
Twenty-seven of 74 patients (37%) lived one year or more after gene therapy, which is longer 
than historical controls. Recently, a randomized controlled trial reported the successful 
adjuvant treatment of malignant glioma patients with Ad5-tk (Cerepro®) 9. Ad5-tk treatment 
produced a significant increase in mean survival from 39 to 71 weeks (P< 0.01) 9. The validity 
of this trial’s conclusions is compromised by the inclusion of newly diagnosed and recurrent 
glioma patients of different grades in both treatment and control groups and the imbalances 
between grade 3 and 4 patients between these groups. Despite these considerations, Ark 
Therapeutics Ltd. embarked on a phase III trial of Cerepro® in 250 newly diagnosed GBM 
patients, the results of which have not yet been reported. 
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A different gene therapy approach tested in clinical trials consisted of tumor suppressor gene 
reconstitution, by using a non-replicating adenoviral vector encoding the p53 gene (Adp53). 
Replacement of p53 in gliomas is a rational approach because of the high frequency of p53 
pathway abnormalities, including p53 mutations, overexpression of murine double minute 2 
(mdm-2; the primary negative regulator of p53), inactivation of p14ARF (an inhibitor of mdm-
2) or interference with p53 post-translational modifications 10. A phase I/II study of 
intratumoral Adp53 administration in 15 patients with recurrent glioma showed excellent 
tolerance and MTD was not reached at a dose of 3 x 1012 viral particles. Despite the fact that 
the exogenous p53 was detected within tumor cells, these infected cells resided, on average, 
only within 5 mm of the needle tract 10.  
 
Figure 1.  
 
 
Figure 1. The world wide clinical gene therapy trials from 1989 to 2007 divided by disease 
and by cancer type. This figure is adapted from http://www.wiley.co.uk/genmed/clinical/ and 
was last updated in January 2007. 
 
Figure 2. 
 
Figure 2. Vectors and genes used in clinical trials for GBM patients. This figure is adapted 
from http://www.wiley.co.uk/genmed/clinical/ and was last updated in January 2007. 
 
Hurdles Limiting the Efficacy of Glioma Gene Therapy 
One major problem relates to the size of gliomas in humans (Figure 3). These tumors cannot 
be entirely covered by the small radius of transgene dissemination that can be accomplished 
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by using nonreplicating vectors 10. In addition, the limited success of adenovirus based 
clinical studies, which is in contrast with results obtained in animal models of gliomas clearly 
indicates additional challenges, including poor  expression of the Coxsackie Adenovirus 
Receptor (CAR) on primary glioma cells resulting in low transduction efficiency compared to 
established cell lines 11, 12. In addition, the viral vectors elicit a strong immune response, 
which limits the efficacy of gene transfer, even in the relatively immune privileged brain 13, 14. 
The high prevalence of neutralizing antibodies (NAb) against Ad5 may further adversely 
affect transduction efficiency. All these issues that limit the efficacy of viral vectors have 
been addressed in the laboratory and will be discussed below. 
 
Improving Spatial Distribution – Alternative Routes of Administration 
To improve tissue penetration of the virus, new delivery methods have been explored. 
Recently, convection enhanced delivery (CED) was developed as a means to improve delivery 
of macromolecules throughout the brain 15, 16. CED is based on continuous infusion of drugs 
via intracranial catheters, enabling convective distribution of high drug concentrations over 
large volumes of the target tissue 17. In experimental models, delivery of viral vectors to the 
normal brain by CED improved distribution 18-21. CED of labelled adenovirus particles (80-90 
nm diameter) to normal rat striatum resulted in a distribution volume (Vd) of approximately 
30 mm3, better than a similarly sized nanosphere particle 22. CED of the much smaller adeno-
associated virus (AAV) particle (23 nm diameter), however, only reached a Vd of 13 mm3. 
These results indicate that convective distribution can be used to distribute therapeutic viral 
vectors in the normal brain 22. In addition to size, surface properties have a major impact on 
the convective distribution of viruses and virus-sized particles in the brain. In a subcutaneous 
U87 glioma xenograft model in nude mice, CED of an adenoviral vector harbouring the sst2 
reporter gene resulted in a Vd of 26 mm3, comparable to Vd after single injection (25 mm3). 
However, the maximum Vd was obtained with multiple intratumoral injections (Vd = 57 mm3) 
23. CED has been successfully applied in clinical glioma trials to administer large molecules, 
including immunotoxins 24-27. Co-infusion of 123I labelled human serum albumin resulted in a 
broad distribution. However, target anatomy and catheter positioning had a significant 
influence on infusate distribution even within non-contrast enhancing regions of the brain. 
Intratumoral infusions tended to be anisotropic with accumulation of infusate in necrotic areas 
followed by eccentric efflux toward the peritumoral region through only a part of the tumor 27. 
In conclusion, CED holds promise to expand virus (in particular adenovirus) distribution in 
glioma patients provided optimal positioning of the catheter in the peritumoral region or 
around the resection cavity. 
Intravascular delivery is the least invasive method to deliver drugs to solid tissues, including 
the brain. However, the blood-brain barrier (BBB) does not allow passage of large and virus-
sized molecules to the brain following intravascular administration. Following disruption with 
both mannitol and bradykinin, several groups have been able to transduce brain tumor cells 
growing orthotopically in rats with both replication defective adenoviruses and attenuated 
herpes viruses 28, 29. Gene transfer with the adenoviruses appeared less effective than with the 
herpes viruses, but it is not clear whether this is the result of herpes virus replication 28. 
Hower, intravascular virus delivery in combination with opening the BBB with these drugs 
may also increase the gene transfer to other areas of the brain, increasing the risk of toxicity. 
A more viable approach may be the targeting of tumor endothelial cells with viruses encoding 
anti-angiogenic molecules. 
An exciting new option is to use the homing properties of neural or mesenchymal stem cells 
to deliver gene therapy vectors to malignant gliomas 30, 31. Although the use of stem cells for 
this application remains confined to the basic science laboratory,  though several groups are 
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committed to translate this technology into clinical trials for patients with central nervous system 
neoplasms 32. 
The striking difference between the success of various gene therapy strategies in animal 
models versus clinical studies may be partly explained by the enormous difference in size of 
the tumor. To better address viral delivery and distribution, some authors have therefore 
proposed the use of larger animal models such as the dog 33, 34. 
 
 
 
Figure 3. Vector distribution must be improved in glioma gene therapy. (A, B) MRI of a 
typical GBM tumor diagnosed in a 35-year old man. (A) On T1-weighted images after 
gadolinium administration, we see an enhancing mass with a diameter of 4.5 cm, 
corresponding to a tumor volume of approximately 43 ml. However, on T2-weighted images, 
the diameter is more than 10 cm, corresponding to a volume of over 600 ml. The treatment 
target, e.g. for radiotherapy, is generally the T2-weighted abnormality with a 2-3 cm margin, 
corresponding to a target volume of >1000 ml. The typical volume of an orthotopic mouse 
glioma in preclinical studies is maximally 100  l, a 4 log difference. (C, D) Intratumoral 
injection of Ad5.tk.sstr by multiple injections resulted in a maximum volume of distribution 
of 57  l, corresponding to a 4-5 mm penetration from the needle tract 23. 
 B 
 C 
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Improving Spatial Distribution – Oncolytic Virotherapy 
Another approach to improve tissue penetration and oncolytic efficacy is the development of 
conditionally replicative viral vectors (virotherapy). The first replicating viruses employed in 
glioma clinical trial were two herpes virus vectors. Rampling et al. evaluated the toxicity of 
low doses of up to 105 pfu of an attenuated HSV named 1716 which has disruptions of the 
two copies of the RL1 gene 35. The other study, by Markert et al. tested a herpes virus (G207) 
with mutations in the RL1 gene and a lacZ insertion disabling the UL39 gene 36. Following 
injection of higher doses, up to 3x109 pfu at five sites, no toxicity or serious adverse events 
could unequivocally be ascribed to G207. No patient developed HSV encephalitis. 
Radiographic and neuropathologic evidence suggestive of anti-tumor activity and long-term 
presence of viral DNA was found in some cases. 
The results of a phase I glioma trial with the E1B attenuated conditionally replicative 
adenovirus ONYX-015 were recently reported 37. None of the 24 patients experienced serious 
adverse events related to ONYX-015 and the MTD was not reached at 1010 pfu. The median 
time to progression was 46 days and the median survival time was 6.2 months. 
A direct side-by-side comparison of the anti-glioma activity of the oncolytic herpes simplex 
virus vector G47Delta with that of a conditionally replicative adenoviral vector for the 
treatment of glioblastoma demonstrated higher oncolytic efficacy and packaging capacity of 
the herpes virus vector compared to adenovirus 38. 
Reovirus replicates selectively in cells with an activated Ras signalling pathway, including 
glioma cells 39. In a Phase I trial of reovirus in malignant glioma patients, the MTD was not 
reached at 109 TICD50; however, there was no sign of antitumor activity either 40. CED of 
reovirus is currently undergoing clinical testing in recurrent glioma 41. 
Another virotherapy approach that is currently being tested in clinical trial in the treatment of 
recurrent GBM is the administration of an oncolytic measles virus (MV) vaccine strain, which 
is engineered to produce carcinoembryonic antigen (CEA) when the virus replicates in tumor 
cells 41, 42. CEA levels measured in the blood can subsequently be used as biomarkers to 
monitor viral gene expression and dose optimization. Another virus that is soon to be tested in 
the clinic is the intergenic poliovirus recombinant 41, 43. 
Many conditionally replicative adenoviral vectors (CRAd’s) have been developed for 
virotherapy of gliomas and other tumors. Two strategies have been used to restrict virus 
replication to tumor cells and spare normal cells; a) mutation-type CRAds; and b) promoter-
controlled-type CRAds. Mutation-type CRAds have for instance deletions in the 
retinoblastoma gene (Rb)-binding region of E1A (e.g. the delta24 adenovirus 44) or in the p53 
binding and inactivation region of E1B (e.g. ONYX-015) 45 in order to increase the tumor 
specificity of viral replication. A disadvantage of mutation-type CRADs is the attenuation of 
viral replication compared to wildtype 44, 46, 47. In addition, the stringency of replication 
control in these CRAds is still under discussion 48, 49.  
Another approach is the use of tissue or tumor specific promoters (TTSP) to drive viral genes 
critical for replication, such as E1A, E1B or E4. Many well-characterized TTSP have been 
investigated in CRAds for cancer gene therapy 46 50. Several CRAds controlled by TTSP have 
been examined in malignant glioma cells lines. These include the GFAP 51, the midkine (MK) 
52, the cyclooxygenase-2 (COX-2) 53 and the hypoxia / hypoxia inducible factor (HIF) 
responsive promoters 54.  
A future development is the design and testing of adenoviral vectors for cancer virotherapy 
that replicate more efficiently on cancer cells than wildtype. 
 
Improving Transduction Efficiency by Adenoviral Vectors 
The limited clinical success of adenovirus-based delivery, which is in contrast with results 
obtained in many animal models of gliomas underlines additional challenges related to the 
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low expression level of CAR in primary glioma cells and tumors as opposed to established 
cell lines 11, 12, 55. Because CAR expression apparently is a rate limiting factor for the 
infectivity with Ad5 50, modifications in adenoviruses are required to improve the infection 
efficiency. Currently, it is possible to use targeted viral vectors to direct gene transfer to 
specific receptors. The use of targeted adenoviruses is likely to increase safety and efficacy, 
reduce toxicity and may even permit systemic administration of these vectors 47.  
One of the first successful genetic modifications of adenoviral tropism was the insertion of the 
RGD motif into the hexon protein, HI loop or C-terminus of the viral fiber protein  
56. This strategy improved adenoviral entry into cells, independent of  CAR expression, but it 
did not enhance cancer specificity. Further attempts are being made to target adenovirus to 
receptors which are highly expressed on gliomas like epidermal growth factor receptor 
(EGFR), fibroblast growth factor receptor (FGFR) or urokinase-type plasminogen activator 
receptor (uPAR) 57, 58. Another strategy is the generation of chimeric adenoviral vectors by 
removing the fiber of Ad5 followed by the insertion of a PCR amplified DNA encoding for a 
fiber derived from an alternative serotype 59, 60. At present, 51 human Ad serotypes have been 
identified that are grouped into six species: A, B (subdivided in B1 and B2), C, D, E and F 61, 
62. The association between serotype and clinical syndrome 63 suggests that diverse organs are 
targets for different serotypes. Although many adenoviral serotypes infect cells through CAR, 
other receptors have been described. Recently, CD46 was found to be the common receptor 
for subgroup B adenoviruses 64, 65. Since CD46 expression is very low on neurons 66 and 
because B-group adenoviral vectors infect glioma cells more efficiently than Ad5 11, 67, 
several chimeric adenoviral vectors, carrying B-serogroup fibers have been examined for the 
treatment of brain tumors. Ulasov et al.68 infected glioma cells with a chimeric Ad5/3 
adenovirus, possessing the receptor binding fiber knob domain of Ad3 in the Ad5 capsid 
retargeting the virus to CD46, and showed increased transduction efficiency compared to Ad5 
in glioma cells. Similarly, Brouwer et al. found increased transduction efficiency of Ad5-
based chimeric vectors carrying B-serogroup fibers, following infection of primary glioma 
cells 11.  
Hoffmann et al. found improved GBM treatment with Ad5/35 fiber chimeric conditionally 
replicating adenoviruses 69. Ulasov et al. found potent anti-glioma activity when combining 
survivin-driven E1A expression with a pk7 fiber modification which selectively binds heparin 
sulfate proteoglycans, which are overespressed in glioma 70. The tropism enhanced oncolytic 
adenovirus Delta24-RGD-4C combines anchoring directly to integrins with E1A attenuation 
resulting in tumor selective replication 44. This virus will soon be tested in clinical trial in 
ovarian cancer and malignant gliomas.  
 
 
Molecular Imaging of Gene Transfer in GBM 
Non-invasive imaging of gene expression will give the possibility to quantify transgene 
expression, which may predict treatment outcome, as well as gain insight into vector 
distribution and, extent and duration of gene expression. At this moment, there is an inability 
to non-invasively measure transduction levels or functional enzyme activity in order to 
correlate this with clinical changes after ganciclovir (GCV) treatment. Jacobs et al. published 
a study in which five patients enrolled in a gene therapy procedure using a liposomal vector 
carrying an HSV-tk gene 71. They performed a dynamic PET scan using 124I-FIAU, a 
radioactive nucleoside analog, which is trapped in the same manner by HSV-tk as GCV. They 
showed a specific HSV-tk-related uptake of FIAU at the site of injection in one patient, who 
also showed a response to treatment. Unfortunately, in the other patients no increased FIAU 
uptake could be measured; they also failed to respond to treatment. This study shows that 
non-invasive imaging of HSV-tk gene expression is feasible and highly desirable in order to 
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assess gene transfer. Dempsey et al. reported on eight GBM patients imaged with SPECT 
using 123I-FIAU prior to and after application of an oncolytic HSV virus 72. Unfortunately, 
no increased uptake of FIAU was determined after viral infection in these patients. A possible 
explanation for this is that FIAU might not be the ideal tracer for monitoring HSV-tk 
expression in subjects with intact BBB, as FIAU does not penetrate it 72, 73. 
Another approach is direct labeling of the viral particles which allows immediate visualization 
of vector distribution, regardless of transgene expression 23, 74. 
 
Conclusions 
The results of the initial clinical gene therapy trials in malignant gliomas have been 
disappointing. However, many of the reasons contributing to these failures have been 
identified and addressed in the laboratory. By lack of truly predictive animal models, new 
clinical trials are required to assess many of newly developed vectors for gene therapy / 
virotherapy. One of the most important issues is the limited distribution of viral particles 
compared to the size of malignant gliomas in patients. Hopefully, a combination of 
convection enhanced delivery and oncolytic virotherapy may lower this hurdle. Clearly, 
molecular imaging tools will provide important information for the evaluation of gene therapy 
in clinical glioma trials. 
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CHAPTER 3 
 
 
 
Treatment of Malignant Gliomas with a Replicating Adenoviral 
Vector Expressing Herpes Simplex Virus-Thymidine Kinase 
 
 
 
D. Nanda, R. Vogels, M. Havenga, C. Avezaat, A. Bout and P. Sillevis Smitt 
CANCER RESEARCH 2001; 61: 8743-8750 
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ABSTRACT 
 
We evaluated the interaction between oncolytic, replication-competent adenoviral vectors and 
the herpes simplex virus-1 thymidine kinase (HSV1-tk) gene/ganciclovir (GCV) suicide 
system for the treatment of malignant gliomas. We constructed a panel of replication-
competent adenoviral  vectors in which the luciferase (IG.Ad5E1+. E3Luc) or HSV1-tk gene 
(IG.Ad5E1+.E3TK) replace the Mr 19,000 glycoprotein (gp19K) coding sequence in the E3 
region. IG.Ad5E1. IG.Ad5.ClipLuc and IG.AdApt. TK are E1-deleted viruses that contain the 
luciferase or the HSV1-tk gene in the former E1 region driven by the human cytomegalovirus 
promoter. IG.Ad5.Sarcoma 1800HSA.E3Luc contains an irrelevant gene in the E1 region, 
whereas the gp19K coding sequence in the E3 region is replaced by the luciferase gene as in 
the replicating virus IG.Ad5E1_.E3Luc. For in vitro experiments, we used a panel of human 
glioma cell lines (U87 MG, T98G, A172, LW5, and U251), a rat gliosarcoma cell line (9 L), 
and human lung (A549) and prostate carcinoma (P3) cell lines. In vitro, GCV sensitivity (10 
µg/ml) was studied in U87 MG cells after infection at a multiplicity of infection of 1 and 10. 
A s.c. U87 MG glioma xenograft model was established in NIH-bg-nu-xid mice. Tumors of 
100–150 mm3 were treated with a single injection of adenovirus 109 IU suspended in 100 µl 
of PBS, and GCV 100 mg/kg was administered i.p. twice daily for 7 days. The cytopathic 
effect of all three replicationcompetent adenoviral vectors was similar to the cytopathic effect 
of wild-type adenovirus 5 on all human cell lines tested, indicating that deletion of the E3 
gp19K sequences did not affect the oncolytic effect of the vectors. In vitro, luciferase 
expression was the same for both E1-deleted vectors (IG.Ad5.ClipLuc and IG.Ad5.Sarcoma 
1800HSA.E3Luc), demonstrating the strength of the internal E3 promoter even in the absence 
of E1A. However, in vitro expression levels obtained with replicationcompetent IG.Ad5E1+. 
E3Luc were 3 log higher (allowing infection with a 2–3-log lower multiplicity of infection) in 
the human cell lines. In U87 MG glioma cells, the oncolytic effect of replication-competent 
IG.Ad5E1+.E3TK was significantly enhanced by the addition of GCV and greatly exceeded 
the cytotoxicity of replication-incompetent IG.AdApt.TK combined with GCV. In established 
s.c. U87 MG glioma xenografts, a single injection of IG.Ad5E1+.E3TK resulted in a 
significant slowing of tumor growth and prolonged survival compared with injection of 
IG.AdApt.TK. Addition of GCV slowed tumor growth, further adding to survival. In 
conclusion, the oncolytic effect of replicating adenoviral vectors and HSV1-tk/GCV have 
potent antitumor effects in gliomas. When combined, these two approaches are 
complementary, resulting in a significantly improved treatment outcome. In addition, 
replicationcompetent adenoviral vectors missing the E3 gp19K coding sequences, have 
oncolytic efficacy comparable with wild type. In combination with high expression levels 
obtained with the natural E3 promoter, such vectors are promising new anticancer agents.  
 
 
INTRODUCTION 
 
The incidence of primary brain tumors in the Western world is 9–10/100,000 persons and 
7/100,000 die of brain tumors each year (1, 2). In children, brain tumors constitute a quarter 
of all cancer deaths, second only after leukemia (3). In adults, malignant gliomas are the most 
common primary brain tumors, and despite advances in neurosurgical techniques, radiation 
treatment, and chemotherapy, the prognosis of these tumors remains dismal, with a median 
survival of <1 year; and <5% survive for 5 years or more (4–6). Limitations of surgery, 
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radiotherapy, and chemotherapy make the development of new treatment strategies necessary 
(7). Despite the fact that individual tumor cells spread through the brain at great distances 
from the primary site (8, 9), ~80% of malignant gliomas recur within a 2-cm margin of the 
contrast-enhancing rim on computed tomography (10, 11). This high rate of local recurrence 
within the region of the original tumor, combined with the very low incidence of distant 
metastases, warrants the additional pursuit of locoregional treatment strategies including gene 
therapy. Gene therapy for brain tumors has demonstrated efficacy in a variety of animal 
models using many different vector systems, including retrovirus (12), adenovirus (13) adeno-
associated virus (14), herpes virus (15), and reovirus vectors (16). Despite promising results 
in experimental studies, clinical gene therapy trials in brain tumor patients have generally 
been disappointing. A Phase III study of adjuvant gene therapy in 248 patients with 
glioblastoma multiforme could not demonstrate any benefit of the injection of HSV-tk3 
retrovirus vector-producing cells (17). A much smaller, Phase I, study of adeno.tk injection 
into malignant gliomas demonstrated that the approach was safe but not very effective (18). A 
small, uncontrolled trial of HSV-tk gene therapy in malignant gliomas demonstrated better 
efficiency of replication-deficient adenovirus vector compared with a retrovirus vector (19). 
Better efficacy is crucial for adenoviral cancer gene therapy to become clinically relevant. 
Most of the adenoviruses used in the clinical studies thus far carry a deletion in the E1 region 
which renders the virus replication defective or helper-dependent. The efficacy of adenoviral 
vectors could be greatly increased by using replicationcompetent vectors (20). The theoretical 
advantages for the use of replication-competent recombinant adenovirus vector are: (a) the 
cytolytic effect on infected cells; (b) the subsequent spread of virus to neighboring cells, 
resulting in additional tumor/tissue penetration; (c) an enhanced immune response; and (d) 
higher levels of expression of the therapeutic gene are achieved as a result of the replication 
of adenovirus DNA. For safety reasons, all replication competent adenoviral vectors are 
conditionally replicating, usually by small deletions in the E1A or E1B gene. These 
modifications may, however, decrease efficiency of viral replication, whereas, in the past, 
intratumoral injection of wild-type adenoviruses has not led to unwanted effects (21). To 
enhance further the tumoricidal effect of the replication-competent vectors and to provide a 
“fail-safe” in case of replication outside the tumor, we left E1 intact and placed the HSV1-tk 
suicide gene in E3 under control of the natural E3 promoter. We then examined the antitumor 
efficacy of  the nonconditional replication-competent adenoviral vectors in a panel of glioma 
cell lines and in an animal model. We could demonstrate a direct lytic effect of the vectors in 
human cell lines and in vivo that was enhanced further by the suicide HSV1-tk/GCVsystem. 
 
 
MATERIALS AND METHODS 
 
Cell Lines 
The human glioma cell lines U87 MG, T98G, and A172 were obtained from the American 
Type Culture Collection (Manassas, VA). The LW5 and U251 human glioma cell lines were 
obtained from Dr.  Langeveld (Department of Pharmacology, Free University Hospital 
Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was 
a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital 
Amsterdam; Ref. 13). The A549 human lung carcinoma cell line was purchased from 
Biowhittaker (Brussels, Belgium; Ref. 13). PC3, a human prostate cell line (22), and human 
embryonic kidney 293 cells (HEK-293) were purchased from the American Type Culture 
Collection. All cell lines were grown in DMEM (Life Technologies, Inc., Breda, the 
Netherlands) containing 10% fetal bovine serum (Life Technologies, Inc.), 100 units/ml 
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penicillin, and 100 µg/ml streptomycin (Life Technologies, Inc.) and cultured at 37°C in a 
5%-CO2 atmosphere. 
 
Virus Constructions 
Fig. 1 shows the structure of the different viruses used in this study. 
 
Fig. 1. Scheme of nonconditional, replicationcompetent adenoviral vectors and replication-incompetent control 
adenoviral vectors. 
 
Nonconditional Replicating Viruses. 
 IG.Ad5E1+. E3Luc and IG.Ad5E1+.- E3TK are replication-competent Ad5-based viruses in 
which the luciferase gene and the HSV1-tk gene, respectively, replace the gp19K coding 
sequence in the E3 region. IG.Ad5E1+. E3_is a replicating vector in which the gp19K gene in 
the E3 region is deleted. Coding sequences of the adenovirus death protein (E3–11.6K) were 
not disrupted (data not shown). The IG.Ad5E1+.E3TK vector was generated as follows: a 2.7 
kb EcoRI fragment from wtAd5 containing the 5’ part of the E3 region was cloned into the 
EcoRI site of pBluescript (KS- ; Stratagene). Next, the HindIII site in the polylinker was 
removed by digestion with EcoRV and HincII and subsequent religation. The resulting clone, 
pBS.Eco-Eco/ad5∆HIII, was used to delete the gp19K coding region. Primers 1 (5’-GGG 
TAT TAG GCC AA AGG CGC A-3’) and 2 (5’-GAT CCC ATG GAA GCT TGG GTG 
GCG ACC CCA GCG-3’) were used to amplify a sequence from pBS.Eco-Eco/ad5∆HIII 
corresponding to sequences 28511–28734 in wtAd5 DNA. Primers 3 (5’-GAT CCC ATG 
GGG ATC CTT TAC TAA GTT ACA AAG CTA-3’) and 4 (5’-GTC GCT GTA GTT GGA 
CTG G-3’) were used on the same DNA to amplify Ad5 sequences from 29217 to 29476. The 
two resulting  PCR fragments were ligated together by virtue of the new introduced NcoI site 
and subsequently digested with XbaI and MunI. This fragment was then ligated into the pBS. 
Eco-Eco/ad5_HIII vector that was digested with XbaI (partially) and MunIgenerating 
pBS.Eco-Eco/ad5_HIII._gp19K. To allow insertion of foreign genes into the HindIII and 
BamHI site, an XbaI deletion was made in pBS.Eco- Eco/ad5.∆HIII.∆gp19K to remove the 
BamHI site in the pBS polylinker. The resulting plasmid pBS.Eco-
Eco/ad5∆HIII∆gp19K_XbaI, contains unique HindIII and BamHI sites corresponding to 
sequences 28733 (HindIII) and 29218 (BamHI) in Ad5. The HSV1-TK gene was then 
introduced as a HindIII-BamHI fragment into these sites, generating pBS.Eco-Eco/ 
Ad5.∆HindIII.∆gp19K.∆Xba.TK. After digestion of this construct with MunI and HindIII, the 
TK-containing fragment was then introduced into pBS.Eco-Eco/ad5∆HIII.∆gp19K, 
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generating pBS.Eco-Eco/Ad5.∆HindIII∆gp19k/TK. The unique SrfI and NotI sites in this 
plasmid were used to transfer the region comprising the TK gene into the corresponding 
region of pBr/Ad.Bam-rITRsp, yielding construct pBr/Ad.Bam-rITR.gpTKsp. pBr/Ad.Bam-
rITRsp is a pBr322-based vector containing adenoviral sequences from Ad nucl.21562  
(BamHI site) to the end of the right ITR, the latter being flanked by a unique PacI site. The 
last step entailed the subcloning of the SpeI-PacI fragment from pBr/Ad.Bam-rITR.gpTKsp 
into the cosmid vector pWE.Ad5.AflII-rITRsp. pWE.Ad5.AflII-rITRsp is an pWE15- 
(CLONTECH) based cosmid clone containing Ad nucl.3534 to the right ITR flanked by PacI 
sites. The final construct, pWE.Ad5.AflII-rITRgpTKsp, was made by ligating the 
PacIdigested cosmid backbone with a PacI-SpeI fragment corresponding to the Ad 
nucl.3534–27082 from  pWE.Ad5.AflII-rITRsp and the SpeI-PacI fragment from 
pBr/Ad.Bam-rITR.gpTKsp. The ligation mixture was packaged in λ-phage packaging extracts 
(Stratagene) according to the manufacturer’s protocol and introduced into DH5α cells to 
isolate cosmid DNA. To generate the IG.AdE1+.E3TK virus, one additional construct was 
made that contains the 5’ end of the Ad5, including the E1 region. Construct pBr.AdLITR-
Sal(9.4) is a pBR322-based construct that contains adenovirus sequences from nucl. 1 to 9462 
(SalI site). Transfection of pBr.AdLITRSal( 9.4) digested with SalI and pWE.Ad5.AflII-
rITRgpTKsp digested with PacI into PER.C6 packaging cells generates viruses through 
recombination of the overlapping sequences in both constructs.  
 
E1-deleted Viruses. IG.Ad5.ClipLuc and IG.AdApt.TK are E1-deleted Ad5-based viruses 
containing the luciferase or the HSV-1 TK gene, respectively, driven by the human CMV 
promoter in the former E1 region. The CMV promoter in IG.AdApt.TK spans nt -735 to nt 
+95 (numbering according to Ref. 23), whereas in IG.Ad5.ClipLuc, a shorter version of the 
CMV promoter is present (nt -601 to nt +14). Furthermore, IG.AdApt.TK lacks the SV40 
intron sequences that are present in IG.Ad5.ClipLuc. Both expression cassettes are terminated 
by the SV40 polyadenylation sequence. IG.Ad5.Sarcoma 1800HSA.E3Luc contains the 
mouse HSA gene (24) driven by a Molony murine leukemia virus long terminal repeat 
fragment (including the retroviral splice donor and splice acceptor site) in the former E1 
region. In addition, the gp19K coding sequence in the E3 region is replaced by the luciferase 
gene as in the replicating virus IG.Ad5E1+.E3Luc. All viruses were produced on PER.C6 cells 
(25). After one round of plaque purification, viruses were amplified further on PER.C6 cells. 
Cells and viruses were harvested 2–3 days after the final amplification in triple-layer flasks, 
and viral particles were purified by a two-step CsCl gradient. Virus particles in purified virus 
batches were determined by high-performance liquid  chromatography (26), and IU were 
determined by end-point titration on 911 cells (27). Virus particles:IU ratios were in all cases 
<30. m.o.i. is expressed as IU/cell. 
 
in Vitro Replication 
To assess replication, we determined the CPE in cultured cell lines after infection with the 
various vectors. Cells were plated in 6-well plates at a density of 105 cells/well. Twenty-four h 
after plating, the cells were infected with the vectors at m.o.i. of 0, 1, or 10. The number of 
days from infection to full CPE or 100% cell death was scored. As positive controls for 
replication, we used the constitutively Ad5 E1-expressing cell line 293 (28) and wtAd5. The 
nonpermissive rat gliosarcoma cell line 9L was used as negative control. All experiments 
were performed in triplicate. In a separate experiment, we tested the potential of HSV1-tk in 
combination with GCV as a “fail-safe” for adenoviral replication. A549 cells were seeded in 
24-well plates at a density of 105 cells/well. Twenty-four h after plating, the cells were 
incubated with IG.Ad5E1+.E3TK or IG.Ad5E1+. E3_ for 2 h at m.o.i. of 0, 0.1, or 1. Cells 
were treated immediately with GCV (Roche, Mijdrecht, Netherlands) or PBS. The medium 
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was refreshed every day, and GCV was kept at a concentration of 10 µg/ml. CPE was scored 
daily, and cell viability was assessed quantitatively at days 3, 6, and 8 using the XTT-assay 
following the manufacturer’s instructions (Sigma Chemical Co., St. Louis, MO). 
 
In Vitro Luciferase Expression 
Cells were plated in 6-well plates at a density of 105 cells/well. After 24 h, the cells were 
infected with the vectors at a m.o.i. of 0, 0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, or 100. Forty-eight h 
after infection, the cells were harvested using Trypsin-EDTA (Life Technologies, Inc.). The 
cells were washed twice with PBS (Life Technologies, Inc.). After the last wash, the cells 
were resuspended in 100 µl Reporter lysis buffer (Promega, Madison, WI). After 
centrifugation at 14,000 rpm for 5 min, the luciferase activity was measured in the 
supernatant. The protein content of the supernatant was measured, and the luciferase 
activity was expressed as relative light units/µg of protein. All experiments were performed in 
triplicate. 
 
In Vitro GCV Sensitivity 
U87 MG cells were plated in 6-well plates at a density of 105 cells/well. After 24 h, the cells 
were infected with the replication-competent and –incompetent vectors carrying the HSV1-tk 
transgene at m.o.i. of 1 and 10. Forty-eight h after infection, the cells were treated with GCV 
(Roche) or PBS for 7 days. Day 0 is the start of treatment with GCV or PBS. The medium 
was refreshed every day, and GCV was kept at a concentration of 10 µg/ml. At days 1–6, the 
living cells were counted using trypan blue exclusion (29). To calculate the percentage of 
living cells, we divided the number of cells in the experimental wells by the number of cells 
in the control wells (no vector, no GCV; x100%). All experiments were performed in 
triplicate.  
 
Animal Experiments 
All experimental protocols were approved by the Institutional Animal Care and Use 
Committee, in compliance with the Guide for the Care and Use of Laboratory Animals, 
University Hospital and Erasmus University Rotterdam, The Netherlands. Female Hsd:NIH-
bg-nu-xid mice 5–6 weeks of age were purchased (Ref. 30; Harlan Sprague Dawley, Inc., 
Oxon, England). Mice were hosted 3–4/cage and allowed access to food and water ad libitum. 
After 1 week, 107 U87 MG cells were inoculated s.c. into both flanks in 500 µl of HBSS (Life 
Technologies, Inc.). The tumor growth was assessed by measuring bidimensional diameters 
three times a week with calipers. The tumor volume was determined by using the simplified 
formula of a rotational ellipse (l x width2 x 0.5; Ref. 31). When the tumor reached a volume of 
100–150 mm3, animals were randomly assigned to treatment groups. Animals were treated 
with a single intratumoral injection of adenovirus 109 IU suspended in 100 µl of PBS or 100 
µl of PBS alone as a control. GCV 100 mg/kg (or PBS) was administered i.p. twice daily for 7 
days beginning 48 h after vector inoculation. The animals were killed by isoflurane when their 
tumors reached a volume of >4000 mm2 or after 60 days. Each treatment group consisted of a 
minimum of three animals (six tumors).  
 
Statistical Analysis 
Data were analyzed using GraphPad Prism version 3.0 software (GraphPad Software, Inc., 
San Diego, CA, 1999). The CPE induced by replicationcompetent IG.Ad5E1+. E3Luc and 
IG.Ad5E1+.E3TK and wtAd5 in the human cell lines were compared and analyzed by 
repeated-measures ANOVA, and posttest analysis was performed using Dunn’s multiple 
comparison test.  The various treatment strategies testing in vitro U87 MG survival were 
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compared side by side and analyzed for significance on days 2 and 6 by Student’s t test. 
Statistical significance of various vector and treatment combinations in vivo were analyzed by 
Student’s t test for normally distributed values and by nonparametric Mann-Whitney test in 
the case of non-normal distribution. All tests were performed two-sided, and P < 0.05 was 
considered statistically  significant. 
 
 
RESULTS 
 
Replication of E1+ Adenoviral Vectors.  
Full CPE was scored on a variety of cell lines (Table 1). Application of all vectors containing 
the wild-type E1 sequences resulted in full CPE at m.o.i. of 1 and 10. This indicates that 
deletion of the gpigK coding sequences in the E3 region had not affected the oncolytic effect 
of the vectors. As expected, no CPE occurred on the nonpermissive rat gliosarcoma 9L cell 
line. On 293 cells, all vectors, replication competent and deficient, gave full CPE within 2 
days after infection. The efficacy of replication of the E1-containing vectors is similar to 
wtAd5, as measured by the time after infection to full CPE at m.o.i. 1 (ANOVA; P =0.19) and 
m.o.i. 10 (ANOVA; P= 0.49). The duration to full CPE seems to be dose dependent 
(ANOVA; P< 0.002). In the posttest analysis, only infection with IG.Ad5E1+. E3Luc resulted 
in significantly shorter time to CPE at m.o.i. 10 than at m.o.i. 1 (P < 0.05). The shorter time 
to CPE after infection with IG.Ad5E1+.E3TK and wtAd5 at m.o.i. 10 versus 1 did not reach 
statistical significance (P < 0.05). The time to full CPE differed largely between cell lines. 
This may indicate more efficient infection or replication in certain cell lines. In the fail-safe 
experiment, the A549 cells that were treated with GCV, immediately after infection with 
IG.Ad5E1+.E3TK remained 96 (m.o.i., 0.1) to 98% (m.o.i., 1) viable whereas the cells treated 
with PBS were only 10 (m.o.i ,1; full CPE) to 38% (partial CPE) viable at day 8 (Fig. 2). The 
A549 cells infected with the replicating empty control vector IG.Ad5E1+. E3- had 
significantly reduced viability at day 8 (full CPE at m.o.i. 1 and partial CPE at m.o.i. 0.1) 
irrespective of treatment with GCV; Fig. 2). These results show that GCV can inhibit the 
replication and subsequent spread of IG.Ad5E1+.E3TK, and that the inhibition of adenoviral 
replication by GCV is HSV1-tkdependent. 
 
In Vitro Luciferase Expression.  
Luciferase expression using the E1+.E3luc replication-competent vector was compared with 
two nonreplicating vectors containing the luciferase transgene in either E1 (driven by a 
modified CMV-promoter) or in E3 (driven by the E3 promoter, as in the replication-
competent vector). The two nonreplicating vectors gave similar luciferase expression levels in 
most cell lines, indicating that the internal E3-promoter is of comparable strength with the 
modified CMV-promoter (Fig. 3). However, at the same m.o.i., the replication-competent 
vector yielded luciferase expression levels that were ~3 log higher than with both 
nonreplicating vectors in all human glioma cell lines tested (U87 MG, T98G, A172, and 
LW5). Alternatively, to obtain a similar expression level, 2–3 log  less IU of the replication-
competent versus the nonreplicating vectors could be used. The A549 cell line showed the 
same pattern as the human glioma cell line. In the nonpermissive rat 9L cell line, expression 
levels with the replication- competent vector were ~1 log higher than with the nonreplicating 
vectors, indicating that some low-level 
replication may occur. 
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In Vitro GCV Sensitivity of U87 MG Cells.  
Results of GCV sensitivity of U87 MG cells, after infection with m.o.i. 10 and 1, are 
summarized in Fig. 4. The addition of GCV at a concentration of 10 µg/ml in the absence of 
adenoviral vectors was not cytotoxic to U87 MG cells (data not shown). Infection with 
nonreplicating control vector IG.AdApt.TK and then the addition of PBS caused no 
significant cytotoxicity on days 2–6 at both m.o.i. (P > 0.1). However, infection with 
replication-competent IG.Ad5E1+.E3TK and then PBS resulted in a significant reduction of 
the percentage of surviving cells compared with IG.AdApt.TK at day 6 [m.o.i. of 1, P= 0.04 
(Fig. 4A); m.o.i. of 10, P< 0.0001 (Fig. 4B)]. Addition of GCV further increased the 
 cytotoxicity of IG.Ad5E1+.E3TK. After infection with IG.Ad5E1+.E3TK at a m.o.i. of 1, the 
percentage of surviving cells subsequent to GCV treatment was significantly lower than  fter 
PBS, on both day 2 (P < 0.0002) and day 6 (P< 0.0001; Fig. 4A). After infection with the 
replicating vector at m.o.i. 10, the number of surviving cells was significantly lower with 
GCV than with PBS on day 2 (P <  0.004), whereas no surviving cells remained on day 6 in 
both groups (Fig. 4B). 
 
We then compared the percentage of surviving cells after infection with either the replication-
incompetent or replicating HSV1-tkcontaining vectors in combination with GCV 
administration. After infection with m.o.i. 1, the percentage of surviving cells was 
significantly lower with the replication-competent  IG.Ad5E1+.E3TK compared with the 
nonreplicating vector at both day 2 (P= 0.04) and day 6 (P = 0.0002; Fig. 4A). After infection 
with m.o.i. 10, the percentage of surviving cells was already low in both groups at day 2 (P = 
0.3), and at day 6, no cells had survived either treatment (Fig. 4B). 
 
In Vivo Treatment of U87 MG Xenografts in bg-nu-xid Mice. 
Treatment results of s.c. U87 MG xenografts in bg-nu-xid mice are summarized in Fig. 5 and 
Table 2, A–C. The growth curve of tumors treated with PBS and then i.p. PBS was identical 
to the growth curve of tumors treated with IG.AdApt.TK and then PBS. Compared with these 
control curves, the intratumoral injection of replication-competent IG.Ad5E1+.E3TK gave 
slowing of tumor growth, resulting in significantly reduced tumor size at days 6, 11, 18, and 
27 (Table 2A and Fig. 5). The oncolytic effect of  IG.Ad5E1+.E3TK was strongly enhanced 
by the administration of GCV, resulting in additional slowing of tumor growth and smaller 
tumor size at days 6, 11, 18, and 27 (Table 2B and Fig. 5). Compared with the combination 
treatment of IG.AdApt.TK and then GCV, replication-competent IG.Ad5E1+.E3TK and then 
GCV was significantly more effective (Table 2C and Fig. 5). Survival curves demonstrate 
prolonged survival of mice treated with IG.Ad5E1+.E3TK in combination with GCV (Fig. 6).  
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 U87MG T98G A172 LW5 A549 PC3 293 9L 
m.o.i. = 10         
IG.Ad5E1+.E3Luc 7 10 3 6 3 5 2 - 
IGAd5E1+.E3TK 6 10 4 7 3 7 2 - 
wtAd5 6 10 4 7 3 5 2 - 
IG.Ad5.S1800HAS.E3Luc - - - - - - 2 - 
IGAdApt.TK - - - - - - 2 - 
         
m.o.i. = 1         
 IG.Ad5E1+.E3Luc 8 11 4 10 6 6 2 - 
IGAd5E1+.E3TK 7 11 6 10 4 8 2 - 
wtAd5 7 11 4 7 4 6 2 - 
 IG.Ad5.S1800HAS.E3Luc - - - - - - 2 - 
IGAdApt.TK - - - - - - 2 - 
 
 
Table 1 Cytopathogenic effect of replication-competent adenoviral vectors  
Cytopathogenic effect of replication-competent adenoviral vectors (IG.Ad5E1+.-E3Luc and  IGAd5E1+.E3TK) is 
compared with wtAd5 and nonreplicating E1-deleted adenoviral vectors (IG.Ad5.S1800HAS.E3Luc and 
IGAdApt.TK) on human glioma cells (U87MG, T98G, A172, and LW5), human lung carcinoma cells (A549), 
human prostate cancer cells (PC3), and a rat glioma cell line (9L). The cells were infected with the adenoviral 
vectors at a m.o.i. of 10 or 1. The days from infection to full CPE are scored. - indicates that no full CPE was 
reached at the end of the experiment, 14 days after infection. Time to full CPE is comparable between wild-type 
and replicationcompetent adenoviral vectors. As expected, no CPE occurred on the nonpermissive rat 9L glioma 
cell line. On the constitutively E1- expressing 293 cell line, all vectors, including the E1-deleted vectors, reached 
full CPE. 
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Fig. 2. Replication of adenovirus vectors containing the HSV1-tk gene is effectively blocked by GCV. A549 
cells were infected at a m.o.i. of 0.1 and 1 with the replication-competent vectors IG.Ad5E1+.E3TK or 
IG.Ad5E1+. The cells infected with IG.Ad5E1+.E3TK and immediately treated with GCV remain almost 100% 
viable. Cells transfected with IG.Ad5E1+.E3TK and subsequently treated with PBS and the cells infected with 
IG.Ad5E1+ (and then either GCV or PBS) are significantly less viable. 
 
 
 
 
. 
Fig. 3. Forty-eight h after infection, the luciferase expression was measured in the human glioma cell lines U87 
MG, T98G, LW5, and A172; the human lung cancer cell line A549; and the nonpermissive rat glioma cell line 
9L. Expression levels with the replication-competent vector IG.Ad5E1+. E3Luc are in the permissive cell lines 3 
log higher than with the replication-incompetent vectors. The expression levels obtained with nonreplicating 
IG.Ad5.ClipLuc (luciferase in E1 driven by a modified CMV promoter) and IG.Ad5.Sarcoma 1800HSA.E3Luc 
(luciferase in E3 driven by the internal E3 promoter) are comparable with each other in most cell lines. , 
IG.Ad5.ClipLuc; , IG.Ad5.S1800HSA.E3Luc; , IG.AdE1+.E3Luc. 
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Fig. 4. In vitro GCV sensitivity of U87 MG glioma cells. Forty-eight h after infection with m.o.i. of 1 (A) or 10 
(B), cells were exposed to PBS or GCV (10 µg/ml). Surviving cells were counted on days 2 and 6 using trypan 
blue exclusion and expressed as a percentage of cells in the control wells. Compared with controls, infection 
with replication-competent vector expressing the HSV1-tk gene (IG.Ad5E1+.E3TK) is more toxic than the 
nonreplicating vector expressing HSV1-tk (IG.AdApt.TK) in combination with PBS. The addition of GCV 
significantly increases the cytotoxicity of both IG.Ad5E1+.E3TK and IG.AdApt.TK. At the lower m.o.i., 
IG.Ad5E1+.E3TK in combination with GCV is more toxic than IG.AdApt.TK. At m.o.i. = 10, both vectors are 
highly effective, killing almost all cells. , no vector/PBS; , IG.AdApt.TK/PBS; , IG.AdApt.TK/GCV; , 
IG.AD5E1+.E3TK/PBS; , IG.AD5E1+.E3TK/GCV. 
 
DISCUSSION 
To improve the efficacy of E1-deleted adenoviral vectors, we constructed several replication-
competent  adenoviral vectors carrying both E1A and E1B sequences and the HSV1-tk suicide 
gene. The HSV1-tk and luciferase genes replaced the coding sequence of the E3 region 
gp19K that binds to class I MHC in the endoplasmic reticulum, preventing antigen 
presentation on the cell surface (32). The transgenes were placed under control of the natural 
E3 promoter, because heterologous promoters were found to be silent when inserted in this 
area (33–35). To examine the transgene expression levels obtained from the internal E3 
promoter, we also constructed an E1-deleted vector carrying the luciferase gene in E3. The 
luciferase expression obtained with this construct was similar to a first-generation, E1- deleted 
vector carrying the luciferase gene in E1 driven by a modified CMV-promoter, indicating the 
strength of the natural E3 promoter in these constructs, even in the absence of E1. Another 
concern was the potential disruption of the adenovirus death protein (E3–11.6K) by our 
cloning strategy. Adenovirus death protein is produced in large amounts at the late stage of 
infection and is required for effective cell lysis and virus release (36). However, the oncolytic 
effect of the gp19K-deleted, replicating vectors was similar to wtAd5, as measured by the 
time after infection to full CPE. The time to full CPE with both wtAd5 and the replication-
competent vectors differed largely between the tested cell lines. The time to CPE seemed not  
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to correlate with the level of luciferase expression, indicating that the efficacy of replication 
may not only depend on the efficacy of cell entry. Elucidating mechanisms affecting the 
efficiency of adenoviral replication in different cell lines requires additional study to enhance 
replication potentially (37). As expected, the replication-competent vectors and wtAd5 did not 
cause CPE in the nonpermissive 9L rat gliosarcoma cell line. 
We then compared the luciferase expression levels of the E1+luciferase vector with both E1-
deleted vectors and found that luciferase expression was ~3 logs higher with the E1+ vector in 
all permissive (human) cell lines tested. Similar expression levels were obtained with ~2 log 
lower m.o.i. of the E1+ vector. Interestingly, infection of the nonpermissive 9L cell line with 
the E1+ vector resulted in significantly higher luciferase expression than with the E1-deleted 
vectors. This may indicate either low-level replication of the E1+ vector in the rodent cell line 
or transactivation of the E3 promoter by E1 proteins. Apart from the direct oncolytic effect on 
tumor cells (38), replication- competent vectors may enhance further the antitumor efficacy 
by increased expression levels of a tumoricidal transgene. To test this hypothesis, we 
examined the antitumor efficacy of E1+ and E1- deleted vectors carrying the HSV1-tk suicide 
gene. In vitro, the E1+ HSV1-tk vector demonstrated cytotoxicity to the U87 MG glioma cell 
line that was greatly enhanced by the addition of GCV. The latter combination was also 
significantly more toxic than infection with the E1-deleted HSV1-tk control vector and then 
GCV. In vivo, a single injection of the replicative E1+ HSV1-tk vector in established s.c. U87 
MG xenografts resulted in a significant slowing of tumor growth. The addition of GCV 
resulted in additional slowing of tumor growth and significantly prolonged survival. Also, the 
E1+ HSV1-tk vector in combination with GCV was significantly more effective than the E1-
deleted HSV1-tk vector with GCV. Replication-competent adenoviral vectors are a new and 
rapidly evolving platform for gene therapy (39). In the past, intratumoral injection of wild-
type adenoviruses has not led to unwanted effects (21). However, “virotherapy” for cancer 
was abandoned because of only a few documented responses and because of the advent of 
more effective chemotherapeutic agents (20). Bischoff et al. (38) reintroduced the oncolytic 
effect of adenoviruses with vectors carrying mutations in the early region of the encoding 
E1B-Mr 55,000. These vectors only replicate in cells with a deficient p53 pathway and cause 
specific cytolysis after intratumoral and i.v. administration (40). Subsequently, an additive 
effect of HSV1-tk/GCV and radiotherapy to the oncolytic effect of E1B-deleted vectors was 
demonstrated (41, 42). The use of conditional replicating vectors that contain deletions in E1B 
(or E1A) carries the risk of reduced replication as compared with wtAd5. The present study 
demonstrates that even vectors replicating as well as wtAd5 don’t cause tumor eradication in 
some models. Therefore, addition of a therapeutic transgene is probably mandatory, and genes 
with improved bystander and cytotoxic effects may add further to the efficacy of replicating 
vectors (43). The toxic genes, such as the HSV1-tk gene, can also function as a fail-safe 
mechanism when replication outside the tumor occurs (41). Here, we demonstrated that 
adenoviral replication and subsequent spread can be effectively blocked by the immediate 
administration of GCV. The complex interactions between viral replication and GCV require 
additional in vivo studies to determine the optimal interval between vector injection and first 
GCV administration. In clinical studies, conditional replication will be required for patient- 
and biosafety. An alternative for selective replication is to drive the E1B or/and E1A genes by 
a tissue or tumor-specific promoter. Such vectors may replicate in target tissue (and tumor) 
even better than wtAd5. Examples include the use of enhancer/promoter sequences of the 
prostate specific antigen gene to drive E1A in prostate cancer (44), the α- fetoprotein 
promoter in hepatocellular carcinoma (45), and the DF3/ MUC1 promoter in breast cancer 
(46). In the present study, we have demonstrated that the addition of the HSV1-tk/GCV 
suicide system enhances the tumoricidal efficacy of replication competent adenoviral vectors 
in glioma cell lines and after intratumoral injection in a glioma xenograft model. The use of a  
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suicide gene has the additional advantage of fail-safe in case of spread of the vector outside 
the tumor. Safety will be increased further by conditional replication, for instance by using a 
glia-specific promoter such as the gfa2 promoter, to drive the E1A gene (47). 
 
 
 
Fig. 5. Growth of U87 MG glioma xenografts in nude mice. U87 MG cells (107) were inoculated s.c. into both 
flanks in 500 µl of HBSS. When the tumor reached a volume of 100–150 mm3, animals were treated with a 
single intratumoral injection with 109 IU of replication-competent IG.Ad5E1+.E3TK, 109 IU of nonreplicating 
IG.AdApt.TK, or PBS. GCV (or PBS) was administered i.p. twice daily for 7 days (days 2–9). No difference was 
observed in tumor growth in animals treated with PBS/PBS IG.AdApt.TK/PBS; addition of GCV to animals 
treated with IG.Ad5E1+.E3TK resulted in a significant slowing of tumor growth; addition of GCV to animals 
treated with IG.AdApt.TK also resulted in a slowing of tumor growth, although to a lesser extent than the 
combined treatment with replication-competent IG.Ad5E1+.E3TK and GCV. , PBS/PBS; 
, IG.AdApt.TK/PBS; , IG.Ad5E1+.E3TK/PBS; , PBS/GCV; 
, IG.AdApt.TK/GCV; , IG.Ad5E1+.E3TK/GCV. 
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Table 2 
A. Replication-competent IG.Ad5E1+.E3TK and then PBS versus control 
Day PBS/PBS IG.Ad5E1+.E3TK/PBS P 
1 85.3 ± 10.2 85.3 ± 10.2 1.0 
6 198.3 ± 51.3 381.9 ± 160.0 0.3 
11 381.6 ± 69.2 204.2 ± 28.7 0.04 
18 723.8 ± 130.0 403.1 ± 71.1 0.05 
27 4299 ± 635.0 2495 ± 517.4 0.05 
 
B. Replication-competent IG.Ad5E1+.E3TK and then PBS or GCV 
Day IG.Ad5E1+.E3TK/PBS IG.Ad5E1+.E3TK/GCV P 
1 85.3 ± 10.2 62.5 ± 0.6 0.2 
6 381.9 ± 160.0 12.8 ± 4.9 0.002 
11 204.2 ± 28.7 1.3 ± 0.8 0.002 
18 403.1 ± 71.1 0.03 ± 0.02 0.002 
27 2495 ± 517.4 124.7 ± 77.7 0.002 
 
C. Replication-competent IG.Ad5E1+.E3TK versus nonreplicating IG.AdApt.TK and then 
GCV 
Day IG.AdApt.TK/GCV IG.Ad5E1+.E3TK/GCV P 
1 85.4 ± 12.7 62.5 ± 0.6 0.2 
6 217.0 ± 61.1 12.8 ± 4.9 0.002 
11 223.0 ± 78.2 1.3 ± 0.8 0.002 
18 345.7 ± 181.9 0.03 ± 0.02 0.002 
27 855.3 ± 385.7 124.7 ± 77.7 0.06 
31 2547 ± 689.1 614.2 ± 314.9 0.06 
 
Table 2 U87MG xenograft tumor growth after adenoviral vector treatment 
Nude mice carrying s.c. U87MG glioma xenografts were treated with a single injection of 109 IU adenoviral 
vector or PBS and then by either GCV or PBS (days 2–9). Administration of replication-competent 
IG.Ad5E1_.E3TK and then PBS results in significant reduction in tumor growth, indicating a direct oncolytic 
effect of the vector (A). Administration of GCV significantly enhances the growth suppression by the 
replication- competent vector (B). The replication-competent vector is more effective than the nonreplicating 
vector in combination with GCV. Tumor volumes (mm3) are expressed as mean ±SE, and each treatment group 
was composed of at least six tumors. 
D. Nanda – Gene Therapy for Malignant Gliomas Pagina 42 van 145 42 
 
Fig. 6. Kaplan-Meier survival analysis of nude mice with s.c. U87 MG xenografts. To establish s.c. tumors, mice 
were inoculated s.c. in both flanks with U87 MG cells (107) in 500 µl of HBSS. The tumor growth was assessed 
by measuring bidimensional diameters, and when the tumor reached a volume of 100–150 mm3, animals were 
assigned randomly to a single intratumoral injection with 109 IU of replication-competent IG.Ad5E1+.E3TK, 109 
IU of nonreplicating IG.AdApt.TK, or PBS. GCV 100 mg/kg (or PBS) was administered i.p. twice daily for 7 
days beginning 48 h after vector inoculation. The animals were killed by isoflurane when the tumors reached a 
volume of >4000 mm2 or after 60 days. Animals treated with replication-competent IG.Ad5E1+.E3TK and GCV 
lived significantly longer than animals treated with IG.Ad5E1+.E3TK alone or with nonreplicating IG.AdApt.TK 
combined with GCV. 
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CHAPTER 4 
 
 
 
Imaging expression of adenoviral HSV1-tk suicide gene transfer using 
the nucleoside analogue FIRU 
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Abstract.  
Substrates for monitoring HSV1-tk gene expression include uracil and acycloguanosine 
derivatives. The most commonly used uracil derivative to monitor HSV1-tk gene transfer is 1-
(2-fluoro-2-deoxy- -D-arabinofuranosyl)-5-[*I]iodouracil (fialuridine; I*-FIAU), where the 
asterisk denotes any of the radioactive iodine isotopes that can be used. We have previously 
studied other nucleosides with imaging properties as good as or better than FIAU, including 
1-(2-fluoro-2-deoxy- -Dribofuranosyl)-5-[*I]iodouracil (FIRU). The first aim of this study 
was to extend the biodistribution data of 123Ilabelled FIRU. Secondly, we assessed the 
feasibility of detecting differences in HSV1-tk gene expression levels following adenoviral 
gene transfer in vivo with 123IFIRU. 9L rat gliosarcoma cells were stably transfected with the 
HSV1-tk gene (9L-tk+). 123I-FIRU was prepared by  radioiodination of 1-(2-fluoro-2-deoxy- -
D-ribofuranosyl)-5-tributylstannyl uracil (FTMRSU; recursor compound) and purified using 
an activated Sep-Pak column. Incubation of 9L-tk+ cells and the parental 9L cells with 123I-
FIRU resulted in a 100-fold higher accumulation of radioactivity in the 9L-tk+ cells after an 
optimum incubation time of 4 h. NIH-bg-nu-xid mice were then inoculated subcutaneously 
with HSV1-tk (–) 9L cells or HSV1-tk (+) 9L-tk+ cells into both flanks. Biodistribution studies 
and gamma camera imaging were performed at 15 min and 1, 2, 4 and 24 h p.i. At 15 min, the 
tumour/muscle, tumour/blood and tumour/brain ratios were 5.2, 1.0 and 30.3 respectively. 
Rapid renal clearance of the tracer from the body resulted in increasing tumour/muscle, 
tumour/blood and tumour/brain ratios, reaching values of 32.2, 12.5 and 171.6 at 4 h p.i. A 
maximum specific activity of 22%ID/g tissue was reached in the 9L-tk+ tumours 4 h after 
123I-FIRU injection. Two Ad5-based adenoviral vectors containing the HSV1-tk gene were 
constructed: a replication-incompetent vector with the transgene in the former E1 region, 
driven by a modified CMV promoter, and a novel replication-competent vector with the 
HSV1-tk gene in E3 driven by the natural E3 promoter. The human glioma cell lines U87MG 
and T98G were infected with a multiplicity of infection (m.o.i.) of 10. Forty-eight hours later 
the cells were incubated with 123I-FIRU and radioactivity was measured in a gamma counter. 
We found significantly higher levels of radioactivity in both cell lines following infection 
with the replication-competent vector (P<0.001). NIH-bg-nu-xid mice were then inoculated 
subcutaneously with U87MG cells. Tumours (approximately 1,000 mm3) were injected with 
108 and 109 Infectious Units (I.U.) of either vector. After 48 h, the tracer was injected, 
followed by gamma camera imaging and direct measurement of radioactivity in the tumours 
at 4 h p.i. Images and direct measurements indicated increased uptake of tracer with higher 
I.U. and also demonstrated increased accumulation of tracer in the tumours treated with the 
replication-competent adenoviral vector (P=0.03). These results demonstrate that 123I-FIRU in 
combination with HSV1-tk is a valuable tracer for in vivo monitoring of adenoviral gene 
transfer.  
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Introduction 
A non-invasive, clinically applicable method for imaging the expression of successful gene 
transduction in target tissue or specific organs of the body would be of considerable 
value. It would facilitate the monitoring and evaluation of gene therapy in human subjects by 
defining the location, magnitude and persistence of gene expression over time [1]. The herpes 
simplex virus I thymidine kinase reporter gene (HSV1-tk) has been explored by several groups 
for the purposes of imaging reporter gene expression [2, 3, 4, 5, 6, 7, 8, 9]. HSV1-tk has a 
substantially broader specificity than the corresponding mammalian enzyme. For this reason, 
it has been possible to develop highly effective, low-toxicity anti-herpes virus agents such as 
acyclovir and ganciclovir. This difference in specificity has made HSV1-tk an excellent choice 
for gene therapy, both as a cytotoxic (e.g. suicide gene therapy) and as a reporter mechanism. 
The HSV1-tk/ganciclovir system is the current standard for suicide gene therapy for cancer 
[10, 11]. After introduction of the HSV1-tk transgene into the cell followed by administration 
of ganciclovir, the HSV1-tk will phosphorylate ganciclovir to ganciclovir monophosphate. 
Cellular enzymes further metabolise the phosphorylated ganciclovir to ganciclovir 
triphosphate [12]. Other nucleoside analogues are phosphorylated in a similar manner by 
HSV1-tk [13]. Once phosphorylated, ganciclovir and similar nucleoside analogues are trapped 
in the cell. The accumulation of the phosphorylated nucleoside analogues in the HSV1-tk 
transfected cells offers the possibility to image the gene transfer by employing radiolabelled 
pharmaceuticals. A good candidate for imaging HSV1-tk with PET is fluorine-18 labelled 
ganciclovir [8, 9]. However, 18F has a very short half-life and the production of 18F-
ganciclovir requires proximity to a cyclotron. The first published compound for HSV1-tk 
imaging in vitro and in animal models was the nucleoside analogue FIAU or fialuridine [1]. 
Long-term treatment of chronic hepatitis B with pharmacological doses of FIAU proved 
severely toxic in humans [14]. Incorporation of FIAU in mitochondrial DNA resulted in lactic 
acidosis, liver failure and pancreatic and neurotoxicity [15]. However, although no toxicity is 
expected when using tracer amounts of radiolabelled FIAU as calculated by Tjuvavjev et al. 
[2], systemic  toxicity implies phosphorylation by non-transduced tissues and thereby implies 
some reduction of selectivity for viral TK-expressing tissues. In theory, since FIAU is also 
phosphorylated by normal tissue, the radiolabelled form can be expected to be phosphorylated 
and trapped by both normal and transduced tissues. We have studied several related 
compounds with high specificity for HSV1-TK: FMAU, IVFRU and FIRU [16, 17]. In vitro 
toxicity studies revealed that the IC50 in non-HSV1-TK expressing cell lines was 2–450 times 
higher for FIRU than for FIAU while the IC50 was 2–8 logs higher in HSV1-TK  expressing 
cells, indicating the greater toxicity of phosphorylated FIAU compared with FIRU in 
replicating cells. We have demonstrated that the uptake ratio of transduced HSV1-TK 
expressing cells and non-transduced cells is better with FIRU than with FIAU. Using FIRU, 
we detected no  incorporation of the phosphorylated compound into the DNA [16]. This could 
indicate that the monophosphate is not converted to the di- or triphosphate, or alternatively 
that the triphosphate is a poor substrate for the DNA polymerase The nucleoside analogue 
FIRU therefore does not have potential for suicide gene therapy, but this property makes it an 
ideal candidate for imaging where information on gene expression is desired without affecting 
future gene expression. Like other nucleoside analogues, FIRU can be labelled with 
radioactive iodine isotopes for single-photon emission tomography (SPET) or positron 
emission tomography (PET) imaging. Iodine-123 was chosen for imaging in these studies 
because of the 13.3-h half-life and favourable imaging characteristics [18]. In the present 
study we demonstrate that 123I-labelled FIRU in combination with a gamma camera is a 
valuable tracer for imaging HSV1-tk gene expression. In addition, with 123I-FIRU it was 
possible to demonstrate in vivo the increased HSV1-tk expression levels obtained with a  
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replication-competent adenoviral vector as compared with an older E1-deleted adenoviral 
vector. 
 
Materials and methods 
Cell culture. 
U87MG and T98G human glioma cell lines were purchased from the American Type Culture 
Collection (ATCC, Manassas, Va.). The rat 9L gliosarcoma brain tumour cell line was a gift 
from Dr. K.M. Hebeda (Dept. of Experimental Neurosurgery, Free University Hospital 
Amsterdam, The Netherlands). 9L cells were stably transfected using an HSV1-tk carrying 
retrovirus construct followed by G418 selection [19]. Clones were further selected for GCV 
sensitivity. All cell lines were grown in Dulbecco’s modified Eagle medium (Life 
Technologies, Breda, The Netherlands) containing 10% foetal bovine serum (Life 
Technologies), 100 units/ml penicillin and 100 µg/ml streptomycin (Life Technologies) at 
37ºC in a 5% CO2 atmosphere. The 9L-tk+ cell line was grown in the presence of G418 (250 
µg/ml) (Life Technologies). 
 
Vectors. 
IG.Ad5.E1+.E3TK is a replication-competent Ad5-based virus in which the HSV1-tk gene 
replaces the gp19K coding sequence in the E3 region (Fig. 1). IG.AdApt.TK is an E1-deleted 
Ad5-based virus containing the HSV1-tk gene driven by the human CMV promoter in the 
former E1 region. The CMV promoter in IG.AdApt.TK spans nt –735 to nt +95 (numbering 
according to [20]). Furthermore, IG.AdApt.TK lacks the SV40 intron sequences. The 
expression cassette is terminated by the SV40 polyadenylation sequence. Figure 1 shows the 
schematic structure of the two viruses used in this study. Expression levels obtained from the 
modified CMV promoter are comparable to expression with the natural E3 promoter [21]. 
Both viruses were produced on PER.C6 cells [22]. After one round of plaque purification, 
viruses were further amplified on PER.C6 cells. Cells and viruses were harvested 2–3 days 
following the final amplification in triple layer flasks and viral particles were purified by a 
two-step CsCl gradient. Virus particles (VP) in purified virus batches were determined by 
HPLC [23] and Infectious Units (I.U.) were determined by endpoint titration on 911 cells 
[24]. VP/I.U. ratios were lower than 30 in all cases.  
 
Synthesis of 1-(2-fluoro-2-deoxy- -d-ribofuranosyl)-5-tributylstannyl 
uracil (FTBSRU) (precursor compound).  
1-(2-Fluoro-2-deoxy- -D-ribofuranosyl)-5-iodouracil (FIRU) was prepared as previously 
described [25]. (Ph3P)4Pd(0) (10 mg, 0.008 mmol) and Bu3SnSnBu3 (0.16 ml, 0.30 mmol) 
were added with stirring to a solution of FIRU (4.0 mg, 0.0107 mmol) in dry dioxane (5 ml), 
and the reaction mixture was stirred for 16 h at 100°C under an atmosphere of argon, at which 
time TLC analysis indicated the reaction was completed. The catalyst precipitated as a black 
solid. Removal of the solvent in vacuo and purification of the residue by silica gel column 
chromatography with methanol-chloroform (1:20, v/v) as eluent afforded FTBSRU as a 
colourless oil (23 mg, 40% yield).  
 
Carrier-added radioiodination and purification of FIRU.  
Labelling of FIRU was adapted from Wiebe et al. [16].  FTBSRU (100 µg) was dissolved in 
10 µl ethanol/acetic acid (v/v; 50/50), vortexed and microcentrifuged. ICl was dissolved in 
ethanol/acetic acid (v/v; 50/50) at a concentration of 1 mg/ml, and 25 µl (25 µg ICl) was 
mixed with 12.5 µl (185 MBq) 123I. The FTBSRU precursor solution was added, the mixture 
was incubated at room temperature for 10 min and then the labelling mixture was pushed 
through an activated Sep-Pak column (activated with 5 ml 2-propanol, rinsed with 5 ml H2O). 
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 Free iodine is first eluted in 15 ml of H2O, followed by elution of FIRU in 50% ethanol (v/v 
ethanol/ H2O). The FTBSRU precursor eluted in 99% ethanol. The mean labelling yield was 
56.4% and the radiochemical purity was >97% (data not shown).  
 
Cellular uptake of 123I-FIRU. 
9L and 9L-tk+ cells were plated in six-well plates at a density of 105 cells per well. When 
cells had reached 80%–100% confluency, each well was incubated with 2 MBq of 123I-
labelled FIRU for 1, 2, 4, 6, 8 and 24 h. Free radioactive 123I-FIRU was removed from the 
cells with two PBS (Life Technologies) washes. In a separate experiment, 123I-FIRU was 
washed off the cells 4 h after incubation, followed by collection of cells, 6, 8 and 24 h after 
incubation. The cells were then harvested and lysed with 0.1 M NaOH (Life Technologies). 
Radioactivity in the lysate was determined using a LKB Wallac 1282 Compugamma gamma 
counter (LKB Instruments, Inc., Gaithersburg, Md.) and corrected for decay. Total protein 
content was determined in the lysate [26] and radioactivity was expressed as counts per 
minute/mg protein. All experiments were performed at least in triplicate. The U87MG and 
T98G cells were plated in six-well plates at a density of 105 cells per well. After 24 h the cells 
were transfected with the replication-competent and replication-incompetent adenoviral 
vectors carrying the HSV1-tk transgene at a multiplicity of infection (m.o.i.) of 10. Forty-eight 
hours after infection, each well was incubated with 2 MBq of 123I-labelled FIRU for 4 h. 
Subsequently, we performed the same procedure as with the 9L and 9L-tk+ cells. 
 
Animal experiments.  
The Institutional Animal Care and Use Committee, in compliance with the Guide for the Care 
and Use of Laboratory Animals, approved all experimental protocols. Five- to 6-week-old 
female NIH-bg-nu-xid mice were purchased [27] (Harlan Sprague Dawley Inc., Oxon., UK). 
Mice were hosted three to four per cage and allowed access to food and water ad libitum. 
After 1 week, 9L, 9L-tk+ or U87MG cells (107 cells in 500 µL HBSS; Life Technologies) 
were inoculated subcutaneously into both flanks. Tumour growth was assessed by measuring 
bidimensional diameters three times a week with callipers. The tumour volume was 
determined using the simplified formula of a rotational ellipse (l x w2 x 0.5) [28]. When the 
9L and the 9L-tk+ tumours had reached a volume of approximately 1,000 mm3, 3 MBq 123I-
FIRU was injected intravenously into the tail vein. To correlate biodistribution results with 
gamma camera images, acquisition of images was performed at 15 min and 1, 2, 4 and 24 h 
after 123I-FIRU injection. At each time point at least four animals were examined. Mice were 
anaesthetized with pentobarbital sodium 15 min before acquisition and placed in a spread 
supine position under the camera. For imaging, a Siemens Rota II gamma camera system 
(Siemens, Erlangen, Germany) equipped with a low-energy high-resolution collimator was 
used. 
 
Biodistribution of 123I-FIRU. 
Biodistribution of 123I-FIRU was determined 15 min and 1, 2, 4 and 24 h after 3 MBq 123I-
FIRU injections in mice carrying either 9L or 9L-tk+ subcutaneous xenografts. Four mice 
were examined at each time point. Tumour, brain, thyroid gland, heart, lungs, stomach, 
kidney, spleen, skin, muscle, femur and blood were collected and weighed, and radioactivity 
was determined in the gamma counter. The radioactivity is expressed as percentage of the 
injected dose/g organ (%ID/g) [6].  
 
Imaging of adenoviral HSV1-tk gene transfer into U87MG xenograft.  
In vivo evaluation of adenoviral HSV1-tk gene transfer was performed in nude mice carrying 
U87MG xenografts in the right flank. Once the tumour had reached a volume of 1,000– 1,500  
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mm3, animals were injected with replication-competent or -incompetent adenoviral vectors 
carrying the HSV1-tk gene, or with PBS. The adenoviral vectors (108 or 109 I.U.) were 
injected into the tumour in 100 µl of PBS. After 48 h, 3 MBq 123I-FIRU was injected 
intravenously and images were acquired 4 h later using the gamma camera with 10 min 
acquisition time. The animals were sacrificed, the tumour was taken out and weighed, and 
radioactivity was determined in the gamma counter. Each treatment group consisted of at least 
four animals. 
 
Statistical analysis.  
Data were analysed using GraphPad Prism version 3.0 software (GraphPad Software, Inc., 
San Diego, Calif., 1999). The uptake of 123I-FIRU by the HSV1-tk expressing cell line 9L-tk+ 
and the parental 9L cell line was compared at all time points with and without removal of 123I-
FIRU from the medium, using ANOVA. 123I-FIRU uptake in U87MG and T98G cells 
following transfection with replication-competent and non-replicating adenoviral vectors was 
compared with controls using ANOVA. Post-hoc analysis was performed with Tukey’s 
Multiple  Comparison Test. In vivo uptake of 123I-FIRU by 9L-tk+ tumours was compared 
with uptake by 9L tumours at all time points by unpaired Student’s t test. The medians of in 
vivo uptake of 123I-FIRU by U87MG xenografts following infection with replication-
competent and non-replicating were compared with each other and with controls using the 
Kruskal-Wallis test. 
 
 
 
 
Fig. 1. Scheme of replication-competent and non-replicating adenoviral vectors. Ad5 is a wild-type adenovirus 5 vector. 
IG.Ad5.E1+.E3TK is a replication-competent adenoviral vector carrying the HSV1-tk gene in E3, replacing the gp19K coding 
sequence, and is driven by the native E3 promoter. IG.AdApt.TK is an E1-deleted Ad5-based vector containing the HSV1-tk 
gene in the former E1 region driven by an adapted CMV promoter. 
 
Results 
Cellular uptake of 123I-FIRU in constitutively HSV1-tk expressing cells  
Figure 2 demonstrates the selective uptake and retention of 123I-FIRU by 9L-tk+ cells as 
compared with the parental 9L cells (ANOVA, P<0.001). The maximum difference between 
the two cell lines occurs at around 4 h of incubation (>2 log difference). Removal of 123I-
FIRU from the medium after 4 h of incubation has no effect on the 123I-FIRU retention in 
HSV1-TK expressing cells atthe later time points (6, 8 and 24 h), indicating entrapment of 
labelled FIRU in the cells, probably by phosphorylation (Tukey’s Multiple Comparison Test, 
P>0.05). 
 
In vivo uptake of 123I-FIRU by constitutively HSV1-tk expressing tumours 
Animals carrying established tumours (either 9L or 9Ltk+) were injected with 123I-FIRU, and 
after imaging (Fig. 3) the animals were sacrificed and the radioactivity in the tumours was 
measured at various time points (Table 1). At all time points, the accumulation of 123I-FIRU 
was significantly higher in the HSV1-tk expressing 9Ltk+ tumours as compared with the 9L  
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tumours (t test: 15 min, P=0.02; 1 h, P=0.0002; 2 h, P=0.0002; 4 h, P=0.0007; 24 h, P=0.03). 
The specific activity in the 9Ltk+ tumours was calculated by subtracting the background 
activity in HSV1-tk negative 9L tumours (Table 1). A maximum specific activity of 22%ID/g 
tissue was reached 4 h after 123I-FIRU injection.  
 
123I-FIRU biodistribution 
Biodistribution studies again show the high and selective uptake of 123I-FIRU in HSV1-tk 
expressing  9L tumours as compared with the parental 9L tumours and other tissues (Table 1). 
In the first hour after injection, 123I-FIRU levels are highest in peripheral blood and in the 
kidney (renal excretion). Also, the radioactivity levels in stomach and thyroid are relatively 
high, indicating in vivo  deiodination. The calculated ratios of 123I-FIRU uptake in 9L-tk+ 
tumours compared with muscle, blood and brain are depicted in Table 2.  
 
Cellular uptake of 123I-FIRU following adenoviral transfection of the HSV1-tk gene 
Infection of U87MG and T98G cells with replicationcompetent IG.Ad5.E1+.E3TK at the 
relatively low m.o.i. of 10 resulted in strong labelling of both cell types with 123I-FIRU 
(ANOVA, both cell lines, P<0.0001) (Fig. 4). In contrast, labelling was significantly lower 
with the replication-incompetent vector IG.AdApt.TK when compared directly with the 
replication-competent vector in 
both U87MG and T98G cells (Tukey’s Multiple Comparison Test, P<0.001 for both cell 
lines).  
 
In vivo uptake of 123I-FIRU following adenoviral intratumoural HSV1-tk gene transfer in 
U87MG Xenografts  
Two days after the injection of both adenoviral vectors into large U87MG s.c. xenograft 
tumours, we could identify the tumours with a gamma camera (Fig. 5). Following imaging, 
the animals were sacrificed and the radioactivity in the tumours was determined and 
expressed as %ID/g tumour tissue. The results of the directly measured radioactivity 
accumulation in the tumours correlated with the gamma camera images (Fig. 5, Table 3). We 
then analysed the dose of the adenoviral vectors used on the one hand and the use of 
replication-competent versus non-replicating virus on the other hand. The differences (Table 
3) were significant (Kruskal-Wallis test, P=0.03), with higher median 123I-FIRU uptake in the 
tumours injected with the replication-competent vector versus the non-replicating vectors, and 
higher uptake in the tumours  injected with the higher dose (m.o.i. 9 vs m.o.i. 8). 
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Fig. 2. Results of in vitro uptake of 123I-FIRU in rat 9L glioma cells that constitutively express the HSV1-tk gene (9L-tk+) 
compared with uptake in non-expressing parental cells (9L). Each well was incubated with 2 MBq of 123I-labelled FIRU for up 
to 24 h. Cells were harvested and lysed, and the radioactivity was measured in a gamma counter. In a separate experiment, 
the FIRU was removed from the medium after 4 h of incubation. Uptake of radioactive FIRU was >2 log higher in the 9L-tk+ 
ells (P<0.001). Removal of 123I-FIRU from the medium after 4 h of incubation did not affect sequestration of radioactivity in 
the cells (P>0.05) 
 
 
 
 
 
 
Fig. 3. Gamma camera images of NIH-bg-nu-xid mice bearing 9L and 9L-tk+ xenografts, 4 h after i.v. administration of 3 
MBq 123I-FIRU. The 9L-tk+ tumours are clearly visualized whereas the 9L control tumours are at background  level. Th, 
Thyroid; St, stomach; Bl, bladder 
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Table 1. Biodistribution of 123I-FIRU in NIH-bg-nu-xid mice carrying HSV1-tk positive (9L-
tk+) or HSV1-tk negative (9L) tumours 
Time 
p.i. 
9L-tk+ 
tumour 
9L 
tumour 
Specific 
activitya Liver Spleen Lung Skin Kidney 
15 min 13.5±3.2 3.5±0.1 10.0±3.3 2.9±0.3 3.3±0.7 4.6±0.4 3.7±0.8 6.4±0.9 
1 h 20.1±2.2 2.3±0.2 17.8±2.4 1.4±0.04 1.4±0.1 2.3±0.2 2.1±0.3 2.9±0.2 
2 h 20.8±2.4 1.4±0.2 19.4±2.6 1.3±0.2 2.1±0.8 1.7±0.4 2.0±0.8 2.5±0.6 
4 h 23.3±3.4 1.3±0.3 22.0±3.7 1.0±0.3 1.5±0.3 1.3±0.3 1.2±0.3 1.5±0.3 
24 h 3.1±0.6 0.06±0.01 3.0±0.6 0.04±0.007 0.05±0.004 0.07±0.005 0.08±0.008 0.07±0.01 
 
Time p.i. Heart Femur Muscle Thyroid Stomach Blood Brain 
15 min 3.5±0.3 2.2±0.2 2.6±0.3 4.1±0.7 4.6±0.6 13.7±6.8 0.5±0.2 
1 h 2.5±0.4 1.0±0.1 1.2±0.1 3.1±0.4 5.5±0.7 13.4±3.8 0.6±0.3 
2 h 2.0±0.4 0.9±0.2 1.1±0.4 1.8±0.4 4.6±1.2 2.1±0.5 0.2±0.05 
4 h 1.0±0.2 0.7±0.2 0.7±0.2 2.2±0.3 6.0±1.0 1.2±0.4 0.1±0.04 
24 h 0.05±0.01 0.04±0.005 0.04±0.005 0.3±0.07 0.7±0.14 0.1±0.05 0.03±0.02 
Values are expressed as mean of the %ID/g tissue ±SE (n=4) 
a"Specific activity" is calculated by subtracting the background activity in HSV1-tk negative 
9L tumour from the activity in the 9L-tk+ tumour 
 
Fig. 4. Results of in vitro uptake of 123I-FIRU in human glioma cells U87MG and T98G. 
Cells were transfected with replication-competent adenoviral vector IG.Ad5.E1+.E3TK or the 
non-replicating IG.AdApt.TK at a multiplicity of infection (m.o.i.) of 10. Forty-eight hours 
after infection, each well was incubated with 2 MBq of 123I-labelled FIRU for 4 h. Cells were 
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then harvested and lysed, and radioactivity was measured in a gamma counter. Differences in 
radioactivity between the three treatment groups were highly significant in both cell lines 
(P<0.0001). Uptake of 123I-FIRU was significantly higher following infection with the 
replication-competent adenoviral vector as compared with the non-replicating vector 
(P<0.001, both cell lines) 
Table 2. Ratios of 123I-FIRU uptake in NIH-bg-nu-xid mice carrying HSV1-tk positive (9L-
tk+) tumours. Tumour/blood, tumour/muscle and tumour/brain ratios were calculated at 
various time points 
 Tumour/muscle Tumour/blood Tumour/brain 
15 min 5.2 1.0 30.3 
1 h 16.3 1.5 32.9 
2 h 18.2 10.0 114.3 
4 h 32.3 19.4 171.6 
24 h 78.7 31.9 122.1 
 
 
Table 3. Tumour uptake of 123I – FIRU, two days after adenoviral injection. Values are the 
ratio of the %ID/gram tissue of tumour divided by %ID/gram of skin and are expressed as 
median (range) of at least 4 tumours per group. Tumours were injected with a multiplicity of 
infection (moi) of 8 or 9 of either the replication competent or nonreplicating adenoviral 
vectors containing the HSV1-tk gene. 
 
Ad.tk 
vector: 
Nonreplicating  Replication 
competent 
Nonreplicating  Replication 
competent 
Control P 
Vector dose 108 I.U. 108 I.U. 109 I.U. 109 I.U. -  
median 
(range) 
1.2  
(0.9 – 2.3) 
3.0 
(1.9 – 9.7) 
3.0  
(1.6 – 3.8) 
4.2  
(1.6 – 8.5) 
1.1  
(1.1 – 1.5) 
0.03 
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Fig. 5. Gamma camera images of tumour-bearing NIH-bg-nuxid mice, 4 h after i.v. 
administration of 3 MBq 123I-FIRU. Two days before imaging, the tumours had been 
injected with PBS (right), 108 I.U. replication-competent HSV1-tk adenovirus (left) or 109 I.U. 
of nonreplicating HSV1-tk adenovirus (middle). The tumour is better visualized in animals 
treated with the lower dose (108 I.U.) of replication-competent HSV1-tk adenovirus than in 
animals injected with a higher dose (109 I.U.) of non-replicating virus. Th, Thyroid; Tu, 
tumour; St, stomach; Bl, bladder 
 
 
Discussion 
Interest in non-invasive imaging for measuring therapeutic transgene expression is growing 
with the  increasing clinical application of gene therapy. Methods used for “molecular 
imaging” include the use of techniques based on bioluminescence [29] and magnetic 
resonance imaging and spectroscopy [30], and the use of radionuclides followed by PET or 
SPET scanning. So far, radionuclide imaging of transgene expression makes use of marker 
genes encoding cell surface receptors such as the type 2 somatostatin [31] and dopamine type 
2 receptors [32], or genes encoding enzymes that selectively metabolise the radionuclide 
tracer to cause intracellular sequestration [2, 3, 4, 5, 6, 7, 8, 9]. The most frequently used 
therapeutic gene in cancer gene therapy is the HSV1-tk gene [11], and various radiotracers 
based on uracil nucleosides and acycloguanosine derivatives have been proposed for the non-
invasive imaging of HSV1-tk gene expression. In a comparative study, we found that FIRU 
provided optimal performance in terms of selectivity for HSV1-tk expressing cells compared 
with the nucleoside analogues FIAU and IVFRU [16]. In this study we determined the value 
of 123I-FIRU for imaging of HSV1-tk expression, and found a highly significant accumulation 
of 123I-FIRU in constitutively HSV1-tk expressing tumours. Following adenoviral transfer of 
the HSV1-tk gene in tumour xenografts, expression of the transgene could be visualised in 
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vivo with a gamma camera. The accumulation of 123I-FIRU increased with larger amounts of 
virus injected and the use of a replication-competent adenovirus. Using the 9L rat glioma cell 
line stably transfected with the HSV1-tk gene, a 100-fold increase in the uptake of 123I-FIRU 
compared with the parental cell line was reached at an optimum of 4 h of incubation. The 
subsequent removal of 123I-FIRU from the medium did not result in substantial loss of 
intracellular 123I-FIRU, indicating efficient sequestration probably caused by effective 
phosphorylation. Biodistribution studies demonstrate selective accumulation of 123I-FIRU in 
HSV1-tk expressing tumours with 23.3% ID/g of 9L-tk+ tumour tissue, 4 h after tracer 
injection. This accumulation compares favourably with the 10.5% ID/g of 125I-FIAU and 
0.15% ID/g of 18F-FHPG [(3-fluoro-1-hydroxy-2-propoxy) methyl guanine] reported for a 
similar model using the TK  expressing murine fibrosarcoma cell line CMS-STK in BALB/c 
mice [33]. The specific accumulation of radioactivity at 4 h is 22% ID/g (calculated by 
subtracting the non-specific accumulation of radioactivity in non-transduced 9L tumours from 
the total radioactivity measured in the 9L-TK tumours) and is higher than the specific 
accumulation obtained with either 125I-FIAU (9.8% ID/g) or 18F-FHPG (0.08% ID/g) [33]. 
Four hours after tracer injection, the ratios of 123I-FIRU uptake in tumour to blood, muscle 
and brain were 19.4, 32.3 and 171.6 respectively. Using 125I-FIAU, Haubner et al. [6] reported 
tumour to blood and tumour to muscle ratios at 4 h p.i. of 32.0 and 88.3. In a more recent 
paper by the same group [33] 125I-FIAU ratios at 4 h p.i., calculated from Table 1, reveal a 
tumour to blood ratio of 24.4 and a tumour to muscle ratio of 21. These results indicate that a 
direct comparison of FIAU and FIRU as substrate for gene imaging is warranted. 
The high ratio with normal brain may make FIRU and similar compounds suitable for 
imaging gene transfer in brain tumours. However, Jacobs et al. [34] demonstrated that 
iodinated FIAU does not penetrate the intact bloodbrain barrier in cats. In a patient with 
recurrent glioblastoma, substantial levels of 124I-FIAU-derived radioactivity were found in 
brain, indicating that the blood-brain barrier in these tumours is disrupted [35]. This study 
demonstrates the feasibility of obtaining relevant levels of radioactivity to image HSV1-tk 
gene expression with SPET or PET following gene therapy of glioblastomas. However, the 
demonstrated uptake in non-transduced tumour also indicates that increased background 
activity may be expected. The high early radioactivity levels in the kidneys demonstrate the 
rapid clearance of 123I-FIRU through the kidneys, similar to 124/125I-FIAU [33, 35]. Early 
radioactivity levels in thyroid and stomach indicate some systemic de-iodination of 123I-FIRU. 
The in vivo stability of FIRU relative to related 5-substituted nucleosides that do not contain 
the 2 -fluoro group has been demonstrated before [25]. We then studied the sequestration of 
123I-FIRU in the human glioma cell lines U87MG and T98G following infection with two 
adenoviral vectors carrying the HSV1-tk transgene.  IG.Ad5.E1+.E3TK is a replication-
competent Ad5-based virus that we constructed to amplify the antitumour efficacy of 
adenovirus-based gene therapy [36]. IG.Ad5.E1+.E3TK results in more efficient cell kill than 
IG.AdApt.TK, an E1-deleted Ad5-based virus containing the HSV1-tk gene driven by the 
human CMV promoter in the former E1 region [36]. Because rodent cells are not permissive 
for adenoviral replication, the evaluation of the performance of replication-competent 
adenoviral vectors requires the use of human cell lines and tumour xenograft models. Here, 
we have demonstrated that the accumulation of 123I-FIRU in U87MG and T98G cells was 
significantly higher following infection with the replication- competent adenovirus compared 
to the non-replicating vector. To investigate the possibility of detecting differences in HSV1-tk 
gene expression levels in vivo we injected U87MG xenografts with either 108 or 109 I.U. of 
replication- competent  IG.Ad5.E1+.E3TK and non-replicating IG.AdApt.TK. Following 
injection of 123I-FIRU, we found that the accumulation of radioactivity was higher in the 
tumours injected with 109 I.U. of either virus compared to the tumours injected with 108 I.U. 
Also, the tumours injected with the replication-competent virus showed higher radioactivity 
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levels than tumours injected with the non-replicating vector. These findings correlate with 
images obtained with the clinical gamma camera and demonstrate the feasibility of detecting 
differences in HSV1-tk expression levels using 123I-FIRU in vivo following adenoviral gene 
therapy. In conclusion, 123I-FIRU accumulates highly selectively in tumour expressing the 
HSV1-tk gene either constitutively or following adenoviral gene transfection. In vivo imaging 
of the level of HSV1-tk expression is possible and will be valuable in both animal studies as in 
ongoing clinical trials. Future studies will compare the imaging characteristics of tracers that 
accumulate in the cell following HSV1-tk transfection with those obtained with tracers 
directed at transfected cell surface receptors such as the type 2 somatostatin receptor. 
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CHAPTER 5 
 
 
 
[123I]FIRU, a tracer for the ‘molecular imaging’ of HSV1-tk suicide 
gene transfer 
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Abstract 
Several radiopharmaceuticals have been proposed for in vivo imaging of the Herpes simplex 
virus-1 thymidine kinase (HSV1-tk) gene expression. We compared the in vitro toxicity of 
FIRU to the related compounds GCV (ganciclovir), FIAU and IVFRU. Furthermore, in vivo 
images using small animal SPECT, biodistribution, early kinetics and toxicity of FIRU were 
examined. Methods: The cytotoxicity of the compounds was determined in cell lines 
constitutively expressing the HSV1-tk gene and non-expressing maternal cell lines, using the 
MTT assay. Small animal SPECT images, biodistribution and early kinetics of [123I]FIRU 
were examined in nude mice carrying 9L and 9L-tk subcutaneous tumors. The in vivo toxicity 
of FIRU was tested in mice and rats. Results: In vitro toxicity studies demonstrated lower 
toxicity of FIRU as compared to FIAU in both non-HSV1-TK expressing cells (IC50 ratio 
3.8–500) and in HSV1-TK expressing cells (IC50 ratio 1.7-2 x 107). SPECT images using 
[123I]FIRU were able to visualize HSV-tk expression in mouse xenografts in vivo. 
Biodistribution and early kinetics studies of [123I]FIRU in tumor bearing mice showed initial 
phase and terminal phase half-lives of respectively 0.8 h and 1.3 h (blood); 0.1 h and 4 h 
(muscle); and 0.5 h and 6.7 h (9L tumor). In 9L-tk+ tumors, [123I]FIRU accumulated for about 
one hour, followed by a slower decrease of activity with a half-life of 11.3 h. Mice and rats 
receiving up to 200 times the projected clinical dose showed no toxicity. Conclusions: The 
favorable toxicity and imaging profile make radiolabeled FIRU a promising agent for imaging 
of HSV1-tk gene transfer in clinical studies. 
 
Introduction 
 
Interest in non-invasive imaging and quantification of therapeutic transgene production is 
growing with increasing clinical applications of gene therapy1-3. The most commonly used 
methods for ‘molecular imaging’ of gene transfer are based on radionuclide’s followed by 
PET or SPECT scanning4. Radionuclide imaging of transgene expression makes use of 
marker genes such as the cell surface gene of the human somatostatin receptor type 2 
(hSSTR2)5,6, genes encoding transporter proteins including the sodium/iodide symporter7, or 
genes encoding enzymes that selectively metabolize the radionuclide tracer resulting in 
intracellular sequestration such as the herpes simplex virus type 1 thymidine kinase (HSV1-
tk) gene8-13. The HSV1-tk gene is the most frequently used therapeutic gene in cancer gene 
therapy14-16. Various radiotracers based on uracil nucleosides and acycloguanosine derivatives 
that are selective substrates for this virus encoded enzyme have been proposed for the non-
invasive imaging of HSV1-tk gene expression. The most commonly used radioiodinated 
substrate for monitoring HSV1-tk gene expression is 1-(2-fluoro-2-deoxy-β-D-
arabinofuranosyl)-5-iodouracil (FIAU; fialuridine)17. Another nucleoside with high sensitivity 
for HSV-TK is 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-thymine (FMAU). Because of 
their severe mitochondrial toxicity in normal cells and fatal toxicity to neurons and liver in 
clinical studies18-23, FMAU and FIAU are not suitable for antiviral therapeutic applications 
but can be used as tracer molecules. Interestingly, the toxicity of FIAU reflects its 
phosphorylation by mammalian nucleoside kinases and subsequent incorporation into 
mammalian DNA21,24,25. Thus, radioiodinated FIAU uptake reflects not only activation by the 
viral kinase (HSV1-TK), but also uptake by mammalian cells not expressing HSV1-TK. This 
limits its selectivity, and may influence sensitivity, depending on the relative activity of the 
viral and mammalian enzymes. 
Other nucleosides with high specificity for HSV1-TK include 1-(2-fluoro-2-deoxy-β-D-
ribofuranosyl)-5-(E)-(2-iodovinyl)-uracil (IVFRU), 1-(2-fluoro-2-deoxy-β-D-ribofuranosyl)-
5-iodouracil (FIRU)11 and 9-(4-fluoro-3-hydroxy-methyl-butyl)guanine (FHGB)26. In a 
comparative study, uptake of FIRU in HSV1-tk expressing cells was similar to uptake of  
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FIAU and IVFRU. Importantly, incorporation of FIRU into nucleic acids was only about one-
tenth the incorporation of FIAU23. Biodistribution studies with [123I]FIRU have demonstrated 
a maximum uptake of 22 % of the injected dose per gram tissue in mice carrying HSV1-tk 
expressing tumor xenografts, and favorable imaging characteristics of [123I]FIRU following 
adenoviral HSV1-tk adenoviral gene transfer in a xenograft tumor model has been 
demonstrated12. The relative performance of several radioiodinated nucleosides in HSV1-tk-
expressing cells depends to some degree on the cell type and the design of the gene cassette23. 
In the present study, we describe a Sep-Pak column-based method for purification of 
radioiodine labeled FIRU that can be easily applied to manufacturing of clinical grade 
batches. We subsequently present small animal SPECT images using [123I]FIRU as a reporter 
probe to visualize HSV-tk expression in mouse xenografts in vivo. Finally, we examined the 
early kinetics of iodine labeled FIRU and its toxicity profile in vitro and in vivo. 
 
Materials and Methods 
 
Compounds 
Ganciclovir (Cymevene; GCV) was purchased from Roche (Mijdrecht, Netherlands). IVFRU, 
FIAU and FIRU were synthesized using literature methods27. The structure formulae of the 4 
compounds are depicted in Fig. 1. Carrier-added (radio)iodination was achieved by 
electrophilic iodination/destannylation of 1-(2-fluoro-2-deoxy-β-D-ribofuranosyl)-5-
tributylstannyluracil (FTBSRU), the FIRU precursor, as previously described12,28. For 
recovery and purification of [123I]FIRU, the labeling mixture was passed through an activated 
Sep-Pak column; iodide was first eluted with H2O, followed by elution of [123I]FIRU in 50 % 
aqueous ethanol and recovery of unreacted FTBSRU precursor in 96 % ethanol. For the in 
vitro and in vivo toxicity experiments, ‘cold’ FIRU was synthesized by a similar procedure, 
but omitting [123I]NaI from the reaction mixture. 
 
HPLC analysis of [123I]FIRU  
An aliquot of eluted [123I]FIRU was diluted with HPLC-solvent, and an aliquot of this 
solution was injected into the HPLC-system (Waters-Instruments (Etten-Leur, The 
Netherlands) using a Partisil 10 column (ODS 4.6 mm x 250 mm; Whatman, Maidstone, 
England). UV-absorbance was measured at 254 nm. The outlet of the UV detector was 
connected to a well-type NaI crystal (Canberra Packard Benelux sa, Zellik, Belgium). 
Isocratic elution (1 mL/min) was carried out using acetonitrile/milliQ-water 10/90 vol %.  
 
Cell culture  
Murine fibrosarcoma KBALB, human osteosarcoma R-970-5 (a TK- mutant of R-970-5) and 
human 143B cell lines were purchased from American Type Culture Collection (ATCC, 
Manassas, VA). The rat 9L gliosarcoma brain tumor cell line was a gift from Dr. K.M. 
Hebeda (Dept. Experimental Neurosurgery, Free University Hospital Amsterdam, The 
Netherlands). The EMT-6 mouse mammary tumor cell line was obtained from the Cross 
Cancer Institute (Edmonton, Canada). The KBALB-STK cell line, which expresses HSV1-tk, 
was obtained from Dr. Scott Freeman (Tulane University Medical Center, New Orleans, 
USA.)29. The 143B and 9L cell lines were stably transfected using an HSV1-tk-carrying 
retrovirus construct, followed by G418 selection (250  g – 1 mg/mL) (Life Technologies, 
Breda, The Netherlands). The corresponding HSV-tk positive cell lines were further selected 
for GCV sensitivity and were named 143B-LTK and 9L-tk+ respectively30,31. Cell lines were 
maintained in Dulbecco’s modified Eagles medium (DMEM; Life Technologies) 
supplemented with 10 % fetal bovine serum (FBS; Life Technologies), penicillin (100 U/mL) 
and streptomycin (100  g/mL). Only EMT-6 cells were routinely maintained in Waymouth  
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medium, and 143B cells were maintained in DMEM containing 5-bromo-2'-deoxyuridine (15 
 g/mL). KBALB-STK, 143B-LTK and 9L-tk+ cells were maintained in medium that had 250 
 g - 1 mg/mL G-418 (Life Technologies) added in addition to FBS and antibiotics. Cells were 
cultured at 37 °C in a 5 % CO2 atmosphere. 
 
MTT Cytotoxicity Assay Method  
Exponentially growing cells were trypsinized, centrifuged and suspended in growth medium 
and readjusted to 8x103 cells/mL. The cells were seeded into 96-well plates at 8x102 cells/well 
and incubated at 37 oC, 5 % CO2 for 24 h. The compounds were dissolved in DMEM medium 
and incubated with the cells in 96-well plates at a volume of 100 µL to produce a final 
concentration of design. Control wells were filled with 100 µL of DMEM medium. The plates 
were incubated for 72 h at 37 oC in a humidified atmosphere containing 95 % air and 5 % 
CO2. At the end of incubation, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide (MTT, Sigma, Zwijndrecht, The Netherlands) was added, and the plates were 
incubated at 37 0C for 4 h. Dimethylsulfoxide was added to dissolve the formazan crystals, 
and the plate wells were then read at 540 nm on a scanning multi-well spectrophotometer. 
 
Animal experiments  
The Institutional Animal Care and Use Committee, in compliance with the Guide for the care 
and Use of Laboratory Animals, approved all experimental protocols. For the biodistribution 
studies, five- to six-week old female NIH-bg-nu-xid mice were purchased32 from Harlan 
Sprague Dawley Inc., Oxon, England. For the animal SPECT experiments two, five- to six-
week old male nu/nu NMRI mice (Charles River, Les Oncins, France) were purchased. Mice 
were hosted 3-4 per cage and allowed access to food and water ad libitum. After one week, 9L 
or 9L-tk+ cells (107 cells in 500  L HBSS; Life Technologies) were inoculated 
subcutaneously into both flanks. Tumor growth was monitored by measuring bidimensional 
diameters three times a week with calipers, and tumor volume was determined by applying 
the simplified formula of a rotational ellipse (l x w2 x 0.5)33. The experiments were performed 
when the 9L and the 9L-tk + tumors had reached a volume of approximately 1000 mm3. For 
the biodistribution experiments, [123I]FIRU (3 MBq) was injected intravenously into the tail 
vein. Biodistribution of [123I]FIRU was determined 15 min, and 1, 2, 4 and 24 h post injection 
(p.i.). Four mice were examined at each time point. Tumor, brain, thyroid gland, heart, lungs, 
stomach, kidney, spleen, skin, muscle, femur and blood were collected, the weight was 
measured and radioactivity was determined in the gamma counter. The radioactivity is 
expressed as percentage of the injected dose / gram organ (%ID/g). 
For the SPECT experiment [123I]FIRU (40 MBq) was injected intravenously into the penis 
vein and the animals were scanned 4 hr later. 
 
SPECT and Software 
SPECT imaging was performed with the four-headed multiplexing multi-pinhole small animal 
SPECT (Bioscan Inc., Washington D.C.). Each head is outfitted with an application specific 
tungsten collimator. For this study we imaged with the 9-pinhole-mouse apertures that are 
comprised of a total of 36 1.3 mm diameter pinholes imaging a cylindrical field of view that is 
32 mm in diameter by 14 mm in length. These mouse apertures provide a reconstruction 
resolution below 1.0 mm at 159 keV with an average sensitivity of 1100 cps/MBq across the 
field of view (FOV). The axial FOV is extended using a step-and-shoot helical scan to 
perform a total body scan of the animal (total distance 85 mm). The energy-peak for the 
camera was set at 159 keV. The window width was ± 10%. An acquisition time of 20 sec. per 
projection was chosen. Acquisition time was 20 min. per animal. After the acquisition the data 
were reconstructed iteratively with the HiSPECT© software (Bioscan Inc., Washington DC),  
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a dedicated ordered subset-expectation maximization (OSEM) software package for 
multiplexing multi-pinhole reconstruction. The SPECT is calibrated with a phantom such that 
voxel values in the reconstruction provide a proper estimate of the activity level without 
further calculation.  
 
In vivo toxicity testing  
Twenty-four male Wistar rats (weight approximately 50 g) and 24 male BALB-c mice (5-6 
weeks old) were purchased from Harlan Sprague Dawley Inc., Oxon, England. Non-
radioactive precursor was iodinated with non-radioactive ICl, followed by Sep-Pak 
purification, as described for [123I]FIRU. For the animal experiments, the ethanol fraction was 
air dried and dissolved in PBS. The FIRU was subsequently administered by tail vein 
injection into the animals, based on the projected dose to be administered to human subjects 
(100 µg of radiolabelled FIRU; nominally 1.4 µg/kg). Rats and mice were divided in 3 groups 
of 8 animals receiving 0, 20 or 200 times the anticipated clinical dose. Animals were observed 
daily and euthanized by pentobarbital sodium injection seven days after FIRU administration. 
Blood was drawn by cardiac puncture for hematological (Hb, Ht, leukocytes and platelets) 
and chemical tests (sodium, potassium, creatinin, ASAT, ALAT, alkaline phosphatase, αGT, 
LDH and amylase). Liver, spleen, pancreas, heart, lungs, kidneys, esophagus, stomach, 
duodenum, bladder, lymph nodes, striated muscle, salivary glands and sciatic nerve were 
dissected out immediately and fixed in formalin. After paraffin embedding, sections were cut 
and stained with H&E and examined by a licensed pathologist (M.K.). 
 
 
Statistical analysis 
The hematological and chemistry parameters in the three dose groups of rats and mice were 
compared using ANOVA. When a significant difference between groups was detected, we 
used post-hoc Dunnett's Multiple Comparison Test to determine the groups that differed 
significantly. All P-values are two-sided and a significance level   = 0.05 was used. All 
statistical analyses were performed using GraphPad Prism version 4.0 software (GraphPad 
Software, Inc., San Diego, CA). 
 
 
Results 
 
Analytic HPLC chromatograms before (a) and after Sep-Pak purification (b) are shown in Fig. 
2. In profile (a), unbound radioactivity, presumably as radioiodide, elutes at the column void 
volume (~1.5 min), and [123I]FIRU is detected at ~ 4 min. Profile (b) is a chromatogram of the 
50 % ethanol Sep-Pak eluant, showing only a single radioactive peak at the FIRU elution 
time. No unreacted FTBSRU was evident in this fraction (by UV detection; data not shown). 
The radiochemical purity was >97 % with a labeling yield of 56 ±10 %; specific activity not 
less than 690 MBq/µmol. This specific activity is lower than achievable using a ‘no carrier’ 
oxidant such as hydrogen peroxide34, but there is no evidence to suggest that this specific 
activity negatively influences uptake. In studies using radioactive IUdR and FIAU, it has been 
reported that uptake in the presence of respective carrier (10 µM) will reduce uptake of 
radioactivity by 3 - 10 fold over a 100 min incubation period34; consequently, in the present 
studies, in which FIRU concentrations are approximately 0.004 µM, little if any effect is to be 
anticipated.  
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In vitro toxicity of FIRU 
Fig. 3 shows the cytotoxicity of increasing concentrations of ganciclovir, FIRU, FIAU and 
IVFRU in the cell lines tested. The relative inhibitory concentration of 50% (IC50)of FIRU 
compared to FIAU and ganciclovir is shown in Table 1. When the compounds are 
phosphorylated (in HSV1-tk expressing cells), FIAU is 7 logs more toxic than FIRU. This 
finding most probably reflects the incorporation of phosphorylated FIAU into cellular DNA 
as opposed to FIRU27 . However, in non-HSV1-tk expressing dividing cells, FIAU is also 
more toxic than FIRU (1-2 logs), presumably reflecting some phosphorylation of FIAU by 
endogenous TK24,25 
 
In vivo imaging of [123I]-FIRU distribution using small animal SPECT 
Animals carrying established 9L tumors in the left flank and 9L-tk+ tumors in the right flank 
were intravenously injected with [123I]-FIRU (40MBq). Four hours later, the animals were 
sacrificed and scanned (Fig. 4). The high-resolution SPECT images clearly visualize the 
uptake of the radiopharmaceutical in the 9L-tk+ tumor, while the 9L tumor remains at 
background level.  
 
Biodistribution and early kinetics of [123I]FIRU 
The biodistribution of [123I]FIRU in 9L-tk+ tumors, 9L tumors, muscle, thyroid, stomach, 
blood and brain at 15 min and 1, 2, 4 and 24 h p.i. (Fig. 5) is compatible with rapid renal 
clearance of the tracer from the body, resulting in increased muscle/muscle, blood/blood and 
brain/brain ratios over time. A maximum tissue uptake of 23 % ID/g tissue was reached in the 
9L-tk+ tumors 4 h after [123I]FIRU injection compared to muscle (<2 %), thyroid (2.2 %), 
stomach (6.2 %), blood (<2 %) and brain (<2 %). The accumulation of radioactivity in thyroid 
and stomach indicates, as reported previously28, some partial de-iodination of [123I]FIRU.  
Blood, muscle and HSV1-tk negative tumors clearly showed bi-exponential elimination 
characteristics (Fig. 6). The half-lives for the initial phase were 0.8 h (blood), 0.1 h (muscle) 
and 0.5 h (9L tumor). The half-lives for the terminal phase were 1.3 h (blood), 4 h (muscle) 
and 6.7 h (wild-type 9L tumor). After an initial accumulation of about one hour of 123I-FIRU 
in the HSV-tk positive 9L-tk+ tumors, the activity decreases more slowly with a half-life of 
11.3 h (Fig 6).   
 
 
 
In vivo toxicity of FIRU 
None of the rats and mice showed clinical signs of disease. Hematological and biochemical 
parameters tested did not differ between animals receiving PBS, 20x or 200x the projected 
human dose of FIRU. Pathological examination of all organs did not demonstrate any 
abnormality indicative of toxicity. 
 
Discussion 
 
This paper describes a simple Sep-Pak based method for the purification of radio-iodinated 
FIRU allowing large scale, clinical grade production. The described carrier-mediated labeling 
method is simple, and purification over a Sep-Pak column is much more convenient than 
preparative HPLC, in particular for the production of clinical grade under GMP conditions. 
Using the described labeling and purification strategy, [123I]FIRU was routinely produced 
with a radiochemical purity > 97 %, a labeling yield of ~ 56 % and a specific activity not less 
than 690 MBq/µmol. The in vitro toxicity of FIRU, FIAU and related compounds was studied 
in a number of cell lines. In constitutively HSV1-tk expressing cell lines, the toxicity of FIRU  
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was significantly lower than FIAU. This lack of toxicity of the phosphorylated FIRU 
compound is most likely due to the fact that FIRU is not incorporated into the DNA of the 
mammalian dividing cell27, as opposed to FIAU24,25. In dividing cells that don’t express 
HSV1-tk, FIRU was also less toxic than FIAU. This difference probably reflects a lower 
affinity of the endogenous TK enzyme for FIRU than for FIAU, but in neither case is uptake 
sufficient to warrant use as a cell proliferation marker35. Uptake of FIAU was reported to be 
about 20-fold higher than that of IUdR in D-247 MG cells, leading those authors to conclude 
that [125I]FIAU might have greater cytotoxicity for this cell line than [125I]IUdR34.  
 
In the past decade significant progress has been made in using PET and SPECT imaging 
methods to detect the expression of specific genes, such as HSV1-tk, in living animals36-38. 
Recently, a multiplexing multi-pinhole small-animal SPECT system has been described with 
greatly improved sensitivity while achieving high resolutions39,40. Using this system, we could 
clearly demonstrate the uptake of FIRU in HSV-tk expressing xenografts (Fig. 4).  
Choi et al41 earlier showed microSPECT images of [123I]FIAU uptake in HSV-tk expressing 
xenografts. These high-resolution SPECT images clearly demonstrated inhomogeneous tracer 
uptake in one of the xenografts, suggesting necrosis of the interior portion of the tumor. In our 
study we did not observe inhomogenous uptake nor did we see necrotic areas on pathological 
examination, probably due to limited tumor size. Progress in nuclear technology and fusion of 
multiple imaging modalities, such as SPECT and CT, will further enhance the sensitivity and 
accuracy of molecular imaging. 
 
The biodistribution (Table 1) and biokinetics (Fig. 5) studies show selective accumulation of 
123I-FIRU in HSV1-tk+ tumors in the first hour after administration. Subsequently, the 
radioactivity incorporated in these tumors decreases with a much longer half-life than in the 
surrounding tissues. The optimal imaging time with [123I]FIRU is 4 h post-injection12,27. 
Finally, in preparation of clinical studies, we performed toxicity studies with ‘cold’ FIRU in 
rats and mice. The injected amount of FIRU per animal was 1x, 20x or 200x fold (mg/kg) of 
the intended human dose for imaging (100  g (0.27  mol) / 70 kg). Because the 
mitochondrial toxicity associated with FIAU manifests mainly as hepatotoxicity, pancreatitis, 
neuropathy or myopathy, we focused on these organs and the hematopoietic system 21. This 
multisystem mitochondrial toxicity is probably caused by the high rate at which FIAU is 
incorporated into mitochondrial DNA42,43. We could detect no clinical, laboratory or 
pathological signs of toxicity due to FIRU. In particular, all liver function tests and amylase 
levels were normal. Pathological examination of liver and pancreas and of the peripheral 
nervous system and muscle was completely normal.  
We conclude that radiolabeled FIRU can be easily produced in clinical grade batches. In 
addition, the safety profile and clear imaging properties make FIRU a good candidate tracer 
for clinical imaging of HSV1-tk gene transfer. 
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Figures  
 
 
 
Fig. 1 Structural formula of ganciclovir (GCV: Mw 255), FIRU (Mw 372), FIAU (Mw 372) and IVFRU (Mw 
398). Note that the only difference between FIAU and FIRU is the 2’-fluoro-arabino (“up”) substitution in FIAU 
versus the 2’-fluoro-ribo (“down”) substitution in FIRU.  
 
 
 
Fig. 2 HPLC analysis of [123I]FIRU. Radiolabeled FIRU elutes from the HPLC column at 4 min. Panel a depicts 
the HPLC result of [123I]FIRU before Sep-Pak purification. Panel b shows HPLC analysis of the 50 % ethanol 
fraction (v/v ethanol/H2O) of the Sep-Pak column, which contains only [123I]FIRU.  
a b 
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Fig. 3 In vitro toxicity of GCV, FIRU, FIAU and IVFRU. At increasing doses, all compounds become toxic in 
all cells. In the HSV1-TK expressing cells, FIRU is clearly less toxic than FIAU, GCV and FIAU. 
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Fig. 4 Small animal SPECT image using [123I]FIRU as reporter probe. 3D-reconstruction of the whole mouse 
acquired by multipinhole SPECT is shown in (a). The transaxial (b), coronal (c) and saggital (d) slices of the 
mouse clearly visualize the HSV-tk positive tumor (9L-tk+) in the left flank. The HSV-tk negative tumor (9L) in 
the right flank remained at back-ground level. Th thyroid; B bladder. 
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Fig. 5 Biodistribution of [123I]FIRU. The percentage of the injected dose per gram of tissue (%ID/g tissue) is 
measured at 15 min and 1, 2, 4 and 24 h after injection. The maximum tumor uptake of 23 %ID/g tissue in 
HSV1-tk expressing tumors is reached four hours after injection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6 Early biokinetics of [123I]FIRU. While the elimination of [123I]FIRU from blood, muscle and HSV1-tk 
negative tumor (9L) is clearly biphasic, the activity accumulates in HSV1-tk positive tumor (9L-tk+) followed 
by a much slower decrease of the incorporated activity. 
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Table 1. Summary of cytotoxicity (IC50 , M) of ganciclovir, FIRU and FIAU in non-HSV1-tk and in HSV1-tk 
expressing cells. 
 
  
IC50 of GCV 
 
IC50 of 
FIAU 
 
IC50 of FIRU 
Ratio IC50  
FIRU:FIAU 
Non-HSV1-TK expressing cells: 
KBALB 
 
4.8 x 10-4 M 
 
1.0 x 10-5 M 
 
1.5 x 10-3 M 
 
150 
143B 1.0 x 10-4 M 2.0 x 10-3 M 7.5 x 10-3 M 3.8 
R-970-5 1.2 x 10-3 M 1.0 x 10-4 M 7.0 x 10-3 M 70 
EMT-6 2.0 x 10-4 M 6.5 x 10-6 M 3.0 x 10-3 M 500 
HSV1-TK expressing cells: 
KBALB-STK 
 
3.0 x 10-8 M 
 
1.0 x 10-10 M 
 
2.0 x 10-3 M 
 
2 x 107 
143B-LTK 6.5 x 10-8 M 3.0 x 10-10 M 5.0 x 10-3 M 1.7 x 107 
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Abstract 
 
Clinical trials in malignant glioma have demonstrated excellent safety of recombinant 
adenovirus type 5 (Ad5) but lack of convincing efficacy. The overall low expression levels of 
the Coxsackie and Adenovirus receptor and the presence of high anti-Ad5- neutralizing 
antibody (NAb) titers in the human population are considered detrimental for consistency of 
clinical results. To identify an adenoviral vector better suited to infect primary glioma cells, 
we tested a library of fiber-chimeric Ad5-based adenoviral vectors on 12 fresh human glioma 
cell suspensions. Significantly improved marker gene expression was obtained with several 
Ad5- chimeric vectors, predominantly vectors carrying fiber molecules derived from B-group 
viruses (Ad11, Ad16, Ad35 and Ad50). We next tested Ad35 sero prevalence in sera derived 
from 90 Dutch cancer patients including 30 glioma patients and investigated the transduction 
efficiency of this vector in glioma cell suspensions. Our results demonstrate that the sero 
prevalence and the titers of NAb against Ad35 are significantly lower than against Ad5. Also, 
recombinant Ad35 has significantly increased ability to transfer a gene to primary glioma 
cells compared to Ad5. We thus conclude that Ad35 represents an interesting candidate vector 
for gene therapy of malignant glioma. 
 
  
Introduction 
 
The prognosis of malignant gliomas is dismal with an overall median survival of less than 1 
year and few if any long-term survivors.1 After initial treatment, the tumors always recur and 
the residual glioma cells cannot be radically excised and are resistant to radiotherapy and 
most chemotherapeutic agents. However, these tumor cells may be eradicated by 
administration of viral vectors carrying suicide genes such as thymidine kinase (TK) or 
cytosine deaminase (CD).2,3 Adenoviral vectors are among the most promising gene delivery 
vehicles currently available because: (1) intratumoral administration of adenovirus type 5 
(Ad5)-based vectors in malignant glioma patients has demonstrated excellent safety;4–7 (2) 
high titer batches of Ad5 can be produced at large scale; (3) large segments of foreign DNA 
can be incorporated into Ad5 and (4) Ad5 does not  integrate into the host genome. In a 
recently published randomized controlled study, Ad5-TK increased the median survival time 
from 38 to 62 weeks in malignant glioma patients.4 However, the antitumor efficacy observed 
thus far remains limited and requires further improvement to become clinically relevant.4–6,8 
At least two parameters have been identified that may contribute to the limited efficacy of 
Ad5-based vectors in malignant glioma trials. The first hurdle is the poor infection of primary 
glioma cells by Ad5, which is most likely caused by the low expression levels of the high 
affinity Coxsackie and Adenovirus receptor (CAR) on these cells. The second parameter is 
the high sero prevalence and antibody titers against Ad5 in the human population9 that may 
significantly hamper gene transfer, at least in experimental animals.10,11 Various strategies 
have been employed to achieve a CAR-independent infection capacity for Ad vectors. These 
include the incorporation of heterologeous-binding proteins at the fiber carboxy terminus or 
the fiber-knob HI-loop.12,13 Another approach is the genetic replacement of Ad5 fiber with its 
structural counterpart from another human or nonhuman serotype.14–17 Resultant vectors have 
shown CAR-independent tropism owing to the natural diversity in receptor recognition and 
identified chimeric vectors with superior infectivity to Ad5 in several clinically relevant cell 
lines.14–17 In pursuit of a better adenoviral vector to treat malignant glioma, we screened an 
Ad5- based fiber-chimeric vector library (n=16) to  identify chimeric vectors with an 
increased ability to transfer nucleic acids to primary glioma cells. We observed that Ad5 
vectors carrying fibers derived from B-group adenoviruses (Ad11, Ad16, Ad35 and Ad50)  
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transferred marker genes more efficiently than Ad5 to primary glioma cells derived from 12 
different patients. The highly prevalent immunity against Ad5 is, however, not  circumvented 
by Ad5-based fiber-chimeric vectors.18 Recent studies have reported that the sero prevalence 
of human Ad35 is significantly lower than Ad5 in healthy blood donors.9 However, B-group 
adenoviruses, including Ad35, have been isolated relatively frequently from 
immunocompromised patients.19  Because the immune system is variably suppressed in 
cancer, we studied the sero prevalence in 90 Dutch cancer patients including 30 patients with 
a malignant glioma. Our results demonstrated that the sero prevalence and neutralizing 
antibody (NAb) titers against Ad35 in cancer patients were low compared to Ad5. Finally, we 
generated a recombinant Ad35 vector and showed that this virus infected primary glioma cells 
significantly better than Ad5. Based on the low sero prevalence of Ad35 and the significantly 
improved infection efficiency as compared to Ad5, we conclude that Ad35-based vectors 
represent a promising new gene transfer vehicle for the treatment of malignant gliomas. 
 
 
Materials and methods 
 
Generation of fiber-chimeric viruses  
All known human wild-type adenoviruses (types 1–51) were propagated on PER.C6 cells,20 
and viral DNA was isolated as described previously.21 Fiber  amplification and generation of 
fiber-chimeric viruses have been described. 16,22 In short, fiber genes were polymerase chain 
reaction (PCR) amplified with distinct sets of ‘subgroupspecific’ oligonucleotides. The two 
amplified products from each fiber were sequenced and confirmed as genuine adenovirus 
fiber molecules by phylogenetic analysis at the DNA and amino-acid level.16 Fiber sequences 
were cloned in an NdeI- and NsiI-digested pBr/Ad.BamR∆FIB plasmid, thus generating a 
library of plasmids coded pBr/ Ad.BamR∆FIBXX (where XX represents the serotype from 
which the fiber was amplified). Plasmid pBr/ Ad.BamR∆FIB contains the Ad5 viral genome 
sequence from the BamHI site (nucleotide [nt] 21562) until the 30 end of the viral genome. 
The Ad5 fiber sequence (nt31042–32787) was deleted by PCR, while simultaneously 
introducing unique restriction sites (NdeI and NsiI) to allow for the insertion of fiber 
molecules derived from other serotypes. Virus was then produced on four T175 triple-layer 
tissue culture flasks and purified with a twostep cesium chloride purification protocol.15 After 
purification, virus was aliquoted and stored at  -80 0C. The virus titer expressed in virus 
particles (VP) per milliliter was  determined by high-pressure liquid chromatography. 23 
Plaque purifications and end point titrations were performed as described previously.20 A total 
of 16 recombinant Ad5-based chimeric viruses were produced with the luciferase marker gene 
driven by a modified cytomegalovirus promoter (Table 1, Clip. Luc).24 A limited number of 
recombinant Ad5-based chimeric virus was produced that contained the enhanced green 
fluorescent protein marker gene (Fibers 5, 16 and 35). An E1- lacking Ad35-based vector 
encoding the luciferase gene was constructed as described elsewhere.9  
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Preparation and propagation of single-cell suspensions 
from glial tumors 
 
Brain tumor tissue was processed immediately after surgery or was stored in a 50ml tube 
containing Rosewell Park Memorial Institute medium (RPMI) 1640 (Invitrogen, Breda, The 
Netherlands) at 41C until further handling. Primary tumor cell cultures were prepared by 
cutting the tissue into small pieces and 1–3 1-h digestion steps in hepatocyte liver digest 
medium (Invitrogen) at 371C. After every digestion step, the suspension was pipetted up and 
down using a 5 or 10 ml pipet to remove loose cells from the tissue. The suspension was then 
placed at 37 0C again to let the debris sink down and the single cells in the suspension were 
transferred to a new  50 ml tube. After digestions, the single-cell suspension was passed 
through a 70 mm filter (Cell Strainer, Becton Dickinson, Franklin Lakes, NJ) to remove 
remaining undigested tissue parts. After centrifugation for 5 min at 1000 r.p.m. and removing 
the supernatant, erythrocytes were lysed for 10 min on ice using 2 ml of shock buffer 
containing 1 vol Shocker Aþ1 vol Shocker Bþ8 vol H2O. Shocker A: 1.55M NH4Cl (Sigma-
Aldrich, Zwijndrecht, The Netherlands), 0.001M Na2-ethylenediaminetetraacetic acid 
(Sigma-Aldrich). Shocker B: 0.1M KHCO3. H2O (Sigma-Aldrich): distilled water 
(Invitrogen). Twenty-four milliliters of phosphate-buffered saline (PBS) (Invitrogen) were 
added and the suspension was centrifuged for 5 min at 1000 r.p.m. Depending on the cell 
pellet size, cell culture medium was added and the singlecell suspension was transferred to a 
cell culture plate. Cell culture medium: RPMI 1640, heat-inactivated fetal bovine serum 10% 
(Invitrogen), penicillin 1% and streptomycin 1% (Invitrogen). Depending on the yield, cells  
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were plated on 96-multiwell plates (Corning, Schiphol-Rijk, The Netherlands) or on 75 cm2 
flasks (Corning). The cells were used for experiments between passage number 6 and 10. 
 
Immunohistochemical characterization of cells cultured from primary gliomas 
Cytospins of the primary glioma cell cultures were incubated for 30 min with monoclonal 
anti-S100 (Dako, Glostrup, Denmark) diluted 1:300 or polyclonal anti-glial fibrillary acidic 
protein (GFAP) (Dako) diluted 1:100 in PBS/bovine serum albumin (BSA) 1%. After 
washing in PBS, the samples were incubated with a secondary antibody for 30 min at room 
temperature (rat antimouse- biotin (Dako) or swine anti-rabbit-biotin (Dako), diluted 1:200 in 
PBS/BSA 1%). After washing in PBS, the samples were incubated with 
StreptABComplex/AP (Dako) for 30 min and flushed with PBS and Tris/HCl, pH 8.0. The 
cytospins were incubated for 30 min at room temperature in the dark with the chromate 
(Naphtol ASMX (Sigma-Aldrich), New Fuchsine (Sigma-Aldrich), NaNO2, Levamisol 
(Across Organic, Geel, Belgium) in Tris/HCl, pH 8), flushed with water and counterstained 
with hematoxylin (Klinipath, Duiven, The Netherlands). Sections were mounted with 
Imsolmount (Klinipath) and dried at 421C. Negative control samples were treated the same 
with the exception that the primary antibody was replaced by the diluent. The cytospins were 
examined under the microscope and cells were scored as positive or negative. 
 
CAR, integrin and CD46 expression on primary glioma tumor cells  
Tumor cells were trypsinized and resuspended in 10 ml medium. After centrifugation for 5 
min at 450 x g at 4 0C, the medium was removed and the cells were taken up in 5ml of 
PBS/BSA (0.5% BSA in PBS). Cells were counted and 105 cells were transferred to a  
fluorescence-activated cell sorting (FACS) tube. After centrifugation and discarding the 
supernatant, 100 ml of PBA was added. Tumor cells were then stained on ice with mouse 
monoclonal antibodies directed against CAR, against integrins (avb3 or avb5) or against 
CD46 for 30 min in PBA. Anti-CAR was used in a dilution of 1:100 (kind gift from JM 
Bergelson, Dana-Farber Cancer Institute, Boston, MA), anti-avb3 (Chemicon International, 
Temecula, CA) 1:100, anti-avb5 (Chemicon) 1:100 and anti- CD46 1:50 (Biotrend, Cologne, 
Germany). After washing, cells were incubated for 25 min at 4 0C with 
phycoerythrinconjugated rat anti-mouse immunoglobulin (IgG (5 mg/ sample, Becton 
Dickinson) or fluorescein isothiocyanateconjugated goat-anti mouse IgG (BD Pharmingen, 
San Diego, CA). After centrifugation and removal of supernatant, 100 ml of PBA was added 
and the samples were analyzed on a FACS-Calibur (Becton Dickinson). 
 
Infection of primary glioma tumor cells with Ad5, Ad5.FibXX and Ad35 
Cells were trypsinized and plated out into 96-well plates at 104 cells/well in 100 ml medium. 
A549 cells were used as control cell line. After 24 h, viruses were added in triplicate at 
concentrations of 1000 and 5000 VP per cell (10 ml of 1x109 and 5x 109 VP/ml). Two hours 
after starting the incubation, the medium was removed, and fresh medium was added. After 
48 h of incubation at 37 0C the medium was removed, the cells were washed with PBS and 
100 ml of Reporter Lysis Buffer (Promega Benelux BV, Leiden, The Netherlands) was added. 
The plates were stored at -80 0C until analysis. To determine luciferase activity, the plates 
were thawed and 20 ml of cell lysate was transferred into a white 96-well flat bottom plate. 
After addition of 100 ml of reagent (Promega BeneluxBV), the relative light units were 
measured in an Ascent plate reader (Thermo Labsystems, Vantaa, Finland).  
 
Quantitation of adenovirus-NAbs 
To determine the titer of Ad-NAbs in patients’ sera, we used the recently validated luciferase-
based Ad neutralization assay.25 Sera were collected from 90 patients with active cancer, 30  
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of whom had a malignant glioma. Sera were heat inactivated at 56 0C for 60 min before a 
serial doubling dilution was performed in a 96-well culture plate. Sera were diluted in 
Dulbecco’s modified Eagle’s medium eventually resulting in dilutions ranging from 1/16 to 
1/32 768 in a volume of 200 ml. No serum was added to the controls, which resulted in 
maximum luciferase activity. This value was used to calculate the 90% neutralization value. 
Patients with ≥90% neutralization at a titer of ≥32 were considered positive for NAbs. 
 
Quantitation of Ad genomes by real-time PCR 
Forty-eight hours after infection with Ad5.Luc and Ad35.Luc (multiplicity of infection (MOI) 
1000), the adenoviral copy number per cell was determined with a multiplexreal-time PCR 
reaction.16 Total DNA was extracted by using a DNeasy Tissue Kit (Qiagen, Valencia, CA). 
To amplify the adenoviral DNA, specific primers Ad5Clip-F (5’-
CGACGGATGTGGCAAAAGT-3’) and Ad5Clip-R (5’-CCTAAAACCGCGCGAAAA-3’) 
were used. Amplification is detected by a fluorogenic probe (Ad5Clip-Pr; 5’-VIC-
CACCGGCGCACACCAAAAACG TAMRA-3’). A second pair of primers and a FAM (6- 
carboxy-fluorescein) probe directed to 18S rDNA determined the number of Ad genomes per 
cell. The PCR mixture contains 1 x buffer A, 3mM MgCl2, 200 mM deoxynucleoside 
triphosphate, 90 nM of each adenovirus primer, 100 nM of each 18S rDNA primer, 200Nm of 
each probe, 0.6U AmpliTaq Gold polymerase (Perkin-Elmer, 
Wellesley, MA) and 5 ml of total DNA sample. To determine the amount of adenoviral 
genomes and cellular DNA, human genomic DNA (Promega) was mixed with plasmid DNA 
as a standard. The PCR was initiated with a hot start at 95 0C for 10 min. Amplification 
occurred during 45 cycles, with each cycle consisting of 15 s at 95 0C and 1 min at 60 0C. 
Results are expressed as  adenoviral DNA copy number per cell. 
 
Statistical analysis 
Data were analyzed using GraphPad Prism version 4.0 software (GraphPad Software, Inc., 
San Diego, CA, 2002). We used analysis of variance to analyze the differences in mean 
luciferase expression between Ad5 and the fiber chimeras taking all 12 tumors together and 
for each primary glioma culture, followed by Dunnett’s multiple comparison test. NAb 
prevalence and titers were compared with Fisher’s exact test and Mann–Whitney test, 
respectively. Following infection of five selected primary glioma cells (# 1, 2, 4, 9 and 11) 
with Ad5.Luc or Ad35.Luc, Ad genome copy number and luciferase expression were 
compared using t-test. Po0.05 was considered statistically significant. 
 
Results 
Characterization of primary human glioma cells Single-cell suspensions were obtained from 
12 primary human gliomas. Of the 12 gliomas, two were diagnosed (WHO26) as Grade I, 
four as Grade II, two as grade III and four as Grade IV (Table 2). All primary glioma cells 
expressed the glia-specific intermediate filament GFAP demonstrating origin and purity of 
cell populations. As Ad5 binds to the CAR receptor and subsequently enters the cell via avb3 
and avb5 integrins, we analyzed the primary tumor cell suspensions for expression of these 
proteins by FACS analysis. In 11 out of the 12 glioma cell suspensions tested, we found very 
low CAR expression (o5% positive cells). Also, avb3 integrin expression proved low, 
whereas expression levels of avb5 were readily detectable (410% of cells) on 10 of 11 glioma 
cell suspensions (Table 2). One cell suspension, clearly of glioma origin (#11), displayed high 
CAR expression (430% positive cells) indicating the high variability between cell 
preparations obtained from different tumors. 
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Infection of primary glioma cells with the Ad5-based fiber chimeric vector library 
Following infection of the primary glioma cells suspensions with the Ad5-based fiber-
chimeric vector library (Table 1), we compared the mean luciferase expression of Ad5.FibXX 
with Ad5 in all 12 tumors. Results demonstrated a statistically significant difference in 
luciferase activity (Figure 1a) between Ad5 and the Ad5-chimeric vectors carrying fiber 
molecules derived from other serotypes (MOI 1000, P¼0.0001; MOI 5000, Po0.0001). Post-
analysis demonstrated that Ad5-chimeric vectors carrying fiber molecules from subgroup B 
serotypes 11, 16, 35 and 50 and the short fiber of the F-group serotype 40 performed 
significantly better than Ad5 following infection with MOI 1000 and MOI 5000. For each 
vector, considerable differences in luciferase expression levels were observed between tumors 
as reflected by the error bars in Figure 1a. We next analyzed, for each tumor separately, which 
of the Ad5.FibXX chimeras gave a significantly higher luciferase expression level than Ad5. 
From these data (Figure 1b), we conclude that in almost all tumors tested the Ad5.Fib11,  
Ad5.Fib16, Ad5.Fib35, Ad5.Fib40S and Ad5.Fib50 performed significantly better than Ad5. 
Only in tumor #11, Ad5 infection resulted in higher expression levels than the chimeras with 
exclusion of Ad5.Fib40S. Four of the five fiber-chimeric vectors that performed better than 
Ad5 belonged to subgroup B (Ad5.Fib11, Ad5.Fib16, Ad5.Fib35 and Ad5.Fib50). In Figure 
2, the transduction efficiency of these four Bgroup chimeric vectors is presented and shows 
that the mean luciferase expression relative to Ad5 is similar for each of these four vectors in 
all primary glioma cultures tested. A more than 10-fold increase in luciferase 
expression relative to Ad5 was obtained with all four Bgroup chimeric vectors in five of 12 
primary tumor cell cultures. This similarity may indicate that Fib11, 16, 35 and 50 have 
similar CD46 receptor affinity or CD46 isoform recognition. Figure 3 demonstrates that the 
BC-1 isoform of the CD46 receptor is readily expressed on the primary glioma cell 
suspensions, although at variable levels. 
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Sero prevalence of Ad5 and Ad35 in Dutch cancer patients 
The finding that B-group fiber-chimeric Ad5 vectors infect primary glioma cells better than 
Ad5 raised the possibility of using a vector backbone completely derived from a B-group 
serotype. Recent reports indicate that the sero  prevalence of Ad35 is low in blood derived 
from healthy donors.9 To further explore the potential of an Ad35-based vector, we compared 
the sero prevalence of Ad5 and Ad35 in a panel of sera derived from Dutch cancer patients. 
Ninety sera from cancer patients were collected, including 30 sera from patients suffering 
from malignant glioma. Screening of the sera (Figure 4a and b) 
demonstrates that Ad5 has high sero prevalence (66%) within this patient group which is 
significantly higher (Po0.0001) than the sero prevalence of Ad35 (31%). Also, NAb titers 
proved significantly higher for Ad5 as compared to Ad35 (Po0.0001). In addition, the 
prevalence of NAbs against Ad35 in patients suffering from malignant glioma was 
significantly (Po0.02) lower (17%) than in the other cancer patients (44%). These results 
demonstrate that the overall sero prevalence of Ad35 is low. Moreover, Ad35 seems as 
prevalent in sera derived from cancer patients as in sera derived from healthy blood donors.9 
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Recombinant Ad35 vector transduction of primary glioma cells 
The increased luciferase marker gene expression levels in primary glioma cells obtained with 
the B-group fiberchimeric Ad5 vectors stems from improved binding of the vector to the cells 
because the only difference between Ad5 and Ad5.Fib35 is the fiber molecule. However, 
when switching from Ad5.Fib35 to Ad35, the improved transduction efficiency owing to 
increased binding might be obscured because of differences in intracellular trafficking 
between  adenovirus serotypes.9 To investigate whether recombinant Ad35 retains its superior 
infection and increased marker gene expression levels as compared to Ad5, we infected 
primary glioma cells and determined the luciferase activity as well as the number of vector 
genome copies per cell using quantitative PCR. Figure 5a demonstrates that the luciferase 
marker gene expression obtained with recombinant Ad35 is significantly higher than with 
Ad5 (P<0.05), as observed with Ad5.Fib35. 
Figure 5b shows that the increased marker gene expression results from better delivery of 
vector genomes into glioma cancer cells by Ad35 than by Ad5 (P<0.01). 
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Discussion 
We tested a panel of 12 different primary human glioma cell preparations for the presence and 
expression level of several molecules associated with attachment and entry of Ad5. Although 
each cell preparation clearly expressed glioma specific markers, significant differences were 
found between tumor isolates in CAR and integrin expression. In vitro culture artifacts are an 
unlikely explanation for these differences, because the tumor cell preparations were screened 
early after tumor isolation. These data confirm an earlier report by Fuxe et al.27 who described  
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variable CAR expression in 34 gliomas of various grade and demonstrated patient-to-patient 
variation that at present is not well understood. Although the exact function of the Ad5 high-
affinity receptor CAR is not known, it is thought to be associated with adhesion and tight 
junction formation between cells. Furthermore, CAR expression may have a tumor 
suppressing effect28–30 and correlates inversely with the aggressiveness of a tumor, explaining 
the low expression levels of CAR in malignant gliomas and primary glioma cells.27,30 In an 
attempt to identify a vector that uses attachment molecules other than CAR, we tested a 
library of 16 different Ad5-based fiber-chimeric adenoviral vectors16 and identified five that 
gave significantly higher luciferase expression than Ad5 in 11 out of the 12 primary glioma 
cultures tested. The most efficient fiber-chimeric vectors contained a fiber molecule derived 
from the B-group adenoviruses Ad5.Fib11, Ad5.Fib16, Ad5.Fib35 and Ad5.Fib50, and the F-
group Ad5.Fib40S. The receptor utilized by Ad40S serotype is currently unknown. The 
Bgroup adenoviruses were recently found to use CD46 as a high-affinity cellular attachment 
molecule.31,32 Skog et al.33 studied the infection of seven low-passage glioma cell lines by 
sixwild-type adenovirus serotypes, including Ad5. As determined by hexon expression, the B-
group viruses Ad16 and Ad21 infected the glioma cells most efficiently, confirming the 
improved binding and entrance by B-group viruses as compared to CAR-binding Ad5. The 
CD46 molecule is ubiquitously expressed in primates and functions to protect ‘self’-cells 
against complement lysis by binding and inactivating C3b and C4b.34 The expression level of 
the BC-1 isoform of CD46 was significantly higher than the CAR expression level on primary 
glioma cells, although both attachment molecules were expressed at highly variable levels. 
The expression of the BC1-isoform (one of four known isoforms of CD46) did not closely 
correlate with marker gene expression levels obtained after infection with the B-group 
fiberchimeric vectors. This may indicate that other isoforms of CD46 are perhaps expressed 
by these cells and may contribute to binding and internalization of the B-group fiber-chimeric 
vectors. As CD46 expression is very low on neurons35 and because B-group chimeric vectors 
infect glioma cells more efficiently than Ad5, a recombinant vector that uses CD46 as 
attachment molecule might have a more favorable targeting ratio in the brain than Ad5. In 
animal models, the efficiency of adenoviral gene transfer by intratumoral injection is seriously 
hampered by the presence of NAbs in serum.10,11 Although the 
normal brain is relatively protected from circulating IgG’s, the disruption of the blood–brain 
barrier in malignant gliomas results in the accumulation of IgG and other large molecules in 
the interstitial space.36 Therefore, circumventing the highly prevalent anti-Ad5- neutralizing 
activity would be important to improve adenoviral gene transfer in malignant gliomas. The 
recent reports of the low prevalence and serum titers of anti- Ad35-neutralizing activity world 
wide further directed attention to Ad5.Fib35. However, vaccine studies in mice demonstrated 
that induced anti-Ad5-neutralizing activity significantly diminished the potency of an 
Ad5.Fib35 vector carrying a measles antigen as compared to naı¨ve animals. This study 
concluded that pre-existing immunity against Ad5 is not circumvented by Ad5.Fib35.18 On 
the other hand, the induced anti-Ad5-neutralizing activity could not diminish the efficiency of 
an Ad35-based Simian immunodeficiency virus-gag vaccine in mice.37 Thus, recombinant 
Ad35 is not affected by the high Ad5 sero prevalence and, in combination with improved 
transduction of primary glioma cells, may represent a better vector than Ad5. Because B-
group viruses, including Ad35, are frequently isolated from immune compromised patients,19 
the sero prevalence of Ad35 might be higher in such patient groups, including patients 
suffering from cancer, than in the general population. Therefore, we tested sera from 90 
cancer patients. In cancer patients, the Ad35 sero prevalence was significantly lower than the 
sero prevalence of Ad5, as in the general population. In addition, Ad35 NAb titers were 
generally low if present. These results are supported by recent data demonstrating that in 
patients progressing towards AIDS and thus becoming more immune compromised, Ad35 
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sero prevalence was low as compared to Ad5 whereas the number of Ad35 positive 
individuals did not increase with progressive immune suppression.38 Finally, we compared the 
transduction efficiency of recombinant Ad35 and Ad5 on primary glioma cells. Human 
adenoviruses, including B-group viruses, differ substantially in intracellular trafficking, 
nuclear transfer efficiency and subsequent transcription and translation of the gene of 
interest.39–41 We therefore examined both the Ad genome copy number per cell and the 
luciferase expression levels after infection of the primary glioma cells with Ad35 and Ad5. 
Following infection with Ad35, the Ad genome copy number per cell proved significantly 
higher than after Ad5 infection. Also, the luciferase marker gene expression was significantly 
higher following infection with Ad35 than with Ad5. These findings indicate that the high 
expression levels obtained by B-group fiber chimeras are due to improved entry. In summary, 
we have shown that primary glioma cells express low levels of the Ad5 receptor CAR, 
seriously reducing the susceptibility of these cells to Ad5-mediated gene transfer. Also, we 
identified Ad5-based vectors carrying fiber molecules, predominantly of B-group origin, that 
improved gene transfer as indicated by significantly increased luciferase marker gene activity. 
We further demonstrate that Ad35 has low sero prevalence among Dutch cancer patients and 
in particular in glioma patients, circumventing the high Ad5 sero prevalence. Finally, we 
demonstrate that recombinant Ad35 is well suited to infect primary glioma cells. Taken 
together, we conclude that recombinant Ad35 represents an interesting new candidate vector 
for gene therapy of malignant glioma. 
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CHAPTER 7 
 
 
 
Clinical trials of adenoviral-mediated suicide gene therapy of 
malignant gliomas 
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Introduction 
Almost 10 years ago, the first clinical gene therapy trial treated patients suffering from a form 
of severe combined immunodeficiency (SCID) caused by a deficiency in the enzyme 
adenosine deaminase (ADA) with disappointing results (Blaese et al., 1995; Hoogerbrugge et 
al., 1996). Despite the lack of efficacy in the early clinical studies, the 1990s saw a large 
number of clinical protocols. The negative results of many if not all of these trials resulted in 
the Orkin–Motulsky report in 1995. This report provided recommendations to the NIH 
director Harold Varmus regarding the current status of gene therapy and future gene therapy 
studies (www.nih.gov/news/panelrep.html). The report concluded that clinical efficacy had 
not been demonstrated in any gene therapy protocol and that results of laboratory and clinical 
studies had been oversold by investigators and their sponsors. The report recommended a 
greater focus on basic aspects of gene transfer and gene expression to improve vectors for 
gene delivery with enhanced level and duration of expression and to achieve tissue-specific 
and regulated expression of the transferred genes. Also, the importance of high standards of 
excellence in clinical protocols was stressed. Now, 5 years later, the first two patients with an 
X-linked form of SCID (SCID-X1) have been successfully treated with gene therapy (for at 
least up to 10 months) (Cavazzana- Calvo et al., 2000). At the same time, vectors for the 
treatment of hemophilia have greatly improved and cardiovascular disorders are treated with 
some success (Isner and Asahara, 1999; Kay et al., 2000). Finally, clinical efficacy has been 
demonstrated in some of the hundreds of cancer patients treated with adenoviral gene therapy. 
 
Brain tumors: scope of treatment 
The overall incidence of primary brain tumors in the Western world is 9–10 per 100,000 
persons and 7/100,000 die of brain tumors each year (Central Brain Tumor Registry, 1998; 
Visser et al., 1998). Approximately 50% of all primary brain tumors are derived from glial 
cells and if 65% of these are malignant, the incidence of malignant gliomas is about 3 per 
100,000 people (450 per year in The Netherlands). Despite advances in neurosurgical 
techniques, radiation treatment and chemotherapy, the prognosis for  patients with malignant 
gliomas remains dismal. The overall median survival is less than 1 year and fewer than 5% 
survive for 5 years or longer (Surawicz et al., 1998). Initial treatment consists of surgery 
followed by radiotherapy and sometimes adjuvant chemotherapy. Eventually all malignant 
gliomas recur and at recurrence, the median survival is 2–3 months. The results of 
chemotherapy depend on the histology subtype of the tumor. Response rates vary from 60% 
in the anaplastic oligodendrogliomas (~10% of malignant gliomas); 40% in anaplastic 
astrocytomas (~15% of malignant gliomas); and 10% in glioblastomas multiforme (75% of 
malignant gliomas) (Friedman et al., 1999; Salcman, 1995; Yung et al., 1999). Limitations of 
surgery, radiotherapy and chemotherapy make the development of new treatment strategies 
necessary. Despite the fact that individual tumor cells spread through the brain at great 
distances from the primary site (Burger, 1983), approximately 80% of recurrences of 
malignant gliomas are within a 2-cm margin of the contrast enhancing rim on CT (Wallner et 
al., 1989). This high rate of local recurrence within the region of the original tumor combined 
with the very low incidence of distant metastases and the poor prognosis of the patients 
warrant the further pursuit of locoregional treatment strategies including gene therapy. Indeed, 
while primary brain tumors constitute approximately 1.5–3% of all cancers, 13% of human 
cancer gene therapy protocols are in brain tumor patients (Central Brain Tumor Registry, 
1998; Visser et al., 1998).  
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Gene therapy: a new treatment strategy for brain tumors 
An Internet search revealed a total of 252 humancancer gene therapy protocols, 33 of which 
were in nervous system tumors. The 29 clinical protocols involving primary brain tumors are 
summarized in Table 1. More than 400 patients with primary brain tumors have been treated 
with gene therapy. Gene therapy for brain tumors has demonstrated efficacy in a variety of 
animal models using many different vector systems including retrovirus, adenovirus, adeno-
associated virus and herpes virus vectors (Culver et al., 1992; Vincent et al., 1996; Kramm et 
al., 1997). Transduction of tumor cells with the herpes simplex virus thymidine kinase (HSV-
tk) gene, which activates the nucleoside prodrug ganciclovir (GCV) has been one of the most 
effective approaches in treating experimental brain tumors (Culver et al., 1992; Chen et al., 
1994; Vincent et al., 1996). The efficacy of this treatment is enhanced by the ‘bystander 
effect’, whereby nontransduced tumor cells are also killed by transfer of toxic metabolites 
through gap junctions (Touraine et al., 1998), induction of apoptosis (Hamel et al., 1996), 
killing of tumor endothelial cells (Ram et al., 1994) and activation of a host immune response 
(Vile et al., 1997). HSV-tk is the most frequently used therapeutic gene in clinical brain tumor 
protocols (Table 1). For the immunotherapy approach, antisense insulin-like growth factor 1, 
antisense transforming growth factor-β2, Interleukin-2, Interleukin-4, Interferon-β and 
granulocyte-macrophage colony stimu-lating factor (G-MCSF) are used. Introduction of wild-
type p53 is achieved by an adenoviral vector. One protocol studies the in vitro transfection of 
CD34C peripheral blood cells with the gene encoding O6-methylguanine DNA 
methyltransferase for chemoprotection in patients treated with intensified PCV (procarbazine, 
CCNU, vincristine) for relatively chemosensitive oligodendroglial tumors (Table 1). 
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Clinical retrovirus HSV-tk trials 
Phase I–II clinical trials in glioblastoma patients first demonstrated the feasibility of 
intratumoral injections of HSV-tk retrovirus vector producer cells (VPC) followed by 
ganciclovir and showed some clinical activity (Ram et al., 1997; Klatzmann et al., 1998; 
Shand et al., 1999). Shand et al. (1999) found a median survival time of 8.6 months, while the 
12-month survival rate was 13 of 48 (27%). This study led to the only randomized controlled 
trial in cancer gene therapy sofar. This phase III trial evaluated 
adjuvant suicide gene therapy in 240 patients with newly diagnosed glioblastomas. Standard 
treatment consisted of ‘gross-total’ resection followed by 55–60 Gy radiotherapy. 120 patients 
received gene therapy consisting of woundbed injections of HSV.tk retrovirus VPCs followed 
by i.v. ganciclovir. Kaplan–Meier analysis did not indicate significant differences in 
progression or survival times between the groups while safety was comparable in both groups 
(Rainov, 2000). Factors involved in failure of the study included the method of delivery, the 
use of VPC and retroviruses, the size and mitotic rate of GBM and ganciclovir delivery. Also, 
interpretation of the results of phase II studies such as those by Shand et al. (1999) requires 
extreme caution due to the variability of survival after re-resection of glioblastomas based on 
patient selection (Table 2). 
 
 
 
Clinical adenovirus HSV-tk trials 
 
More recently, six clinical phase I/II brain tumor protocols started using adenoviral vectors 
that were recombinant for HSV-tk in four, including our study in Rotterdam (Eck et al., 1996; 
Trask et al., 2000). The advantages of adenovirus vectors are the relatively efficient entry into 
many cell types, ease of high titer vector production, and high levels of expression and 
transduction of stationary cells. We started our study of adeno.tk in recurrent glioblastomas 
after the successful treatment of experimental brain tumors with this and similar adeno.tk 
vectors (Chen et al., 1994; Vincent et al., 1996, 1997). Toxicity studies of intracerebral 
injection of adeno.tk followed by GCV administration in cotton rats, which are permissive for 
adenoviral infection, and in other rodent models did not result in clinical toxicity nor systemic 
pathological changes (Shine et al., 1997; Driesse et al., 1998). Similar toxicity studies in 
primates resulted in dose-dependent clinical and pathological toxicity in two studies 
(Goodman et al., 1996; Smith et al., 1997) while no clinical toxicity occurred in the study 
conducted at our institution (Driesse et al., 1998). In addition, the injection of high doses of 
adeno.tk into the cerebrospinal fluid (as may occur during intratumoral injection) followed by 
ganciclovir was evaluated in nonhuman primates. Despite the absence of clinical symptoms, 
analysis of the cerebrospinal fluid and histopathological examination were consistent with a 
viral meningitis (Driesse et al., 2000). Based on these preclinical studies, approval was  
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obtained to treat a maximum of 15 patients with a recurrent glioblastoma in a phase I study 
with adeno.tk (IG.Ad.MLPI.TK) followed by ganciclovir.  
 
Objectives 
The primary objective of the study was to determine the maximum tolerated dose (MTD) of 
adeno.tk followed by ganciclovir treatment in patients with relapsed glioblastoma assessing 
clinical and laboratory parameters. The secondary objective was to determine if there is 
evidence of anti-tumor efficacy assessing clinical and neuroradiological  parameters.  
 
Patient selection  
Key inclusion criteria were: patients aged 18–75 years with relapsing histologically confirmed 
glioblastoma multiforme, Karnofsky performance status ≥60, any anticancer therapy 
completed .4 weeks prior to study entry, ability to give informed consent, men and women of 
child-bearing potential must practice a medically approved method of contraception for the 
duration of the 28-day treatment phase. The key exclusion criteria were: patients with 
multifocal tumors or tumors involving the brainstem, both hemispheres, cerebellum; plan for  
any concomitant anticancer therapy (e.g. chemotherapy), other than that foreseen in this 
protocol, active infection.  
 
Treatment plan  
Sequential cohorts of three patients are entered at each of the four planned dose levels, three 
patients more are entered at the highest planned dose level for additional safety and efficacy 
data. Should the highest planned dose not be reached, then additional patients are entered at 
the maximum tolerated dose, up to a total sample size of 15 patients in the entire study. 
Treatment consists of 10 ml of adeno.tk vector suspension injected on day 0 after optimal 
tumor resection into the surgical margins of the resection cavity, evenly distributed at 
approximately 50 sites 0.5–1 cm deep into the tissue (Fig. 1). The dose levels are 4.6 x 108, 
4.6 x 109, 4.6 x 1010, 4.6 x 1011 vector particles. On day 2 ganciclovir will start and will be 
given by i.v. infusion over 1 h, 5 mg/kg b.i.d. for 14 days. End of treatment evaluation will be 
performed on day 28, thereafter follow up will be initiated and evaluations will be performed 
until the patient dies. 
 
Treatment evaluations.  
Safety and tolerability will be assessed by physical examination, vital signs laboratory 
evaluations, neuroradiological examinations, adverse events and concomitant medication 
usage. Dose escalation will proceed until 4.6 x 1011 particles. If, however, at any dose level, 
grade 3 or 4 (severe) adverse events judged to be probably or definitely related to study 
treatment occur in two patients within 15 days following the application, then the maximum 
tolerated dose of adeno.tk shall be defined as the dose below the one where these adverse 
events occurred. The main efficacy criteria are: patients’ survival time, time to a Karnofsky 
functional score below 60, time to tumor progression and tumor response. 
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Resu l t s  
 
Eleven patients have been enrolled since December 1998 in the study with four patients to 
follow (Table 3). All patients had recurrent glioblastoma (WHO) and all had received prior 
radiotherapy. The patients were treated with four adeno.tk dose levels ranging from 4.6 x 108 
to 4.6 x 1011 particles. No dose-limiting toxicity was observed indicating the safety of 
intratumoral injection of adeno.tk into the woundbed of glioblastomas. In particular the early  
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postoperative MRI did not show new bleeding or edema in any of the patients. Severe 
thrombocytopenia caused by ganciclovir occurred in one patient. This was the only patient 
who did not finish GCV treatment. Four patients had mild and transient increases in liver 
function tests for 1–3 weeks following vector administration. No shedding of recombinant 
adenovirus was demonstrated by culture on 293 and Hep2 cells (see Table 1). Assay for titers 
of  neutralizing antibodies will follow completion of the study. The survival time and time to 
progression are summarized in Table 3. All four patients who died had documented tumor 
progression on MRI. None of these patients were autopsied. 
 
Discussion 
 
The trial was designed to assess the safe/toxic dose levels of adeno.tk that can be injected into 
the woundbed of glioblastomas in combination with ganciclovir. In our study, we have not yet 
encountered dose-limiting toxicity at dose levels up to 4.6 x 1011 viral particles, indicating the 
safety of multiple woundbed injections of adeno.tk followed by GCV. The results of two 
other reported phase I adeno.tk studies in brain tumors are summarized in Table 4. In the 
Baylor study, patients were treated with a single stereotactic injection of adeno.tk. In the 
University of Pennsylvania study, the patients were treated with stereotactic injections 
followed by resection and a second injection into the residual tumor (Eck et al., 1996). In the 
Rotterdam study, patients received only woundbed injections (50). Only the Baylor study 
encountered dose-limiting toxicity in two patients treated with 2 x 1012 viral particles and 
MTD was set at 2 x 1011 viral particles (Trask et al., 2000). The central nervous system 
toxicity consisted of confusion, hyponatremia, seizures and fever. Neuropathological 
examination of six autopsy brains revealed minimal to moderate intratumoral inflammation 
and foci of coagulative necrosis in all specimens, related to the needle tract in some 
suggesting an anti-tumor immune response. In none of the specimens was inflammation or 
demyelination found in the normal brain such as described by Dewey et al. (1999) in the 
normal brain of rats successfully treated for experimental glioma with an adenoviral vector. 
Ten of 12 patients had post-treatment elevations of neutralizing adenoviral antibody titers 
relative to the pretreatment level (Trask et al., 2000). 
 
Safety of adenoviral gene therapy 
Recently, the safety of adenovirus gene therapy was seriously questioned after a fatal incident 
(Lehrman, 1999). An 18-year-old patient developed diffuse intravascular coagulation, ARDS 
and multiple organ failure within hours of treatment to correct partial ornithine 
transcarbamylase (OTC) deficiency. The patient had received 3.8 x 1013 particles of an E1-
deleted adenovirus vector carrying the normal OTC gene by injection into the hepatic artery. 
This first gene therapy death led to FDA and RAC hearings. During the hearings it became 
clear that over 450 cancer patients have been treated with replication deficient adenovirus 
vectors and analyzed (Chang, 2000; Fernandez-Chacon, 2000). Most patients were enrolled in 
phase I/II trials and treated with adeno.p53 for either head and neck cancer or ovarian cancer. 
For intratumoral and intraperitoneal administration the maximum tolerated dose (MTD) has 
not been reached (> 7.5 x 1013 viral particles). For administration into the hepatic artery (IHA) 
one vector-related serious adverse event occurred at 7.5 d 1013 viral particles and MTD was 
set one dose level lower for IHA administration. The most common related adverse events at 
high doses (phase II) were fever/chills/flu-like syndrome (60%), and pain at the injection site 
(39%). The general conclusion is that high doses of adenoviral vectors can be safely 
administered by intratumoral and intraperitoneal injection, whereas injection into the hepatic 
artery should be performed with more stringent monitoring (Brenner, 2000; Chang, 2000). 
Although the exact cause of death may never be determined, it is likely to relate to one or 
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more of the toxicities seen in animal models. During the first few hours of infection, 
adenoviral vectors provoke an aspecific acute phase response with rapid release of 
inflammatory cytokines including IL-1, IL-6, IL-8 and TNF-α (Crystal et al., 1994; Bruder 
and Kovesdi, 1997; Cartmell et al., 1999; Driesse et al., 2000). Over the next 24–96 h, most of 
the adenoviral toxicity can be attributed to the production of viral proteins. Subsequently, the 
immune system specifically recognizes and destroys adenovirus vectors and infected cells 
(Byrnes et al., 1996; Kajiwara et al., 1997). The large amounts of adenoviral vectors used in 
current clinical trials result in strong inflammatory reactions, short duration of expression and 
a narrow therapeutic index. Therefore, adenoviral vectors are not suitable for gene 
replacement strategies that require long-term expression and no inflammatory reactions. 
However, for cancer gene therapy, the immune reaction that adenoviral vectors elicit may be 
advantageous and the short-term expression of toxic and/or immunostimulatory genes may be 
favorable (Brenner, 2000). Targeting may increase the specificity of adenoviral vectors 
resulting in the need for lower doses or increased efficacy at a similar dose. The use of 
replication competent adenoviral vectors may further increase their effectivity. Although the 
presence of neutralizing antibodies in patient serum is an obstacle to systemic administration, 
it also protects against adenoviral hepatotoxicity. Most patients harbor neutralizing antibodies 
against adenovirus serotype 5. In patients without these neutralizing antibodies, unexpected 
severe hepatotoxicity might occur (Verlinden et al., 2000). Unfortunately, we do not know the 
antibody status in the fatal incident.   
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The human glioma cell lines U87MG, T98G, A172 and LW5, 293 cells and the nonpermissive rat 9L glioma cells were transfected 
at m.o.i. 10. Replication competent adenoviral vectors had E1 sequences in situ while the HSV.tk (Ad5RepTK) or luciferase 
(Ad5RepLuc) gene were cloned in E3, driven by the natural E3 promoter. Helper-dependent E1A deleted vectors had the HSV.tk 
gene in E1A driven by a modified CMV promoter (Ad5APTTK) or the luciferase in E3, driven by the natural E3 promoter 
(Ad5E3Luc). The replicating recombinant vectors caused full cytopathogenic effect (CPE) similar to wild-type adenovirus 5 in 
the human glioma and 293 cells but not in the nonpermissive rat 9L cells. CPE was scored as follows: ++++, full CPE  2  days; 
+++,  4  days; ++,  7  days;+,  1 0 days. 
 
Future developments of adenoviral glioma gene theray 
Clearly, the efficacy of the clinically tested adenoviral vectors has been disappointing and 
recently, toxicity has been added to the disappointment. A major obstacle in the clinical 
application of adenoviral vectors is the limited specificity necessitating the use of very high 
doses that results in a strong immune responses. For cancer gene therapy, conditionally 
replicating adenoviral vectors (CRAds) are currently developed to enhance effectivity and 
specificity is increased by targeting.  
 
Replication competent adenoviral vectors 
 
Most of the adenoviruses used in clinical studies sofar, carry a deletion in the E1 region which 
renders the virus replication defective (helper dependent). Heterologous genes are cloned in 
place of the E1 genes, usually under the direction of a heterologous promoter. In addition, 
viruses have been constructed and clinically applied that are replication competent or helper 
independent (Berkner, 1992; Tacket et al., 1992). Those vectors necessarily contain and 
express the E1 region, usually in its ‘natural position’ (Berkner, 1992). The theoretical 
advantages for the use of replication competent recombinant adenovirus vectors in cancer 
gene therapy are: (a) cytolytic effect on infected cells (Table 5); (b) subsequent spread of 
virus to neighboring cells, resulting in further tumor/tissue penetration; (c) enhanced immune 
response; and (d) higher levels of expression of the therapeutic gene (Fig. 2). In the past, 
intratumoral injection of wild-type adenoviruses has not led to unwanted effects (Smith et al., 
1956). Bischoff et al. (1996) reintroduced the oncolytic effect of adenoviruses with vectors 
carrying mutations in the early region of the gene encoding E1B-55kD. These vectors 
replicate in cells with a deficient p53 pathway 
and cause tumor specific cytolysis after intratumoral and intravenous administration (Heise et 
al., 1999). Subsequently, an additive effect of HSV-TK/GCV and radiotherapy to the 
oncolytic effect of E1B deleted vectors was demonstrated (Wildner et al., 1999; Rogulski et 
al., 2000). An alternative approach to obtain tumor specific cell lysis is to place genes that are 
essential for adenoviral replication under control of a tissue- or tumor- specific promoter. 
Examples include the use of enhancer/promoter sequences of the PSA (prostate specific 
antigen) to drive the E1A gene in prostate cancer (Rodriguez et al., 1997) and the α-
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fetoprotein promoter to drive E1A in hepatocellular carcinoma (Hallenbeck et al., 1999). 
Because 90% of primary brain tumors are of glial origin, promoter/enhancer elements from 
the GFAP gene are ideal candidates to render replication glia specific (Fukuyama et al., 
1996). Other interesting promoters for tumor specific replication within the mitotically 
quiescent environment of the brain include cell cycle-dependent promoters, such as the trident 
promoter (Korver et al., 1997). Also, hypoxia-responsive elements (HREs) derived from the 
VEGF gene (Minchenko et al., 1994) are interesting candidates because direct measurements 
have demonstrated that large parts of malignant gliomas are severely hypoxic (Collingridge et 
al., 1999).   
 
 
 
 
 
Fig. 2. Effectivity of replication competent adenoviral vectors. Luciferase activity is measured 48 h after transfection of three human 
glioma cell lines (T98G, U87MG, A172) and one rat glioma cell line (9L). In the human cell lines, luciferase expression is 3 log higher 
with replication competent Ad5RepLuc (luciferase in E3 driven by the natural E3 promoter) compared to E1A deleted Ad5CLIPLuc 
(luciferase in E1 driven by a modified CMV promoter) and Ad5E3Luc (luciferase in E3 driven by the natural E3 promoter. In the 
nonpermissive 9L rat glioma cell line, expression levels with the three vectors are similar. 
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Receptor targeting increases the number of infected tumor cells 
 
Adenoviral vectors are dependent for their entry into target cells on binding to specific 
receptors on the cell membrane. This a two-step process that offers additional opportunities 
for targeting the vector to glioma cells and increasing transfection rates. The first step is 
normally mediated by attachment of the adenoviral fiber protein to the coxsackie adenoviral 
receptor (CAR) (Bergelson et al., 1998). The 3-dimensional structure of CAR and the regions 
binding to the COOH-terminal knob domain of the adenovirus fiber protein have recently 
been defined (Bewley et al., 1999; Roelvink et al., 1999). After virus attachment, 
internalization via receptor-mediated endocytosis occurs through the binding of RGD motifs 
in the viral penton base protein to cellular αvβ3 and αvβ5-integrins (Wickham et al., 1993). In 
high grade gliomas, low CAR expression limited the utility of adenoviral vectors for gene 
transfer to primary glioma cultures in vitro. However, retargeting the vector to the epidermal 
growth factor receptor (EGFR) proved valuable for increased and tumor specific gene transfer 
(Miller et al., 1998). One method of receptor targeting (redirecting) of adenoviruses involves 
the development of bispecific antibodies that block the adenoviral knob (that normally 
recognizes CAR) and are chemically conjugated to an antibody or the ligand reactive with the 
membrane receptor of choice (Douglas et al., 1996). However, to obtain maximum benefit 
from a receptor targeted vector, genetic modification of the adenoviral knob is mandatory. 
The conserved receptor binding sites of CAR binding Adenoviridae within the COOH-
terminal knob domain of the fiber protein have been defined (Bewley et al., 1999; Roelvink et 
al., 1999). Mutations in the AB loop of the Ad5 fiber and introduction of a HA tag into the HI 
loop of the fiber resulted in a vector that no longer binds to CAR but is, instead, redirected to 
a new receptor. Subsequent removal of the RGD (Arg–Gly–Asp) sequence from the penton 
base protein resulted in vector that has no affinity to either CAR or αv-integrins. Krasnykh et 
al. (1996) demonstrated that the incorporation of an RGD-containing peptide in the HI loop of 
the fiber knob domain resulted in the ability of the virus to utilize an alternative receptor 
during the cell entry process. Due to its expanded tissue tropism, this vector was capable of 
efficient transduction of primary tumor cells resulting in a 2–3 log increase in gene transfer 
(Dmitriev et al., 1998). Soon, the methods will be available to genetically modify the knob 
and to produce vectors with stable expression of a target molecule on their surface, avoiding 
the need of a chemical conjugate (Douglas et al., 1999). The advantages of receptor targeting 
are two-fold: (a) transfection efficiency of tumor cells is increased; and (b) the liver and other 
non-target organ and CAR-mediated toxicity is reduced. As a result, lower doses of the vector 
are required for a similar or better result. 
 
Conclusion 
In conclusion, the first clinical trials with adenoviral vectors in cancer gene therapy 
demonstrated disappointing efficacy and, when administered at very high doses, toxicity. 
Ongoing vector development has led to major clinical improvements in other fields of gene 
therapy. For the treatment of glioma, new carefully designed small clinical studies are 
required to optimally assess conditionally replicating and targeted adenoviral vectors. 
 
Abbreviations 
SCID           severe combined immunodeficiency 
ADA            adenosine deaminase 
HSV-tk        herpes simplex virus thymidine kinase 
SCID-X1     X-linked form of SCID 
GCV            glanciclovir 
G-MCSF     granulocyte-macrophage colony stimulating 
factor 
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VPC            vector producer cells 
MTD           maximum tolerated dose 
OTC            ornithine transcarbamylase 
IHA             into hepatic artery 
CRAds        conditionally replicating adenoviral 
vectors 
PSA             prostate specific antigen 
HREs         hypoxia-responsive elements 
CAR          coxsackie adenoviral receptor 
EGFR        epidermal growth factor receptor 
RGD          Arg–Gly–Asp 
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CHAPTER 8 
 
 
 
Summary and general discussion 
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Due to the locoregional nature of malignant gliomas and their poor prognosis, recurrent 
malignant gliomas proved an excellent model to study gene therapy approaches. Several 
phase I/II clinical trials were performed using non-replicating Adenovirus serotype 5 (Ad5) 
based vectors, expressing the HSV-tk gene in combination with ganciclovir in recurrent 
malignant gliomas. These trials have clearly demonstrated the feasibility and safety of the 
approach 1-6. However, the results of the initial clinical gene therapy trials in malignant 
gliomas have been disappointing. The limited clinical success of adenovirus-based gene 
therapy is in strong contrast with results obtained in many animal models of gliomas . In 
chapter 2, the many hurdles that are implicated in the limited success of clinical gene therapy 
trials in gliomas are discussed. These include the low expression level of CAR on primary 
glioma cells and tumors as opposed to established cell lines 7,8, the limited distribution of 
adenoviral vectors following intratumoral injection 5,9 and the high Ad5 seroprevalence in the 
general population 10-12. Identification of these hurdles in carefully conducted clinical trials 9 
led to dramatic improvements in vector design as outlined in chapter 2. An important 
development has been the construction of adenoviral vectors that replicate selectively in 
glioma cells (recently reviewed by Jiang et al. 13). The selectivity and efficacy of adenoviral 
vectors is further increased by genetic modification of their tropism 10,13. Hopefully these 
modifications will not only increase the safety and efficacy of these vectors but also reduce 
their toxicity and even permit systemic administration. To further improve vector distribution, 
new methods of administration have been pioneered, including convection enhanced delivery 
and intravascular administration 14. Molecular imaging techniques are being developed that 
may provide surrogate endpoints in clinical glioma trials when they predict treatment 
outcome. Ideally, it will become feasible to non-invasively measure transduction levels or 
functional enzyme activity in order to correlate this with clinical changes after e.g. ganciclovir 
(GCV) treatment. Direct labeling of viral particles with radioactive molecules allows 
immediate visualization of vector distribution 14. 
 
In chapter 3, we attempted to improve the efficacy of E1-deleted adenoviral vectors, by 
constructing several replication-competent  adenoviral vectors carrying both E1A and E1B 
sequences and the HSV1-tk suicide gene. In these vectors, the luciferase (IG.Ad5E1+. E3Luc) 
or HSV1-tk gene (IG.Ad5E1+.E3TK) replaced the coding sequence of the E3 region gp19K 
that binds to class I MHC in the endoplasmic reticulum, preventing antigen presentation on 
the cell surface 15. The transgenes were placed under control of the natural E3 promoter, 
because heterologous promoters were found to be silent when inserted in this area 16-18. To 
examine the transgene expression levels obtained from the internal E3 promoter, we also 
constructed an E1-deleted vector carrying the luciferase gene in E3 (IG.Ad5.Sarcoma 
1800HSA.E3Luc). For in vitro experiments, we used a panel of human glioma cell lines (U87 
MG, T98G, A172, LW5, and U251), a rat gliosarcoma cell line (9 L), and human lung (A549) 
and prostate carcinoma (P3) cell lines. The luciferase expression obtained with 
IG.Ad5.Sarcoma 1800HSA.E3Luc was similar to a first-generation, E1- deleted vector 
carrying the luciferase gene in E1 driven by a modified CMV-promoter (IG.Ad5.ClipLuc), 
indicating the strength of the natural E3 promoter in these constructs, even in the absence of 
E1.  
We then compared the luciferase expression levels of the E1+luciferase vector with both E1-
deleted vectors and found that luciferase expression was ~3 logs higher with the E1+ vector in 
all permissive (human) cell lines tested. Similar expression levels were obtained with ~2 log 
lower m.o.i. of the E1+ vector. Interestingly, infection of the nonpermissive 9L cell line with 
the E1+ vector resulted in significantly higher luciferase expression than with the E1-deleted 
vectors. This may indicate either low-level replication of the E1+ vector in the rodent cell line 
or transactivation of the E3 promoter by E1 proteins. Apart from the direct oncolytic effect on 
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tumor cells 19, replication- competent vectors may enhance further the antitumor efficacy by 
increased expression levels of a tumoricidal transgene. 
A concern was the potential disruption of the adenovirus death protein (E3–11.6K) by our 
cloning strategy. Adenovirus death protein is produced in large amounts at the late stage of 
infection and is required for effective cell lysis and virus release 20. However, the oncolytic 
effect of the gp19K-deleted, replicating vectors was similar to wtAd5, as measured by the 
time after infection to full CPE on our panel of cell lines. Interestingly, the time to CPE 
seemed not to correlate with the level of luciferase expression, indicating that the efficacy of 
replication may not only depend on the efficacy of cell entry. Elucidating mechanisms 
affecting the efficiency of adenoviral replication in different cell lines requires additional 
study to enhance replication potentially 21. As expected, the replication-competent vectors and 
wtAd5 did not cause CPE in the nonpermissive 9L rat gliosarcoma cell line. 
In vitro, GCV sensitivity (10 µg/ml) was studied in U87 MG cells after infection at a 
multiplicity of infection of 1 and 10. The oncolytic effect of replication-competent 
IG.Ad5E1+.E3TK was significantly enhanced by the addition of GCV and greatly exceeded 
the cytotoxicity of replication-incompetent IG.AdApt.TK combined with GCV.  
We then treated s.c. U87 MG glioma xenografts (volume 100–150 mm3) in NIH-bg-nu-xid 
mice with a single injection of adenovirus 109 IU suspended in 100 µl of PBS, and GCV 100 
mg/kg was administered i.p. twice daily for 7 days. A single injection of IG.Ad5E1+.E3TK 
resulted in a significant slowing of tumor growth and prolonged survival compared with 
injection of IG.AdApt.TK. Addition of GCV slowed tumor growth, further adding to survival. 
Also, the E1+ HSV1-tk vector in combination with GCV was significantly more effective 
than the E1-deleted HSV1-tk vector with GCV.  
Replication-competent adenoviral vectors are a new and rapidly evolving platform for gene 
therapy 13,22. In the past, intratumoral injection of wild-type adenoviruses has not led to 
unwanted effects 23. However, “virotherapy” for cancer was abandoned because of only a few 
documented responses and because of the advent of more effective chemotherapeutic agents 
24. Bischoff et al. 19 reintroduced the oncolytic effect of adenoviruses with vectors carrying 
mutations in the early region of the encoding E1B-Mr 55,000. Subsequently, an additive 
effect of HSV1-tk/GCV and radiotherapy to the oncolytic effect of E1B-deleted vectors was 
demonstrated 25,26. The use of conditionally replicating vectors that contain deletions in E1B 
(or E1A) carries the risk of reduced replication as compared with wtAd5. The present study 
demonstrates that even vectors replicating as well as wtAd5 don’t cause tumor eradication in 
some models. Therefore, addition of a therapeutic transgene is probably mandatory, and genes 
with improved bystander and cytotoxic effects may add further to the efficacy of replicating 
vectors 27. The toxic genes, such as the HSV1-tk gene, can also function as a fail-safe 
mechanism when replication outside the tumor occurs 26. Here, we demonstrated that 
adenoviral replication and subsequent spread can be effectively blocked by the immediate 
administration of GCV. The complex interactions between viral replication and GCV require 
additional in vivo studies to determine the optimal interval between vector injection and first 
GCV administration. In clinical studies, conditional replication will be required for patient- 
and biosafety. An alternative for selective replication is to drive the E1B or/and E1A genes by 
a tissue or tumor-specific promoter for instance by using a glia-specific promoter such as the 
gfa2 promoter, to drive the E1A gene 28,29. 
 
In chapter 4, we examined the value of 123I-FIRU for imaging of HSV1-tk expression. In vitro 
incubation of 9L-tk+ cells and the parental 9L cells with 123I-FIRU resulted in a 100-fold 
higher accumulation of radioactivity in the 9L-tk+ cells after an optimum incubation time of 4 
h. The subsequent removal of 123I-FIRU from the medium did not result in substantial loss of 
intracellular 123I-FIRU, indicating efficient sequestration probably caused by effective 
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phosphorylation. NIH-bg-nu-xid mice were then inoculated subcutaneously with HSV1-tk (–) 
9L cells or HSV1-tk (+) 9L-tk+ cells into both flanks. Biodistribution studies and gamma 
camera imaging were performed at 15 min and 1, 2, 4 and 24 h p.i. At 15 min, the 
tumour/muscle, tumour/blood and tumour/brain ratios were 5.2, 1.0 and 30.3 respectively. 
Rapid renal clearance of the tracer from the body resulted in increasing tumour/muscle, 
tumour/blood and tumour/brain ratios, reaching values of 32.2, 12.5 and 171.6 at 4 h p.i. A 
maximum specific activity of 22%ID/g tissue was reached in the 9L-tk+ tumours 4 h after 
123I-FIRU injection. This specific accumulation of radioactivity is higher than the specific 
accumulation obtained with either 125I-FIAU (9.8% ID/g) or 18F-FHPG (0.08% ID/g) 30. 
Using 125I-FIAU, Haubner et al. 31 reported tumour to blood and tumour to muscle ratios at 4 
h p.i. of 32.0 and 88.3. In a more recent paper by the same group 30 125I-FIAU ratios at 4 h p.i., 
calculated, reveal a tumour to blood ratio of 24.4 and a tumour to muscle ratio of 21. These 
results indicate that a direct comparison of FIAU and FIRU as substrate for gene imaging is 
warranted. 
We then studied the sequestration of 123I-FIRU in the human glioma cell lines U87MG and 
T98G following infection with two adenoviral vectors carrying the HSV1-tk transgene.  
IG.Ad5.E1+.E3TK is a replication-competent Ad5-based virus that we constructed to amplify 
the antitumour efficacy of adenovirus-based gene therapy 32. IG.Ad5.E1+.E3TK results in 
more efficient cell kill than IG.AdApt.TK, an E1-deleted Ad5-based virus containing the 
HSV1-tk gene driven by the human CMV promoter in the former E1 region 32. The 
accumulation of 123I-FIRU in U87MG and T98G cells was significantly higher following 
infection with the replication- competent adenovirus compared to the non-replicating vector. 
To investigate the possibility of detecting differences in HSV1-tk gene expression levels in 
vivo we injected U87MG xenografts with either 108 or 109 I.U. of replication- competent  
IG.Ad5.E1+.E3TK and non-replicating IG.AdApt.TK. Following injection of 123I-FIRU, we 
found that the accumulation of radioactivity was higher in the tumours injected with 109 I.U. 
of either virus compared to the tumours injected with 108 I.U. Also, the tumours injected with 
the replication-competent virus showed higher radioactivity levels than tumours injected with 
the non-replicating vector. These findings correlate with images obtained with the clinical 
gamma camera and demonstrate the feasibility of detecting differences in HSV1-tk expression 
levels using 123I-FIRU in vivo following adenoviral gene therapy.  
The high ratio with normal brain may make FIRU and similar compounds suitable for 
imaging gene transfer in brain tumours. Jacobs et al. published a study in which five patients 
enrolled in a gene therapy procedure using a liposomal vector carrying an HSV-tk gene 33. 
They performed a dynamic PET scan using 124I-FIAU, similar to radiolabeled FIRU. They 
showed a specific HSV-tk-related uptake of FIAU at the site of injection in one patient, who 
also showed a response to treatment. Unfortunately, in the other patients no increased FIAU 
uptake could be measured; they also failed to respond to treatment. This study shows that 
non-invasive imaging of HSV-tk gene expression is feasible and highly desirable in order to 
assess gene transfer. Dempsey et al. reported on eight GBM patients imaged with SPECT 
using 123I-FIAU prior to and after application of an oncolytic HSV virus 34. However, no 
increased uptake of FIAU was determined after viral infection in these patients. A possible 
explanation is that FIAU might not be the ideal tracer for monitoring HSV-tk expression in 
subjects with an intact blood brain barrier, as FIAU does not penetrate it 34,35. 
In conclusion, 123I-FIRU accumulates highly selectively in tumor expressing the HSV1-tk 
gene either constitutively or following adenoviral gene transfection. In vivo imaging of the 
level of HSV1-tk expression is possible and will be valuable in both animal studies as in 
ongoing clinical trials. Future studies will compare the imaging characteristics of tracers that 
accumulate in the cell following HSV1-tk transfection with those obtained with tracers 
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directed at transfected cell surface receptors such as the type 2 somatostatin receptor 36or 
dopamine type 2 receptor 37, or the sodium-iodide symporter (NIS) 38,39. 
 
Chapter 5 describes a simple Sep-Pak based method for the purification of radio-iodinated 
FIRU allowing large scale, clinical grade production. The described carrier-mediated labeling 
method is simple, and purification over a Sep-Pak column is much more convenient than 
preparative HPLC, in particular for the production of clinical grade under GMP conditions. 
Using the described labeling and purification strategy, [123I]FIRU was routinely produced 
with a radiochemical purity > 97 %, a labeling yield of ~ 56 % and a specific activity not less 
than 690 MBq/µmol. The in vitro toxicity of FIRU, FIAU and related compounds was studied 
in a number of cell lines, using the MTT assay. These studies demonstrated lower toxicity of 
FIRU as compared to FIAU in both non-HSV1-TK expressing cells (IC50 ratio 3.8–500) and 
in HSV1-TK expressing cells (IC50 ratio 1.7-2 x 107). The lack of toxicity of the 
phosphorylated FIRU compound is most likely due to the fact that FIRU is not incorporated 
into the DNA of the mammalian dividing cell40, as opposed to FIAU 41,42. In dividing cells 
that don’t express HSV1-tk, FIRU was also less toxic than FIAU. This difference probably 
reflects a lower affinity of the endogenous TK enzyme for FIRU than for FIAU, but in neither 
case is uptake sufficient to warrant use as a cell proliferation marker 43. Uptake of FIAU was 
reported to be about 20-fold higher than that of IUdR in D-247 MG cells, leading those 
authors to conclude that [125I]FIAU might have greater cytotoxicity for this cell line than 
[125I]IUdR 44. 
Recently, a multiplexing multi-pinhole small-animal SPECT system has been described with 
greatly improved sensitivity while achieving high resolutions 45. Using this system, we could 
clearly demonstrate the uptake of FIRU in HSV-tk expressing xenografts. Choi et al46 earlier 
showed microSPECT images of [123I]FIAU uptake in HSV-tk expressing xenografts. These 
high-resolution SPECT images clearly demonstrated inhomogeneous tracer uptake in one of 
the xenografts, suggesting necrosis of the interior portion of the tumor. Progress in nuclear 
technology and fusion of multiple imaging modalities, such as SPECT and CT, will further 
enhance the sensitivity and accuracy of molecular imaging. 
Biodistribution and early kinetics studies of [123I]FIRU in tumor bearing mice showed initial 
phase and terminal phase half-lives of respectively 0.8 h and 1.3 h (blood); 0.1 h and 4 h 
(muscle); and 0.5 h and 6.7 h (9L tumor). In 9L-tk+ tumors, [123I]FIRU accumulated for about 
one hour. Subsequently, the radioactivity incorporated in these tumors decreased with a much 
longer half-life (11.3 h) than in the surrounding tissues. The optimal imaging time with 
[123I]FIRU is 4 h post-injection 40,47. 
Finally, in preparation of clinical studies, we performed toxicity studies with ‘cold’ FIRU in 
rats and mice. The injected amount of FIRU per animal was 1x, 20x or 200x fold (mg/kg) of 
the intended human dose for imaging (100  g (0.27  mol) / 70 kg). Because the 
mitochondrial toxicity associated with FIAU manifests mainly as hepatotoxicity, pancreatitis, 
neuropathy or myopathy, we focused on these organs and the hematopoietic system 48. This 
multisystem mitochondrial toxicity is probably caused by the high rate at which FIAU is 
incorporated into mitochondrial DNA49,50. We could detect no clinical, laboratory or 
pathological signs of toxicity due to FIRU. In particular, all liver function tests and amylase 
levels were normal. Pathological examination of liver and pancreas and of the peripheral 
nervous system and muscle was completely normal. In conclusion, radiolabeled FIRU can be 
easily produced in clinical grade batches. In addition, the safety profile and clear imaging 
properties make FIRU an attractive candidate tracer for clinical imaging of HSV1-tk gene 
transfer. 
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In chapter 6, we set out to identify an adenoviral vector better suited to infect primary glioma 
cells than Adenovirus serotype 5 (Ad5). The overall low expression levels of the Coxsackie 
and Adenovirus receptor (CAR) and the presence of high anti-Ad5- neutralizing antibody 
(NAb) titers in the general population are considered detrimental for consistency of clinical 
results. We tested a library of 16 fiber-chimeric Ad5-based adenoviral vectors on 12 primary 
human glioma cell suspensions. Compared to Ad5, we found significantly improved marker 
gene expression with several chimeric vectors, predominantly vectors carrying fiber 
molecules derived from B-serogroup viruses (Ad11, Ad16, Ad35 and Ad50). To explain this 
remarkable finding, we examined the expression of several molecules involved in adenoviral 
binding and entry on the primary glioma cells, including CAR, CD46 and  v  integrins. We 
found significant differences between tumor isolates in CAR and integrin expression. In vitro 
culture artefacts are an unlikely explanation for these differences, because the tumor cell 
preparations were screened early after tumor isolation. These data confirm an earlier report by 
Fuxe et al. 51 who also described variable CAR expression in 34 gliomas of various grade and 
demonstrated patient-to-patient variation that at present is not well understood. Although the 
exact function of the Ad5 high affinity receptor CAR is not known, CAR expression may 
have a tumor suppressing effect 52-54 and correlates inversely with the aggressiveness of a 
tumor, explaining the low expression levels of CAR in malignant gliomas and primary glioma 
cells 51,54. The B-group adenoviruses were recently found to use CD46 as a high affinity 
cellular attachment molecule 55,56. The CD46 molecule is ubiquitously expressed in primates 
and functions to protect “self”-cells against complement lysis by binding and inactivating C3b 
and C4b 57. The expression level of the BC-1 isoform of CD46 was significantly higher than 
the CAR expression level on primary glioma cells although both attachment molecules were 
expressed at highly variable levels. The expression of the BC1-isoform (one of four known 
isoforms of CD46) did not closely correlate with marker gene expression levels obtained after 
infection with the B-group fiber-chimeric vectors. This may indicate that other isoforms of 
CD46 are perhaps expressed by these cells and may contribute to binding and internalization 
of the B-group fiber-chimeric vectors. Since CD46 expression is very low on neurons 58 and 
because B-group chimeric vectors infect glioma cells more efficiently than Ad5, a 
recombinant vector that uses CD46 as attachment molecule might have a more favorable 
targeting ratio in the brain than Ad5. 
Skog et al 59 studied the infection of seven low-passage glioma cell lines by six wildtype 
adenovirus serotypes, including Ad5. As determined by hexon expression, the B-group 
viruses Ad16 and Ad21 infected the glioma cells most efficiently, confirming the improved 
binding and entrance by B-group viruses as compared to CAR-binding Ad5.  
 
Hoffmann et al. 60 recently compared several conditionally replicative adenoviral vectors, 
including Ad5 based chimeric vectors with an Ad35 fiber (Ad5/35). Animals treated with the 
Ad5/35-based vectors showed significantly smaller tumors and longer survival than those 
treated with the homologous Ad5 vectors and no significant toxicity was observed in the 
intracranial model. These data confirm that Ad5/35-based vectors are promising tools for 
glioblastoma treatment 60. 
We next tested Ad35 sero prevalence in sera derived from 90 Dutch cancer patients including 
30 glioma patients and investigated the transduction efficiency of this vector in glioma cell 
suspensions. Our results demonstrated that the sero prevalence and the titers of NAb against 
Ad35 were significantly lower than against Ad5. Also, recombinant Ad35 has significantly 
increased ability to transfer a gene to primary glioma cells compared to Ad5. We thus 
conclude that Ad35 represents an interesting candidate vector for gene therapy of malignant 
glioma. 
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Between November 1998 and December 2001, we treated 14 patients with advanced recurrent 
high grade gliomas with a total dose of 4.6 x 108, 4.6 x 109, 4.6 x 1010 or 4.6 x 1011 viral 
particles (VP) of a replication incompetent adenoviral vector harboring the herpes simplex 
virus thymidine kinase (HSV-tk) gene driven by the adenoviral major late promoter 
(IG.Ad.MLPI.TK), followed by ganciclovir (GCV) treatment 61. Inclusion was temporarily 
suspended following the tragic death of Mr. Gelsinger in the fall of 1999 62. In the spring of 
2000, CCMO approved continued inclusion of patients and the study was reopened. Chapter 
7 describes the preliminary results in the first eleven patients that were enrolled before the fall 
of 1999.  
The VP to infectious unit ratio was 40 and the vector was administered by 50 intra-operative 
woundbed injections of 0.2 mL each (total volume 10 mL). The study’s primary objective was 
to determine the safety of this treatment and establish the maximum tolerated dose (MTD). 
Injection of all doses of IG.Ad.MLPI.TK followed by GCV was safely tolerated and MTD 
was not reached. All patients had recurrence or progression of the tumor 1-24 months (median 
3.5 months) after gene therapy 61. The overall median survival was 4 months 61. Four patients 
survived longer than one year following gene therapy and three of these patients had non-
GBM pathology upon review (anaplastic oligodendroglioma in two and anaplastic mixed 
oligoastrocytoma in one 61). Ten patients died within 8 months of treatment, all from 
progression of the tumor 61. In five patients residual and measurable tumor was visible on the 
direct (<48 hours) postoperative MRI. No objective radiological response was documented on 
subsequent MRI 61.  
Recently, a randomized controlled trial reported the successful adjuvant treatment of 
malignant glioma patients with Ad5-tk (Cerepro®). Ad5-tk treatment produced a significant 
increase in mean survival from 39 to 71 weeks (P< 0.01) 6. The validity of this trial’s 
conclusions is compromised by the inclusion of newly diagnosed and recurrent glioma 
patients of different grades in both treatment and control groups and the imbalances between 
grade 3 and 4 patients between these groups. Nevertheless, based on these results a phase III 
trial in 250 newly diagnosed GBM has been conducted by Ark Therapeutics Ltd. The results 
of this study have not yet been reported. 
 
Future studies.  
Based on promising results in many animal models, the first clinical gene therapy trials in 
malignant gliomas were initiated with unrealistic optimism. As a result, the outcome of these 
first clinical trials was mostly disappointing. However, the careful conduct of many clinical 
trials has allowed us to pinpoint many of the barriers that limited the clinical efficacy and 
most of these barriers have been more or less successfully addressed in the laboratory. It is 
now time to assess the improved viral vectors in clinical trial. 
Adenoviral vectors are still very promising candidates to further explore in malignant glioma 
trials because of their proven safety in thousands of cancer patients. In addition, the 
adenoviral genome has been well studied and the function of most adenoviral genes are 
understood. A new adenoviral vector to test in the clinic should a) be (conditionally) 
replication competent; b) have a genetically altered tropism; c) be armed with a therapeutic 
gene; d) allow in vivo imaging of vector distribution and duration and extent of transgene 
expression; and e) be able to evade naturally existing immunity in the general population. 
An interesting candidate vector that will soon be studied in GBM patients in the Department 
of Neurosurgery of Erasmus MC (Principal Investigator, Prof.dr. C. Dirven). This Delta-24-
RGD adenovirus encompasses an E1A deletion in the retinoblastoma (Rb) protein-binding 
region and has an RGD-4C peptide motif inserted into the adenoviral fiber, which allows the 
adenovirus to anchor directly to integrins 63. The vector will be administered by convection 
enhanced delivery into the woundbed following resection of the tumor.  
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Another interesting candidate vector to study would by Ad35 based replication competent 
adenoviral vector ´armed´ with the HSV1-tk suicide gene that can also be used to image the 
extent and duration of transgene expression following administration of the vector and 
ganciclovir treatment. In addition, a proportion of the vector can be radioactively labelled to 
allow direct visualization of the vector distribution 14,64.  
Other vector systems that are promising for glioma ´virotherapy´ include conditionally 
replicating Herpes simplex virus based vectors and reovirus vectors 65-68. 
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Vanwege het locoregionale groeipatroon van maligne gliomen en hun slechte prognose, zijn 
deze tumoren een uitstekend model gebleken om gentherapie te bestuderen. Verscheidene 
fase I/II klinische trials zijn uitgevoerd, gebruik makend van niet-replicerende op Adenovirus 
serotype 5 (Ad5) gebaseerde vectoren, welke het HSV-tk gen tot expressie brengen in 
combinatie met ganciclovir, in recidief maligne gliomen. Deze trials hebben duidelijk de 
haalbaarheid en veiligheid van de benadering gedemonstreerd 1-6. Echter, de resultaten van de 
initiële klinische gentherapie trials van maligne gliomen zijn teleurstellend. Het beperkte 
succes van deze klinische studies contrasteert sterk met de resultaten verkregen in vele glioom 
diermodellen.  
In hoofdstuk 2 worden enkele obstakels besproken die bijdragen aan het beperkte succes van 
klinische glioom gentherapie trials. Tot deze obstakels behoren het lage expressieniveau van 
CAR op primaire glioomcellen en tumoren, in tegenstelling tot cellijnen 7,8, de matige 
distributie van adenovirale vectoren na intratumorale injectie 5,9 en de hoge Ad5 sero-
prevalentie in de algemene populatie 10-12. Identificatie van deze obstakels in zorgvuldig 
ontworpen klinische trials9 heeft geleid tot verbeteringen in vectorontwerp, als behandeld in 
hoofdstuk 2. Een belangrijke ontwikkeling is de constructie van adenovirale vectoren die 
selectief repliceren in glioomcellen (recente review door Jiang et al. 13). De selectiviteit en 
effectiviteit van adenovirale vectoren is verder toegenomen door genetische aanpassing van 
hun tropisme 10, 13. Hopelijk zullen deze aanpassingen niet alleen de veiligheid en effectiviteit 
van de vectoren doen toenemen, maar ook de toxiciteit reduceren en wellicht zelfs 
systemische toediening mogelijk maken. Om de vectordistributie verder te verbeteren, worden 
nieuwe toedienings methoden uitgetest, waaronder “convection enhanced delivery” en 
intravasculaire toediening 14. Moleculaire ‘imaging’ technieken worden ontwikkeld die als 
‘surrogate’ eindpunten in klinische glioomtrials zouden kunnen dienen. Idealiter zal het 
mogelijk zijn op een non-invasieve manier transductieniveau of functionele enzymactiviteit te 
meten, om deze te correleren met klinische veranderingen na bijvoorbeeld ganciclovir (GCV) 
behandeling. Direct labelen van virale partikels met radioactieve moleculen maakt 
onmiddellijke visualisatie van vectordistributie mogelijk 14. 
 
In hoofdstuk 3 hebben we getracht om de doeltreffendheid van de E1- gedeleteerde 
adenovirale vectoren te verbeteren, door verscheidene replicatiecompetente adenovirale 
vectoren te construeren die zowel E1A en E1B-sequenties als het HSV1-tk suïcide-gen 
dragen. In deze vectoren, vervangen het luciferase (IG.Ad5E1+. E3Luc) of HSV1-tk-gen 
(IG.Ad5E1+E3TK) coderingssequentie van gp19K, in deE3 regio, dat in het endoplasmatisch 
reticulum klasse I MHC bindt en zo antigenpresentatie op het celoppervlak voorkomt 15. De 
transgenen werden geplaatst onder controle van de natuurlijke E3 promoter, omdat heterologe 
promoters in deze regio geen expressie geven 16-18. Om de transgen expressieniveaus met de 
interne E3 promoter te onderzoeken, hebben we ook een E1-gedeleteerde vector 
geconstrueerd met het luciferase gen in E3 gekloneerd (IG.Ad5.Sarcoma 1800HSA.E3Luc). 
Voor in vitro experimenten gebruikten we een panel van menselijke glioomcellijnen 
(U87MG, T98G, A172, LW5, en U251), een rat gliosarcoomcellijn (9 L), en menselijke long- 
(A549) en prostaatcarcinoom (P3) cellijnen. De luciferase expressie verkregen met 
IG.Ad.Sarcoma 1800HSA.E3Luc was gelijk aan een eerste generatie, E1-gedeleteerde vector, 
met het luciferase gen in E1, aangedreven door een CMV-promoter (IG.Ad5.ClipLuc), 
waaruit de sterkte van de natuurlijke E3 promoter in deze constructen blijkt, zelfs in de 
afwezigheid van E1. 
Daarna hebben we de luciferase expressieniveaus van de E1+luciferase vector met beide E1-
gedeleteerde vectoren vergeleken en vonden dat de luciferase expressie ~3 logs hoger was 
met de E1+vector, in alle geteste permissieve (menselijke) cellijnen. Gelijke expressieniveaus 
werden verkregen met ~2 log lagere m.o.i.’s van de E1+vector. Infectie van de niet-
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permissieve 9L cellijn met de E1+ vector resulteerde in significant hogere luciferase expressie 
dan met de E1-gedeleteerde vectoren. Dit kan duiden op low-level replicatie van de 
E1+vector in de rattencellijn of transactivatie van de E3 promoter door E1 eiwitten. Los van 
het directe oncolytische effect op tumorcellen19, kunnen replicatiecompetente vectoren de 
antitumor effectiviteit versterken door toegenomen transgen expressie. 
Een punt van zorg was dat de kloneerstrategie het ‘adenovirus death protein’ (ADP; E3-
11.6K) had ontwricht. ADP wordt geproduceerd in het late stadium van infectie en is nodig 
voor effectieve cellysis en virusrelease 20. Echter, het oncolytische effect van de gp19K-
gedeleteerde, replicerende vectoren was gelijk aan wtAd5, gemeten aan de tijd van infectie tot 
volledige CPE in ons panel van cellijnen. Interessant is, dat de CPE-tijd niet bleek te 
correleren met het niveau van luciferase expressie, wat aanduidt dat de doeltreffendheid van 
replicatie niet alleen afhangt van de efficiency van infectie. Het verhelderen van de 
mechanismen welke invloed hebben op de efficiency van adenovirale replicatie, vereist 
additionele studies21. Zoals verwacht veroorzaakten de replicatiecompetente vectoren en 
wtAd5 geen CPE in de niet-permissieve 9L rat gliosarcoom cellijn.  
In vitro werd de GCV gevoeligheid (10 µg/ml) bestudeerd in U87 MG cellen, na infectie met 
een m.o.i. van 1 en 10. Het oncolytische effect van het replicatiecompetente 
IG.Ad5E1+.E3TK werd significant verhoogd door de toevoeging van GCV en overtrof de 
cytotoxiteit van replicatie-incompetente IG.AdApt.TK gecombineerd met GCV. 
Vervolgens hebben we s.c. U87 MG glioom xenograften (volume 100-150 mm3) in NIH-bg-
nu-xid muizen behandeld met een enkele injectie van 109 IU adenovirus in 100 µl PBS en 
GCV 100 mg/kg intraperitoneaal 2 maal daags, gedurende 7 dagen. Een enkele injectie van 
IG.Ad5E1+.E3TK resulteerde in een significante vertraging van de tumorgroei en verlenging 
van overleving vergeleken met injectie van IG.AdApt.TK. Toevoeging van GCV vertraagde 
de tumorgroei en verlengde de overleving. Tevens was de E1+HSV1-tk vector in combinatie 
met GCV significant effectiever dan de E1-gedeleteerde HSV1-tk met GCV. 
Replicatiecompetente adenovirale vectoren vormen een nieuw en snel evoluerend platform 
voor gentherapie13,22. In het verleden hebben intratumorale injecties van wild-type 
adenovirussen niet geleid tot ernstige bijwerkingen 23. Echter, deze “virotherapie” voor kanker 
werd niet verder ontwikkeld doordat er maar enkele gedocumenteerde responses waren en 
door de komst van meer effectieve chemotherapeutische behandelingen 24. Bischoff et al. 19 
herintroduceerden het oncolytische effect van adenovirussen met vectoren welke mutaties 
droegen in de E1B-Mr 55,000 regio. Vervolgens werd een additief effect van HSV1-tk/GCV 
en radiotherapie aan het oncolytische effect van E1B-gedeleteerde vectoren gedemonstreerd 
25,26. Het gebruik van conditioneel-replicerende vectoren met deleties in E1B  (of E1A)  
vermindert het risico op ongecontroleerde replicatie, in vergelijking met wtAd5. De huidige 
studie demonstreert dat in sommige modellen zelfs wtAd5 geen tumor eradicatie tot stand kan 
brengen. Daarom is toevoeging van een therapeutisch transgen waarschijnlijk vereist. Genen 
met verbeterde bystander en cytotoxische effecten kunnen de doeltreffendheid van 
replicerende vectoren verder vergroten 27. Toxische genen, zoals het HSV1-tk-gen, kunnen 
tevens functioneren als een “failsafe” mechanisme wanneer zich replicatie buiten de tumor 
voordoet 26. Hier demonstreerden we dat adenovirale replicatie en daarop volgende 
verspreiding effectief geblokkeerd kan worden door onmiddellijke toediening van GCV. De 
complexe interacties tussen virale replicatie en GCV vereisen additionele in vivo studies om 
het optimale interval tussen vectorinjectie en de eerste GCV toediening vast te stellen. In 
klinische studies is het gebruik van conditioneel replicerende vectoren waarschijnlijk 
noodzakelijk uit het oogpunt van patiëntveiligheid en biosafety. Een alternatief voor 
selectieve replicatie is het aandrijven van het E1B en/of E1A-gen door een weefsel of 
tumorspecifieke promoter, bijvoorbeeld de glia-specifieke gfa2 promoter 28,29. 
 
D. Nanda – Gene Therapy for Malignant Gliomas Pagina 135 van 145 135 
In hoofdstuk 4 hebben we de waarde van 123I-FIRU onderzocht, om de HSV1-tk expressie in 
beeld te kunnen brengen. In vitro incubatie van 9L-tk+cellen en 9L cellen met 123I-FIRU 
resulteerde in een 100 keer hogere accumulatie van radioactiviteit in de 9L-tk+ cellen, na een 
optimale incubatietijd van 4h. Verwijdering van 123I-FIRU van het medium na 4h incubatie, 
resulteerde niet in substantieel verlies van intracellulair 123I-FIRU, waarschijnlijk veroorzaakt 
door effectieve fosforylatie. NIH-bg-nu-xid muizen werden toen subcutaan geïnjecteerd met 
HSV1-tk (-) 9L cellen of HSV1-tk (+) 9L-tk cellen in beide flanken. Biodistributiestudies en 
gamma camera beeldvorming werden uitgevoerd 15 min en 1, 2, 4 en 24 h na injectie van 3 
MBq 123I-FIRU. Na 15 min waren de tumor/spier, tumor/bloed en tumor/brein- ratio’s 
respectievelijk 5.2, 1.0 en 30.3. Snelle renale klaring van de tracer resulteerde in toenemende 
tumor/spier, tumor/bloed en tumor/brein- ratio’s, die waarden bereikten van 32.2, 12.5 en 
171.6 op 4 h p.i. Een maximum specifieke activiteit van 22%ID/g weefsel werd bereikt in de 
9L-tk+tumoren 4 h na 123I-FIRU-injectie. Deze specifieke accumulatie van radioactiviteit is 
hoger dan de specifieke accumulatie verkregen met 125I-FIAU (9.8% ID/g) of 18FFHPG 
(0.08% ID/g) 30. Haubner et al. 31 bereikten met 125I-FIAU tumor/bloed en tumor/spier ratio’s 
van 32.0 en 88.3, 4h p.i. In een recentere studie meldde dezelfde groep 30 125I-FIAU ratio’s, 4 
h p.i. van 24.4 (tumor/bloed) en van 21 (tumor/spier), als berekend uit Tabel 1. Deze 
resultaten geven aan dat een directe vergelijking van FIAU en FIRU als substraat voor ”gene 
imaging” op zijn plaats is. 
Daarna hebben we de sequestratie van 123I-FIRU onderzocht in de humane glioomcellijnen 
U87MG en T98G, na infectie met twee adenovirale vectoren, die het HSV1-tk transgen 
droegen. IG.Ad5.E1+.E3TK is een replicatiecompetente, op Ad5 gebaseerd vector, die we 
hebben geconstrueerd om de antitumor-effectiviteid  van adenovirale gentherapie te 
vergroten32.  IG.Ad5.E1+.E3TK heeft een sterker oncolytisch effect dan IG.AdApt.TK, een op 
Ad5 gebaseerde vector met het HSV1-tk-gen aangedreven door de CMV promoter in de 
voormalige E1-regio 32. De accumulatie van 123I-FIRU in U87MG en T98G cellen, was 
significant hoger na infectie met het replicatiecompetente adenovirus, vergeleken met de niet-
replicerende vector. Om de verschillen in HSV1-tk-gen expressie in vivo te bestuderen, 
injecteerden we U87MG xenograften met 108 en 109 I.U. van het replicatiecompetente 
IG.Ad5.E1+.E3TK en het niet-replicerende IG.AdApt.TK. Na injectie van 123I-FIRU, vonden 
we dat de accumulatie van radioactiviteit hoger was in de tumoren die met 109 I.U. waren 
geïnjecteerd, vergeleken met de tumoren geïnjecteerd met 108 I.U. Tevens toonden de 
tumoren die geïnjecteerd waren met het replicatiecompetente virus hogere 
radioactiviteitniveaus dan tumoren geïnjecteerd met de niet-replicerende vector. Deze 
bevindingen correleren met de beelden verkregen met de klinische gamma camera. 
De hoge ratio met normaal brein, zou FIRU en zijn analogen geschikt maken voor imaging 
van gentransfer in hersentumoren. Jacobs et al. behandelden vijf hersentumor patiënten met 
HSV1-tk-gentherapie middels een liposomale vector 33. Zij verrichtten dynamische PET-scans, 
gebruik makend van 124I-FIAU, en toonden specifieke HSV-tk-gerelateerd opname van FIAU 
aan op de plaats van injectie bij een patiënt, die ook een response liet zien op de behandeling. 
Helaas kon bij de andere patiënten geen toegenomen FIAU-opname worden gemeten; dezen 
respondeerden echter ook niet op de behandeling. Deze studie laat zien dat het mogelijk is, 
met non-invasieve beeldvorming, expressie van HSV1-tk-gen vast te stellen. Dempsey et al. 
rapporteerden SPECT-studies gebruik makend van 123I-FIAU bij acht GBM patiënten, 
voorafgaand aan en na toediening van een oncolytisch HSV virus34. Bij deze patiënten vonden 
zij geen toegenomen opname van FIAU. Een mogelijke verklaring is dat FIAU niet de ideale 
tracer is om HSV-tk expressie te monitoren, bij patiënten met een intacte bloedhersen barrière 
omdat FIAU de bloedhersen barrière niet zou penetreren 34,35.  
Concluderend accumuleert 123I-FIRU zeer selectief in tumoren die het HSV1-tk-gen tot 
expressie brengen, zowel constitutief als na adenovirale transfectie. In vivo imaging van  
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HSV1-tk-expressie is mogelijk en kan waardevol zijn in zowel preklinische studies als in 
klinische trials. Toekomstige studies zullen de beeldkarakteristieken vergelijken van tracers 
welke in de cel accumuleren na HSV1-tk transfectie met die van tracers gericht op 
getransfecteerde celoppervlak receptoren, zoals het type 2 somatostatin receptor 36 of 
dopamine type 2 receptor 37, of de natrium-iodide symporter (NIS) 38,39.   
 
Hoofdstuk 5 beschrijft een eenvoudige Sep-Pak gebaseerde methode voor de zuivering van 
radiogeïodeerd FIRU, welke grootschalige productie toelaat voor klinische doeleinden. De 
beschreven ”carier-mediated labeling” is eenvoudig en zuivering over een Sep-Pak column is 
voor klinische toepassing meer geschikt dan preparatieve HPLC. Gebruik makend van de 
beschreven labeling en zuiveringstrategie, werd [123I]FIRU routinematig geproduceerd met 
een radiochemische zuiverheid > 97%, een labeling opbrengst van ~56% en een specifieke 
activiteit van niet minder dan 690 MBq/µmol. De in vitro toxiciteit van FIRU, FIAU en de 
gerelateerde producten werden bestudeerd in een aantal cellijnen, met behulp van de MTT-
assay. Deze studies demonstreerden de lagere toxiciteit van FIRU, vergeleken met FIAU in 
zowel HSV1-tk negatieve cellen (IC50 ratio 3.8-500) als in de HSV1-tk tot expressie 
brengende cellen (IC50 ratio 1.7-2 x 107). Het ontbreken van toxiciteit van gefosforyleerd 
FIRU is hoogstwaarschijnlijk te danken aan het het feit dat FIRU niet geïncorporeerd wordt in 
het DNA van delende zoogdiercellen 40, in tegenstelling tot FIAU 41,42. In delende cellen die 
HSV1-tk niet tot expressie, is FIRU ook minder toxisch dan FIAU. Dit verschil reflecteert 
waarschijnlijk een lagere affiniteit van het endogene TK-enzym voor FIRU, dan voor FIAU, 
maar in beide gevallen is de opname onvoldoende als cel proliferatiemarker te gebruiken43. In 
D-247 cellen is de gerapporteerde opname van FIAU ongeveer 20-keer hoger dan van IUdR; 
hierdoor zou [125I]FIAU een grotere cytotoxiciteit kunnen hebben voor deze cellijn, dan 
[125I]IUdR 44. 
Onlangs is een “multiplexing multi-pinhole SPECT-systeem” beschreven voor kleine 
proefdieren met een sterk verbeterde sensitiviteit en hoge resoluties 45. Gebruik makend van 
dit systeem, kunnen we duidelijk de opname van FIRU in HSV-tk tot expressie brengende 
xenografts demonstreren. Choi et al46 toonde eerder micro-SPECT-beelden van [123I]FIAU-
opname in HSV-tk tot expressie brengende xenografts aan. Deze hoge resolutie SPECT-
beelden lieten duidelijk inhomogene tracer opname in een van het xenografts zien, suggestief 
voor necrose van het interne deel van de tumor. Vooruitgang in nucleaire technologie en fusie 
van veelvoudige beeldmodaliteiten, zoals SPECT en CT, zullen de sensitiviteit en 
accuraatheid van moleculaire beeldvorming verder doen toenemen.  
Biodistributie en vroege kinetische studies van [123I]FIRU in tumor-dragende muizen, toonden 
een initiële fase en terminale fase halfwaardetijd van respectievelijk 0.8 en 1.3 h (bloed); 0.1 h 
en 4 h (spier); en 0.5 h en 6.7 h (9L tumor). In 9L-tk+tumoren, accumuleerde [123I]FIRU 
gedurende ongeveer een uur. Daarna verdween de radioactiviteit in deze tumoren met een 
langere halfwaardetijd (11.3 h) dan in de omgevende weefsels. De optimale beeldtijd met 
[123I]FIRU is 4 h post-injectie 40, 47.  
Uiteindelijk, ter voorbereiding op klinische studies, hebben we toxiciteitsstudies met “koude” 
FIRU op ratten en muizen uitgevoerd. De geïnjecteerde hoeveelheid FIRU per dier was 1x, 
20x of 200x hoger (mg/kg) van de bedoelde dosering op mensen voor beeldvorming (100 µg 
(0.27 µmol)/70 kg). Omdat de door FIRU veroorzaakte mitochondriële toxiciteit zich 
hoofdzakelijk manifesteert als hepatotoxiciteit, pancreatitis, neuropathie of myopathie, hebben 
we op deze organen en het hematopoietische systeem gefocust 48. Deze multisysteem 
mitochondriële toxiciteit wordt waarschijnlijk veroorzaakt door de hoge mate waarin FIAU 
wordt ingecorporeerd in mitochondrieel DNA 49, 50. We konden geen door FIRU veroorzaakte 
klinische, laboratorium of pathologische tekenen van toxiciteit detecteren. Met name waren 
alle levertesten en amylaseniveaus normaal. Pathologisch onderzoek van lever en pancreas en 
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van het perifere zenuw- en spierstelsel was geheel normaal. Concluderend, radioactieve FIRU 
batches kunnen gemakkelijk worden geproduceerd voor klinische doeleinden. Bovendien 
maken het veiligheidsprofiel en de duidelijke beeldeigenschappen FIRU tot een aantrekkelijke 
kandidaat tracer voor klinische beeldvorming van HSV1-tk-gen transfer. 
 
In hoofdstuk 6 trachtten wij een adenovirale vector te identificeren die beter geschikt is om 
primaire gliomacellen te infecteren dan Adenovirus serotype 5 (Ad5).. De lage 
expressieniveaus van de Coxsackie en Adenovirus receptor (CAR) op tumorcellen en de 
aanwezigheid van hoge anti-Ad5-neutraliserende antilichaam (Nab) titers in de algemene 
populatie, lijken goede klinische resultaten in de weg te staan. We hebben een bibliotheek van 
16 fiber-chimere Ad5-gebaseerde adenovirale vectoren op 12 primaire menselijke 
glioomcelsuspensies getest. Vergeleken met Ad5, hebben we met verscheidene chimere 
vectoren significant verbeterde markergenexpressie gevonden. Het betrof vooral vectoren met 
fiber moleculen die afgeleid zijn van B-serogroep adenovirussen (Ad11, Ad16, Ad35 en 
Ad50). Om deze opmerkelijke bevinding te verklaren, hebben we de expressie van 
verscheidene moleculen onderzocht, betrokken bij adenovirale binding en entry in de primaire 
glioma cellen, inclusief CAR, CD46 en αvβ integrins. We vonden significante verschillen 
tussen tumorcellen in CAR en integrine expressie. In vitro kweekartefacten vormen geen 
waarschijnlijke verklaring voor deze verschillen, omdat de primaire tumorcellen vroeg na 
isolatie getest zijn. Deze data bevestigen een eerdere studie van Fuxe et al. 51 die ook 
variabele CAR-expressie beschreef in 34 gliomen van verschillende graderingen. Hoewel de 
exacte functie van de Ad5 hoge affiniteitreceptor CAR niet bekend is, zou CAR expressie een 
tumoronderdrukkingseffect hebben52-54 en omgekeerd evenredig correleren met de 
agressiviteit van een tumor, de lage CAR expressieniveaus verklarend in maligne gliomen en 
de primaire glioomcellen 51,54. Recent is gebleken dat de B-groep adenovirussen CD46 
gebruiken als een hoge affiniteit cellulair bindingsmolecuul 55,56. Het CD46 molecuul wordt 
uitgebreid tot expressie gebracht in primaten en beschermt “zelf”-cellen tegen complement 
lysis door binding en inactiveren van C3b en C4b 57. Het expressieniveau van de BC-1 
isoform van CD46 was significant hoger dan het CAR-expressieniveau op primaire 
glioomcellen. De expressie van de BC1-isoform (een van vier bekende isoforms van CD46) 
correleerde echter slecht met markergenexpressieniveaus, verkregen na infectie met de B-
groep fiber-chimere vectoren. Dit kan erop wijzen dat andere isoformen van CD46 misschien 
bijdragen aan binding en entry van de B-groep fiber-chimere vectoren. Omdat CD46-
expressie erg laag is op neuronen 58 en omdat B-groep chimere vectoren efficiënter 
glioomcellen infecteren dan Ad5, zou een recombinante vector, die CD46 als 
bindingsmolecuul gebruikt, een meer gunstige doelratio in het brein kunnen hebben, dan Ad5.   
Skog et al 59 bestudeerde de infectie van zeven ”low-passage”  glioomcellijnen door zes 
wildtype adenovirale serotypes, inclusief wtAd5. Gebaseerd op hexon expressie bleken de B-
groep virussen Ad16 en Ad21 de glioomcellen het meest efficiënt te infecteren. Deze 
bevinding bevestigt de verbeterde binding en entry door de B-groepvirussen, vergeleken met 
Ad5. 
Hoffmann et al. 60 heeft onlangs verscheidene conditioneel-replicerende adenovirale vectoren 
vergeleken, inclusief Ad5-gebaserde chimere vectoren met een Ad35 fiber (Ad5/35). 
Proefdieren, behandeld met de Ad5/35 vectoren, vertoonden significant kleinere tumoren en 
langere overleving dan degene die behandeld werden met de homologe Ad5 vectoren. 
Bovendien werd in het intracraniële model geen significante toxiciteit geobserveerd. Deze 
data bevestigen dat Ad5/35-gebaseerde vectoren veelbelovend kunnen zijn voor glioblastoma 
behandeling 60. 
Vervolgens testten we de seroprevalentie van Ad35 in serum van 90 Nederlandse 
kankerpatiënten, waaronder 30 glioompatiënten en onderzochten de transductie efficiency van 
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deze vector in glioomcelsuspensies. Onze resultaten demonstreerden dat de seroprevalentie en 
de NAb-titers tegen Ad35, significant lager waren dan tegen Ad5. Omdat Ad35 primaire 
glioomcellen ook nog efficiënter transfecteert dan Ad5 kunnen we concluderen dat Ad35 een 
interessante kandidaat-vector is voor gentherapie van maligne gliomen. 
 
Tussen november 1998 en december 2001 hebben we 14 patiënten behandeld met recidief 
hooggradige gliomen, met een totaaldosering van 4.6 x 108, 4.6 x 109, 4.6 x 1010 of 4.6 x 1011 
virale partikels (VP) van een replicatie-incompetente adenovirale vector, die het herpes 
simplex virus thymidine kinase (HSV-tk) gen bevat, gestuurd door de adenovirale ‘major late 
promoter’ (IG.Ad.MLPI.TK), gevolgd door ganciclovir (GCV) behandeling 61. Inclusie werd 
tijdelijk opgeschort na de tragische dood van dhr. Gelsinger in de herfst van 1999 62. In de 
lente van 2000, heeft de CCMO de verdere inclusie van patiënten weer toegestaan en is de 
studie heropend. Hoofdstuk 7 beschrijft de voorlopige resultaten van de eerste elf patiënten, 
die werden geïncludeerd voor de herfst van 1999.  
De VP:infectious unit ratio was 40 en de vector werd toegediend middels 50 intra-operatieve 
wondbed injecties van elk 0.2 mL (totaal volume 10 mL). Het primaire doel van de studie was 
om de veiligheid van deze behandeling vast te stellen en om de maximaal getolereerde dosis 
bepalen (MTD). Injectie van alle doses IG.Ad.MLPI.TK gevolgd door GCV werd goed 
verdragen en MTD werd niet bereikt. Echter alle patiënten hadden een recidief of progressie 
van de tumor 1-24 maanden (gemiddeld 3.5 maanden) na gentherapie 61. De overall mediane 
overleving was 4 maanden 61. Vier patiënten overleefden langer dan 1 jaar, drie van deze 
patiënten hadden non-GBM pathologie bij revisie (anaplastische oligodendroglioom bij twee 
en anaplastisch gemengd oligoastrocytoom bij één 61). Tien patiënten overleden binnen acht 
maanden na de behandeling, allen door progressie van de tumor 61. Bij vijf patiënten was een 
meetbare resttumor zichtbaar op de direct (<48 uur) postoperatieve MRI. Er werd geen 
objectieve radiologische respons op de daaropvolgende MRI gedocumenteerd 61. 
Onlangs zijn de resultaten gerapporteerd van een kleine gerandomiseerde, gecontroleerde trial 
welke de adjuvante behandeling van maligne glioompatiënten met Ad5-tk (Cerepro ®) 
bestudeerde. Ad5-tk behandelde patienten toonden  een significante toename van de 
gemiddelde overleving van 39 naar 71 weken (P<0.01)6. De resultaten van deze trial zijn 
echter niet goed te interpreteren door de inclusie van zowel nieuw gediagnosticeerde als 
recidief glioompatiënten van verschillende graden en de onbalans tussen graad 3 en 4-
patiënten tussen de behandel- en controlegroep. Desalniettemin is er, gebaseerd op deze 
resultaten, een fase III trial gestart bij 250 nieuw gediagnosticeerde GBM-patiënten. De trial 
wordt geleid door Ark Therapeutics Ltd en de resultaten van deze studie zijn nog niet bekend. 
 
Toekomstige studies. 
Gebaseerd op veelbelovende resultaten in vele diermodellen, werden de eerste klinische 
gentherapietrials bij maligne gliomen geïnitieerd met onrealistisch optimisme. De uitkomst 
van deze eerste klinische trials waren dan ook ronduit teleurstellend. Door de gedegen opzet 
van vele klinische trials is het mogelijk gebleken enkele barrières nauwkeurig aan te wijzen, 
die de klinische doeltreffendheid beperkt hebben. De meeste barrières zijn min of meer 
succesvol aan de orde gesteld in het laboratorium. Nu is de tijd om de verbeterde virale 
vectoren in klinische trials te beoordelen.  
Adenovirale vectoren zijn nog steeds veelbelovende kandidaten om verder te onderzoeken in 
maligne glioomtrials door hun bewezen veiligheid bij duizenden kankerpatiënten. Bovendien 
is het adenovirale genoom goed bestudeerd en wordt de functie van de meeste adenovirale 
genen begrepen. Een nieuwe adenovirale vector om in de kliniek te testen zou a) 
(conditioneel) replicatiecompetent moeten zijn; b) een genetisch gewijzigd tropisme moeten 
hebben; c) gewapend moeten zijn met een therapeutisch gen; d) in vivo beeldvorming van 
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vectordistributie en duur en mate van transgenexpressie moeten toestaan; en e) in staat moeten 
zijn om natuurlijk voorkomende immuniteit in de algemene populatie te omzeilen. Een 
interessante vectorkandidaat zal binnenkort bestudeerd worden bij GBM patiënten op de 
Afdeling Neurochirurgie van het Erasmus MC (Hoofdonderzoeker, Prof.dr. C. Dirven). Dit 
Delta-24-RGD adenovirus is gekenmerkt door een E1A-deletie in de retinoblastoma (Rb) 
eiwit-bindende regio en heeft een RGD-4C peptidenmotief in het adenovirale fiber 63. De 
vector zal worden toegediend via de zogenaamde “convection enhanced delivery” na tumor 
resectie. Een andere interessante vectorkandidaat om te bestuderen zou zijn een Ad35-
gebaseerde replicatiecompetente vector, ‘gewapend’ met het HSV1-tk suïcide-gen, dat ook 
gebruikt kan worden om de mate en de duur van transgen expressie in beeld te brengen na 
toediening van de vector en ganciclovirbehandeling. Bovendien kan een deel van de vector 
radioactief gelabeld worden om de vectordistributie direct na injectie te visualiseren 14,64. 
Andere veelbelovende vectorsystemen voor glioom ‘virotherapie’ zijn conditioneel 
replicerende Herpes simplex virus-gebaseerde vectoren en reovirus vectoren 65-68. 
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